

CURRICULUM VITAE

JULIE A. JOHNSON

September 2021

PERSONAL INFORMATION

Address: Residence - 5828 NW 72nd St
Gainesville, Florida 32653

Office - College of Pharmacy
Office of the Dean
The University of Florida
Box 100484
Gainesville, FL 32610-0484

Email - julie.johnson@ufl.edu

Telephone: Office - (352) 273-6309
FAX - (352) 273-6306

Place of Birth: Greenville, Ohio (raised Delaware, Ohio)

Date of Birth: March 22, 1962

Personal information: Married: John J. Lima, Pharm.D.
Children: Sarah M. Lima (11/1/94)
Elizabeth T. Lima (10/29/98)

EDUCATION AND TRAINING

Bachelor of Science in Pharmacy, The Ohio State University, Columbus, Ohio, June 1985.

Doctor of Pharmacy, The University of Texas at Austin and The University of Texas Health Science Center at San Antonio, August 1987.

Postdoctoral Fellowship in Pharmacokinetics/Clinical Pharmacology - The Ohio State University, Columbus, Ohio. July 1987 to June 1989.

LICENSURE AND BOARD CERTIFICATION

Licensure – Registered Pharmacist: Ohio #03317131 (1987 to present)
Florida #PS 36111 (2001 to present)
Tennessee #007898 (1990 to 1999)
Texas #28598 (1985-1988)

Board Certification: Board Certified Pharmacotherapy Specialist
October 1992, #292162 (renewed 2000, 2008)
Added Qualifications in Cardiology, 2004

PROFESSIONAL APPOINTMENTS

1989-1993 Assistant Professor of Clinical Pharmacy - Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis, Tennessee.

- 1993-1998 Associate Professor of Clinical Pharmacy - Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis, Tennessee. Tenure granted July 1995.
- 1995-1998 Associate Professor of Pharmaceutical Sciences with Graduate Faculty Status - Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee, Memphis, Tennessee. July 1995 to April 1998.
- 1998-2001 Associate Professor of Pharmacy Practice (now Pharmacotherapy and Translational Research) – College of Pharmacy, University of Florida, Gainesville, Florida. Tenure granted July 1999.
- 1999-2001 Associate Professor of Medicine – Department of Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida.
- 2001-2011 Professor of Pharmacy, tenured, Department of Pharmacotherapy and Translational Research (primary), and Department of Pharmaceutical Sciences (graduate faculty member), College of Pharmacy, University of Florida, Gainesville, Florida.
- 2001-2011 Professor of Medicine – Department of Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida.
- 2001-2013 Director, University of Florida Center for Pharmacogenomics.
- 2002-2011 Chair, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida.
- 2004-2013 V. Ravi Chandran Professor of Pharmaceutical Sciences, endowed professorship.
- 2011-present Distinguished Professor of Pharmacy, tenured, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida.
- 2011-present Distinguished Professor of Medicine – Department of Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Florida.
- 2011-2019 Director, UF Health Personalized Medicine Program (renamed Precision Medicine Program), Clinical and Translational Science Institute.
- 2013-present Dean, College of Pharmacy, University of Florida
- 2019-present Board member, UF Health Shands Hospital Board of Directors

EXECUTIVE LEADERSHIP SUMMARY

Executive leadership roles have included 9 years of service as department chair, and current service (in 9th year) as CEO Dean of the College of Pharmacy. As department chair, I was asked to build a strong research footprint in my clinical department. Within three years (2005), we went from the 4th (of 5) highest research funding in the college to the top funded department, a position maintained most years since then. Academic Analytics data indicate the department is the top ranked department of its type in the nation and the 2nd highest ranked of all college of pharmacy departments in the nation. Since I assumed the CEO dean role in 2013, the college has risen in US News and World Report rankings from #14 to #5, research funding has increased 3.3-fold, moving in national rankings from the high teens/low twenties to #3 for NIH funding and #4 for total funding (currently about \$28M). The faculty size increased by 75%, and we completely revamped the professional curriculum to a flipped classroom approach, with online lectures and active learning in the classroom. Intentional approaches to diversity, inclusion and equity have led to 34% of the PharmD student body being comprised of under-represented minorities (URM),

nearly doubling in my time as dean, placing us 5 points ahead of the next highest professional college at UF, and #1 among top 10 colleges of pharmacy. Percentages of URM entering graduate students has increased 4-fold from 5% average in the first 3 years of my deanship to 20% average in the most recent three years, through programs that encouraged faculty to recruit Americans and URMs into the graduate program. Addition of an Associate Dean for Diversity, Inclusion and Health Equity, and creation of a strong faculty/staff/student Diversity and Inclusion Committee in the college has created an environment for positive change for the college in achieving inclusive excellence.

PROFESSIONAL PRACTICE EXPERIENCE

Community Pharmacy Intern - SuperX Drug Stores, Dublin, Ohio. May 1980 to May 1983.

Hospital Pharmacy Intern - Riverside Methodist Hospital, Columbus, Ohio. May 1983 to June 1985.

Part-time Staff Pharmacist - Bexar County Hospital District, Medical Center Hospital, San Antonio, Texas. July 1985 to July 1987.

Part-time Staff Pharmacist - Drug Emporium, San Antonio, Texas. March 1986 to July 1987.

Part-time Staff Pharmacist - SuperX Drug Stores, Columbus, Ohio, March 1988 to July 1989.

Clinical Pharmacist - Cardiac Intensive Care Unit - Regional Medical Center at Memphis. July 1990 to March 1995 (CICU was closed by the hospital in March 1995).

Clinical Pharmacist - Cardiology/CCU - Veterans Administration Medical Center at Memphis. April 1996 to April 1998.

Clinical Pharmacist – Heart Failure/Heart Transplant Clinic – Shands Hospital at University of Florida. 1998 to 2002.

PROFESSIONAL AFFILIATIONS

American Association for the Advancement of Science

American Association of Colleges of Pharmacy

American College of Clinical Pharmacy

American Heart Association

American Society for Clinical Pharmacology and Therapeutics

American Society of Human Genetics

American Pharmacists Association

Florida Pharmacy Association

Florida Society for Health System Pharmacists

National Academy of Medicine

Academy for Science Engineering and Medicine Florida

AWARDS AND HONORS (reverse chronological order)

Precision Medicine World Conference Luminary Award recipient, September 2021

Rawls Palmer Progress in Medicine Award, American Society for Clinical Pharmacology and Therapeutics, March 2021.

American Association for the Advancement of Science, elected Fellow. November 2020.

American College of Clinical Pharmacy Paul Parker Medal recipient, for Distinguished Contributions to the Profession of Pharmacy. October 2019

American College of Clinical Pharmacology Distinguished Investigator Award, September 2019

Commencement speaker, University of Texas at Austin College of Pharmacy, May 2019

Commencement speaker, University of Michigan College of Pharmacy, April 2019

Clarivate Analytics Highly Cited Scientist in Cross Discipline – designation for being among top 1% of authors of highly cited papers globally for the preceding decade. 2018

Charles M Gruber Distinguished Lecturer. Thomas Jefferson University Sidney Kimmel Medical College. May 2018.

Milap Nahata Distinguished Lecturer, The Ohio State University College of Pharmacy, March 2018.

Clarivate Analytics Highly Cited Scientist in Pharmacology and Toxicology – designation for being among top 1% of authors of highly cited papers globally for the preceding decade. 2017

Varro E. Tyler Distinguished Lecturer, Purdue University College of Pharmacy, October 2017.

Leon Goldberg Endowed Lectureship, University of Chicago Department of Medicine, October 2017

Grant Wilkinson Distinguished Lectureship, Vanderbilt University College of Medicine, June 2017.

Thomson Reuters Highly Cited Scientist in Pharmacology and Toxicology – designation for being among top 1% of authors of highly cited papers globally for the preceding decade. 2016

Volwiler Research Achievement Award, American Association of Colleges of Pharmacy, July 2016.

Commencement Speaker, University of California at San Diego School of Pharmacy, May 2016

William B. Abrams Lectureship Award, American Society for Clinical Pharmacology and Therapeutics and The US Food and Drug Administration, April 2016

Mentoring Award, Functional Genomics and Translational Biology Council of the American Heart Association. November 2015

Thomson Reuters Highly Cited Scientist in Pharmacology and Toxicology – designation for being among top 1% of authors of highly cited papers globally for the preceding decade. 2015

Southeastern Universities Research Association Distinguished Scientist Award. April 2015

National Academy of Medicine (formerly Institute of Medicine) member. Elected 2014

Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Science, University of Buffalo. October 2014

Honorary Fellow Award, American College of Clinical Pharmacology September 2014

University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award. December 2013

University of Florida Research Foundation Professorship Award, University of Florida, 2013-2015.

The Sebok Pharmacy Lecture, Raabe College of Pharmacy, Ohio Northern University, January 2013.

Distinguished Investigator Award, American College of Clinical Pharmacy Cardiology Practice and Research Network, October 2010.

Russell Miller Award for Contribution to the Literature, American College of Clinical Pharmacy, October 2010.

Gutkey Memorial Lecture and Dean's Convocation, University of Colorado School of Pharmacy, September 2010.

Loius C. Littlefield Research Excellence Day Plenary Speaker, University of Texas at Austin, April 2010.

Julius Koch Memorial Lecturer, University of Pittsburgh College of Pharmacy, March 2010.

Fellow, American Heart Association; Functional Genomics and Translational Biology Council, November 2009.

Therapeutic Frontiers Award, American College of Clinical Pharmacy, October 2009. This is the highest research award in ACCP and is not limited to ACCP members.

Robert G. Leonard Memorial Lecture Award, Texas Society of Health System Pharmacists and University of Texas at Austin, April 2008.

First Tennessee Chair of Excellence Visiting Professor, University of Tennessee College of Pharmacy, January 2008.

Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy, July 2007.

University of Florida Faculty Achievement Recognition Award, April 2007

David E. Guttman Memorial Lecturer, University of Kentucky College of Pharmacy, September 2006

Ohio State University College of Pharmacy Distinguished Alumni Award, May 2005

V. Ravi Chandran Professor of Pharmaceutical Sciences, endowed professorship, 2004 – 2013

University of Florida Research Foundation Professorship Award, 2004-2006

Leon I. Goldberg Young Investigator Award, American Society for Clinical Pharmacology and Therapeutics, March 2004

31st Annual Albert Ebert Lecturer, University of Illinois-Chicago College of Pharmacy, April 2003

Philip C. and Ethel R. Ashby Lecturer, University of Oklahoma College of Pharmacy, February 2003

Outstanding Faculty of the Year, Working Professional Pharm.D. Program, University of Florida, 2001

Phi Lambda Sigma – National Pharmacy Leadership Honor Society, inducted 2000

FDA Committee Appointee – Nonprescription Drug Advisory Committee, 2000-2004

Elected Officer (Regent) – American College of Clinical Pharmacy Board of Regents, 2000-2003

Ohio State University William Oxley Thompson Alumni Award, 1997 – awarded for distinctive career achievement to an Ohio State University alumnus less than 36 years old.

Elected Fellow - American College of Clinical Pharmacy, 1996

Teaching Excellence Award, 1996 - Presented by the UT Student Government Association

The Robert G. Leonard Memorial Scholarship, University of Texas, 1986

The University of Texas Competitive Scholarship, 1985

Lemmon Company Award for Outstanding Achievement in the Study of Pharmacy, 1985

Mortar Board National Senior Honor Society, Ohio State University chapter - initiated May 1984.

Rho Chi Society, Upsilon Chapter - initiated May 1984

Ohio State University Scholarship - 1980, 1981

GRANTS AND CONTRACTS (EXTRAMURAL)

Current funding

Source: NIH, National Human Genome Research Institute; U01 HG007269 (competitive renewal)
Title: Sparking Advancements in Genomic Medicine
Time Period: July 2018 to June 2023
Amount: \$1,646,289 (direct), \$2,396,110 (total)
Base funding for IGNITE Network
Role: Principal Investigator (Contact MPI; added Larisa Cavallari as MPI July 2020)

Source: NIH, National Human Genome Research Institute; U01 HG007269-07S1
Title: Sparking Advancements in Genomic Medicine
Time Period: July 2020 to June 2021- in NCE
Amount: \$1,457,314 (direct), \$2,185,969 (total)
Funding for leadership of IGNITE Pharmacogenetics Working Group
Year 7 funding for execution of GUARDD-US and ADOPT-PGx clinical trials
Role: Principal Investigator

Source: NIH, National Human Genome Research Institute; U01 HG007269-06S1
Title: Sparking Advancements in Genomic Medicine
Time Period: September 2019 to June 2020 (in NCE)
Amount: \$1,679,834 (direct), \$2,344,174 (total)
Funding for leadership of IGNITE Pharmacogenetics Working Group and
Year 6 funding for execution of GUARDD-US and ADOPT-PGx clinical trials
Role: Principal Investigator

Source: NIH, National Human Genome Research Institute; T32HG008958
Title: Training Program for Applied Research and Development in Genomic Medicine (PARADIGM)
Time Period: January 2018 to December 2022
Amount: \$1,349,472 (direct), \$1,451,296 (total)
Role: Contact MPI, with Tom Pearson

Source: American Heart Association Predoctoral Award (for Manasa Chekka)

Title: Personalizing thiazide therapy through clinical and microRNA biomarkers of response to thiazides
Time Period: January 2020 to December 2021
Amount: \$62,032
Role: Mentor

Previous funding (reverse chronological order)

Source: NIH, National Human Genome Research Institute; U01 HG007269-06S1
Title: Sparking Advancements in Genomic Medicine
Time Period: September 2019 to June 2020
Amount: \$50,492 (direct), \$77,000 (total)
Funding for leadership of IGNITE Pharmacogenetics Working Group
Role: Principal Investigator

Source: NIH, National Human Genome Research Institute; U01 HG007269
Title: Genomic Medicine Implementation: The Personalized Medicine Program
Time period: May 2013 to June 2019
Amount: \$2,504,467 (direct), \$3,749,997 (total)
Role: Principal Investigator

Source: NIH, National Human Genome Research Institute; U01 HG007269-04S1
Title: Genomic Medicine Implementation: The Personalized Medicine Program
Time period: May 2016 to June 2019
Amount: \$379,111 (direct), \$576,249 (total)
Role: Principal Investigator

Source: NIH, National Human Genome Research Institute; U01 HG007269-04S2
Title: Genomic Medicine Implementation: The Personalized Medicine Program
Time period: May 2017 to June 2019
Amount: \$612,215 (direct), \$930,567 (total)
Role: Principal Investigator

Source: UF CTSA Award (Pilot Funding) UL1TR001427
Title: Genomic-guided pain therapy in patients undergoing arthroplastic surgery
Time Period: May 2018- April 2019
Amount: \$75,000 (direct)
Role: MPI with Lari Cavallari

Source: Food and Drug Administration; U01-FD005235
Title: Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs
Time Period: September 2014- August 2018 (NCE)
Amount: \$1,555,246 (direct), \$2,332,870 (total)
Role: MPI with Larisa Cavallari (contact PI)

Source: NIH, National Institute of General Medical Sciences, U01 GM074492
Title: Pharmacogenomic Evaluation of Antihypertensive Responses
Time period: August 2010 to July 2017 (NCE)
Amount – current funding period: \$9,183,953 (direct); \$10,621,007 (total)
Lifetime of grant (2005 to 2015): \$18,453,012 (direct), \$21,190,060 (total)
Role: Principal Investigator

Source: Source: NIH, National Human Genome Research Institute; U01 HG007269-02S1
Title: Genomic Medicine Implementation: The Personalized Medicine Program
Time period: September 2014 to April 2017
Amount: \$194,056 (direct), \$242,218 (total)

Role: Principal Investigator

Source: Source: NIH, National Human Genome Research Institute; U01 HG007269-03S1
Title: Genomic Medicine Implementation: The Personalized Medicine Program
Time period: September 2015 to April 2017
Amount: \$39,450 (direct), \$59,175 (total)
Role: Principal Investigator

Source: NIH, National Institute of Neurological Disease and Stroke; R01 NS073346
Title: "Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy
Time period: March 2011 to February 2016 (NCE)
Amount: \$1,739,616 (direct), \$2,065,191 (total)
Role: Principal Investigator/MPI (contact PI); co-MPIs Oscar Benavente and Alan Shuldiner

Source: American Heart Association Predoctoral Fellowship Award
Title: "Using different omics for the identification of novel biomarkers of blood pressure response to antihypertensives"
Time Period: July 2014-June 2016 (award returned January 1, 2016 due to graduation of Dr. Shahin)
Amount: \$52,000 (total)
Role: Mentor to Mohamed Shahin

Source: NIH, National Heart Lung Blood Institute; U01 HL105198
Title: "PGRN Network Project: Translational Pharmacogenetics Project"
Time period: July 2011 to June 2015
Amount: \$240,000 (direct); \$351,600 (total)
Role: Local site PI

Source: NIH National Institute for General Medical Sciences, U01 GM092655
Title: "Expression Genetics in Drug Therapy"
Time Period: July 2010 to June 2015
Amount: \$85,324 (direct); \$125,000 (total)
Role: Subcontract PI, co-investigator (PI: Wolfgang Sadec, Ohio State University)

Source: NIH, National Center for Research Resources, UL1 TR 000064 (PI: D. Nelson)
Title: "University of Florida Clinical and Translational Science Award"
Time period: April 2009 to March 2014
Role: Strategic Planning Committee; Genotyping Core Director; Personalized Medicine Program Director – resigned funded roles on grant when appointed as dean

Source: NIH Clinical Trial; Data Coordinating Center and Contractor: University of Pennsylvania
Title: "Clarification of Optimal Anticoagulation Through Genetics"
Time period: March 2009 to March 2014
Amount: \$205,040 (direct), \$256,300 (total)
Role: Site Principal Investigator (Trial PI: S Kimmel); Executive Committee Vice Chair; Steering Committee member

Source: NIH National Heart Lung Blood Institute T32 HL083810 (PI: C. Baylis)
Title: "Multidisciplinary Training Program in Hypertension
Time period: April 2007 to March 2012
Role: Co-program director

Source: NIH, National Heart Lung Blood Institute, R01 HL090957
Title: "Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction"
Time period: September 2008 – June 2012
Role: Co-investigator

Source: NIH, National Institute of General Medical Sciences, RC2 GM092729-01
Title: Metabolomics Network for Drug Response Phenotype.
Time period: Oct 2009 to September 2011, NCE to September 2012
Amount: \$2,296,687 (total); Subaward: \$211,931 (direct); \$310,479 (total)
Role: Co-investigator (PI: RF Kaddurah-Daouk)

Source: NIH, National Center for Research Resources, 1UL1RR029890-03S2
Title: "University of Florida Clinical and Translational Science Award" – Personalized Medicine
Program administrative supplement
Time period: April 2011 to March 2012, NCE to March 2013
Amount: \$369,809 (direct); \$499,920 (total)
Role: Lead Investigator; (CTSA PI: D Nelson)

Source: NIH, National Institute of General Medical Sciences, U01 GM74492-05S109
Title: "Pharmacogenomic Evaluation of Antihypertensive Responses" supplement
Time period: October 2009 – September 2010; NCE through July 2011
Amount: \$132,947 (direct); \$149,635 (total)
Role: Principal Investigator

Title: AHA Predoctoral Fellowship; Fellow: Hrishikesh Navare, B.S., M.S.
Time period: July 2008-June 2009
Amount: \$43,540
Role: Mentor, graduate committee chair

Title: American Association of University Women Dissertation Fellowship; Fellow: Anzeela Schentrup,
Pharm.D., M.S.
Time period: July 2008 to June 2009
Amount: \$20,000
Role: Mentor, graduate committee chair

Title: Amgen Nephrology Fellowship; Fellow: Mohamed Shafiu, M.D.
Time period: July 2008-June 2009
Amount: \$40,000
Role: Co-mentor (with Rick Johnson, M.D.)

Source: NIH, National Heart Lung and Blood Institute, R01 HL74730
Title: "Hypertension pharmacogenetics"
Time period: September 2003 to August 2009
Amount: \$2,513,387 (direct), \$3,517,699 (total)
Role: Principal Investigator

Source: NIH, National Heart Lung and Blood Institute, K24 HL68834
Title: "β-receptor polymorphisms and cardiovascular pharmacogenomics"
Time period: July 2002 to June 2008
Amount: \$554,425 (direct), \$598,779 (total)
Role: Principal Investigator

Source: American Heart Association, Florida/Puerto Rico Affiliate
Title: AHA Predoctoral Fellowship; Fellow: Maximilian Lobmeyer, B.S.
Time period: July 2006-June 2008
Amount: \$43,540
Role: Mentor, graduate committee chair

Source: American Heart Association, Florida/Puerto Rico Affiliate
Title: AHA Predoctoral Fellowship; Fellow: Anzeela Schentrup, Pharm.D.
Time period: July 2006-June 2008

Amount: \$43,540
Role: Mentor, graduate committee chair

Source: American Heart Association, Florida/Puerto Rico Affiliate
Title: AHA Postdoctoral Fellowship; Fellow: Michael Pacanowski, Pharm.D.
Time period: July 2006-June 2008
Amount: \$93,224
Role: Mentor

Source: American Heart Association, Florida/Puerto Rico Affiliate
Title: AHA Postdoctoral Fellowship; Fellow: Jaekyu Shin, Pharm.D.
Time period: July 2005-June 2007
Amount: \$93,224
Role: Mentor

Source: NIH, National Heart Lung Blood Institute, R01 HL64924
Title: "Altered renin angiotensin system as a mechanism for coronary microvascular dysfunction"
Time period: May 1, 2001 to April 30, 2006
Amount: \$1,686,594 (direct); \$2,080,127 (total)
Role: Co-Investigator

Source: University of Florida Opportunity Fund
Title: "Pharmacogenomic Evaluation of Antihypertensive Responses" – Equipment grant
Time period: May 2005
Amount: \$95,000
Role: Co-principal Investigator

Source: Abbott Laboratories
Title: Heart Disease Outcomes: Impact of Genetics and Pharmacogenetics
Time period: July 2002 to June 2006
Amount: \$1,121,482 (direct); \$1,385,310 (total)
Role: Principal Investigator

Source: NIH, National Heart Lung and Blood Institute, R01 HL64691
Title: "β-adrenergic receptor polymorphisms and hypertension"
Time period: May 2000 to April 2005
Amount: \$500,000 (direct), \$722,500 (total)
Role: Principal Investigator

Source: Orchid Biosciences, Inc
Title: "β-adrenergic receptor polymorphisms and response to β-blockers in heart failure"
Time period: March 2001 to April 2004
Amount: \$248,298 (direct), \$303,058 (total)
Role: Principal Investigator

Source: NIH, National Heart Lung Blood Institute, Supplement to U01 HL69758
Title: "β-blocker pharmacogenetics in ethnic populations"
Time period: November 2001 to October 2003
Amount: \$99,988 (direct); \$144,983 (total)
Role: Principal Investigator of Supplement

Source: American Heart Association, Florida/Puerto Rico Affiliate
Title: AHA Postdoctoral Fellowship; Fellow: Issam Zineh, Pharm.D.
Time period: July 2002-June 2004
Amount: \$76,500
Role: Mentor

Source: American Foundation for Pharmaceutical Education
Title: Post-Pharm.D. Fellowship in Biomedical Research Sciences; Fellow: Christina L. Aquilante, Pharm.D.
Time period: July 2002-June 2004
Amount: \$55,000
Role: Mentor

Source: NIH, National Heart Lung Blood Institute, R03 HL65729
Title: "β-adrenoceptor genetic polymorphisms and obesity"
Time period: April 1, 2001 to March 31, 2003
Amount: \$100,000 (direct), \$144,500 (total)
Role: Principal Investigator

Source: Orchid Biosciences, Inc
Title: "Dobutamine pharmacogenetics"
Time period: March 2001 to February 2003
Amount: \$58,654 (direct), \$73,317 (total)
Role: Principal Investigator

Source: American Foundation for Pharmaceutical Education
Title: Post-Pharm.D. Fellowship in Biomedical Research Sciences; Fellow: Steven G. Terra, Pharm.D.
Time period: July 2001-June 2002
Amount: \$27,500
Role: Mentor

Source: University of Florida Opportunity Fund
Title: "Genetic and pharmacogenetic determinants of outcomes in cardiovascular disease"
Time period: March 2001-February 2003
Amount: \$175,000
Role: Co-principal Investigator

Source: American College of Clinical Pharmacy Research Institute
Title: Merck and Company Cardiovascular Fellowship - Fellow: Steven G. Terra, Pharm.D., BCPS
Time period: July 2000 to June 2001
Amount: \$22,500
Role: Preceptor (Mentor)

Source: American Foundation for Pharmaceutical Education
Title: Post-Pharm.D. Fellowship in Biomedical Research Sciences; Fellow: Larisa M. Humma, Pharm.D.
Time period: July 1999 to December 2000
Amount: \$55,000
Role: Mentor

Source: American Heart Association, Florida/Puerto Rico Affiliate
Title: "β₂-adrenoceptor polymorphisms and hypertension"
Time period: July 1999 to June 2001 (Award returned upon activation of R01)
Amount: \$100,000 (direct), \$110,000 (total)
Role: Principal Investigator

Source: American College of Clinical Pharmacy Research Institute
Title: Merck and Company Cardiovascular Fellowship - Fellow: Larisa M. Humma, Pharm.D.
Time period: accepted, then declined when AFPE fellowship (below) awarded
Amount: \$22,500

Role: Preceptor (Mentor)

Source: NIH, National Institute on Aging, R03 AG16854
Title: " β_2 -adrenoceptor polymorphisms and hypertension"
Time period: April 1999 to March 2000
Amount: \$50,000 (direct), \$72,250 (total)
Role: Principal Investigator

Source: Searle
Title: "The effects of Covera-HS on diurnal variation in forearm vascular resistance and blood pressure in hypertensive patients"
Time period: July 1997 to June 1999
Amount: \$101,000
Role: Principal Investigator

Source: NIH, National Institute of General Medical Sciences, R15 GM54297
Title: "Racial differences in propranolol 4-hydroxylation"
Time period: June 1996 to November 1998
Amount: \$70,000 (direct), \$99,750 (total)
Role: Principal Investigator

Source: Glaxo Regional Research Institute
Title: " β_2 -receptor sensitivity in black and white asthmatics"
Time period: July 1995 to May 1998
Amount: \$43,500
Role: Principal Investigator

Source: American Heart Association, Tennessee Affiliate Grant-in-Aid
Title: "Racial differences in α_1 - and β_2 -receptor mediated responses"
Time period: July 1994 to June 1996
Amount: \$50,000
Role: Principal Investigator

Source: American Heart Association, Tennessee Affiliate
Title: AHA Fellowship - Fellow: Kevin M. Sowinski, Pharm.D.
Time period: July 1993 to June 1995
Amount: \$37,608
Role: Sponsor (Mentor)

Source: National Heart Lung and Blood Institute, NIH, R15 HL50055.
Title: "Racial differences in propranolol kinetics and response"
Time period: May 1993 to April 1996
Amount: \$74,983 (direct), \$106,851 (total)
Role: Principal Investigator

Source: American College of Clinical Pharmacy Research Institute
Title: Genentech Cardiovascular Research Fellowship - Fellow: Wendell S. Akers, Pharm.D.
Time period: July 1993 to June 1994
Amount: \$19,500
Role: Preceptor (Mentor)

Source: Glaxo, Inc.
Title: "Racial differences in antihypertensive response to β -blockade"
Time period: December 1992 - November 1994
Amount: \$15,600
Role: Principal Investigator

Source: American Heart Association, Tennessee Affiliate Grant-in-Aid.
Title: "Racial differences in antihypertensive response to β -blockade"
Time period: July 1992 to June 1994
Amount: \$50,000
Role: Principal Investigator

Source: Baker Norton Pharmaceuticals, Inc.
Title: "Determination of verapamil and norverapamil enantiomer concentrations by HPLC"
Time period: April 1992 to December 1993
Amount: \$173,530
Role: Principal Investigator

Source: American Association of Colleges of Pharmacy, New Investigator Grants Program
Title: "Mechanisms of racial differences in propranolol pharmacokinetics"
Time period: March 1992 to February 1993
Amount: \$5,000
Role: Principal Investigator

Source: American Heart Association Tennessee Affiliate, New Investigator Award
Title: "Racial differences in β -blocker response: Examination of receptor mediated mechanisms"
Time period: July 1990 to June 1992
Amount: \$70,000
Role: Principal Investigator

Source: American College of Clinical Pharmacy Research Institute
Key Pharmaceuticals Hypertension Research Award.
Title: "Role of β -receptor density and function in the antihypertensive response to metoprolol"
Time period: July 1990 to June 1992
Amount: \$5,000
Role: Principal Investigator

PUBLICATIONS

Original Articles

1. Nahata MC, **Johnson JA**, Powel DA. Prophylactic antibiotics in plastic surgery. J Qual Assurance 1985;7:29-30.
2. Nahata MC, **Johnson JA**, Powel DA. Management of bronchiolitis. Clin Pharm 1985;4:299-303. PMID:3891201.
3. Nahata MC, **Johnson JA**, Powel DA. Management of pediatric patients with bronchiolitis in the emergency department. J Qual Assurance 1986;8:18-21.
4. Lima JJ, Binkley PF, **Johnson JA**, Leier CV. Dose- and time-dependent binding and kinetics of pindolol in patients with congestive heart failure. J Clin Pharmacol. 1986;26:253-57. PMID:3700683.
5. **(Johnson) Krukemyer JA**, Talbert RL. Lovastatin: A new cholesterol lowering agent. Pharmacotherapy 1987;7:198-210. PMID:3328165.
6. Lima JJ, **(Johnson) Krukemyer JA**, Boudoulas H. Drug- or hormone-induced adaptation: model of adrenergic hypersensitivity. J Pharmacokinetic Biopharm 1989;17:347-364. PMID:2572688.

7. **(Johnson) Krukemyer JA**, Boudoulas H, Binkley PF, Lima JJ. Biphasic pattern of hypersensitivity following acute propranolol withdrawal in normal subjects. Life Sci 1989;45:1547-1551. PMID:2586219.
8. **(Johnson) Krukemyer JA**, Boudoulas H, Binkley PF, Lima JJ. Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. Am Heart J 1990;120:572-579. PMID:2389694.
9. **(Johnson) Krukemyer JA**, Boudoulas H, Binkley PF, Lima JJ. Comparison of single dose and steady state nadolol plasma concentrations. Pharm Res 1990;7:953-956. PMID:2235896.
10. **(Johnson) Krukemyer JA**. Use of β -adrenergic blocking agents in congestive heart failure. Clin Pharm 1990;9:853-863. PMID:1980240.
11. **(Johnson) Krukemyer JA**, Boudoulas H, Binkley PF, Lima JJ. Relationship between lymphocyte β -receptor density and physiologic response during and after propranolol and nadolol treatment. Pharmacol (Life Sci Adv) 1990;9:385-91.
12. **Johnson JA**. Diastolic dysfunction in congestive heart failure. Clin Pharm 1991;10:850-861. PMID:1794221.
13. **Johnson JA**, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther. 1992;51:495-500. PMID:1587062.
14. Herring VL, **Johnson JA**. Direct high performance liquid chromatographic determination in urine of the enantiomers of propranolol and its major basic metabolite 4-hydroxypropranolol. J Chromatogr 1993;612:215-221. PMID:8468379.
15. **Johnson JA**. Racial differences in lymphocyte β -receptor sensitivity to propranolol. Life Sci. 1993;53:297-304. PMID:8392129.
16. **Johnson JA**, Robinson JL, Rich JM, Boudoulas H, Lima JJ. Differences in apparent sensitivities of chronotropy and inotropy to propranolol. Hellenic J Cardiol 1993;34:256-262.
17. **Johnson JA**, Burlew BS, Stiles RN. Racial differences in β -adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol. 1995;25:90-96. PMID:7723360.
18. **Johnson JA**, Akers WS, Miller ST, Applegate WB. Metoprolol minimizes nighttime blood pressure dip in hypertensive black males. Am J Hypertens 1995;8:254-259. PMID:7794574.
19. **Johnson JA**, Akers WS, Miller ST, Applegate WB. Lymphocyte β_2 -receptor activity, metoprolol kinetics and response to metoprolol in hypertensive black men. Pharmacotherapy 1995;15:150-157. PMID:7624261.
20. **Johnson JA**, Akers WS. Influence of metabolites on protein binding of verapamil enantiomers. Br J Clin Pharmacol. 1995;39:536-538. PMID:7669491.
21. Sowinski KM, Burlew BS, **Johnson JA**. Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy males. Clin Pharmacol Ther 1995;57:678-683. PMID:7781268.
22. Sowinski KM, Lima JJ, Burlew BS, Massie JD, **Johnson JA**. Racial differences in propranolol enantiomer kinetics following simultaneous IV and oral administration. Br J Clin Pharmacol 1996;42:339-346. PMID: 8877025.

23. **Johnson JA**, Burlew BS. Metoprolol metabolism via cytochrome P450 2D6 in ethnic populations. Drug Metab Dispos 1996;24:350-355. PMID:8820427.
24. **Johnson JA**, Livingston TN. Differences between blacks and whites in plasma protein binding of drugs. Eur J Clin Pharmacol 1997;51:485-488. PMID:9112064.
25. **Johnson JA**. Influence of race or ethnicity on pharmacokinetics of drugs. (Invited review) J Pharm Sci 1997;86:1328-1333. PMID:9423140.
26. Nguyen BNT, **Johnson JA**. The role of endothelin-1 in heart failure and hypertension. Pharmacotherapy 1998;18:706-719. PMID:9692645.
27. Mohamed MHN, Lima JJ, Eberle LV, Self TH, **Johnson JA**. Effects of gender and race on albuterol pharmacokinetics. Pharmacotherapy 1999;19:157-161. PMID:10030766.
28. Deitcher SR, Tuller J, **Johnson JA**. Intranasal DDAVP-induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity Factor VIII concentrates in severe hemophilia A patients. Haemophilia 1999;5:88-95. PMID:10215955.
29. Lima JJ, Thomason DB, Mohamed MHN, Eberle LV, Self TH, **Johnson JA**. Impact of genetic polymorphisms of the β_2 -adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999 May;65:519-25. PMID:10340917.
30. **Johnson JA**. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs (Invited review). Int J Clin Pharmacol Ther. 2000 Feb;38:53-60. PMID:10706191.
31. **Johnson JA**, Akers WS, Herring VL, Wolfe MS, Sullivan JM. Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy 2000;20:622-628. PMID:10853616.
32. Herring VL, **Johnson JA**. Simple method for determination of terbutaline plasma concentration by high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;741:307-312. PMID:10872601.
33. Lima JJ, Mohamed MHN, Self TS, Eberle LV, **Johnson JA**. Importance of β_2 adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. Pulm Pharmacol Ther 2000;13:127-134. PMID:10873550.
34. Nguyen BNT, Parker RB, Noujedehi M, Sullivan JM, **Johnson JA**. Effects of COER-verapamil on circadian pattern of forearm vascular resistance and blood pressure. J Clin Pharmacol 2000;40(12 Pt 2):1480-1487. PMID:11185670.
35. Humma LM, Farmerie WG, Wallace MR, **Johnson JA**. Sequencing of β_2 -adrenoceptor gene PCR products using *Taq* BigDye terminator chemistry results in inaccurate base-calling. Biotechniques. 2000;29:962-964, 966, 968 passim. PMID:11084855.
36. **Johnson JA**, Herring VL, Wolfe MS, Relling MV. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000;294:1099-1105. PMID:10945865.
37. Tuteja S, Alloway RR, **Johnson JA**, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001;71:1303-1307. PMID:11397967.
38. Evans WE, **Johnson JA**. Pharmacogenomics: the inherited basis for inter-individual differences in drug response. (Invited review) Annu Rev Genomics Hum Genet 2001;2:9-39. PMID:11701642.

39. Wang J, Humma LM, Mougey EB, David CJ, **Johnson JA**, Lima JJ, Sylvester JE. Determination of human β_2 -adrenoceptor haplotypes by denaturation selective amplification and subtractive genotyping. Am J Pharmacogenomics 2001;1:315-322. PMID:12083963.
40. Humma LM, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL, Farmerie WG, Wallace MR, Lewis JF, McNamara DM, Picoult-Newberg L, Pepine CJ, **Johnson JA**. Effects of β_1 -adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 2001;88:1034-1037. PMID:11704005.
41. **Johnson JA**. Drug target pharmacogenomics: an overview. (Invited review). Am J Pharmacogenomics 2001;1:271-281. PMID:12083959.
42. **Johnson JA**, Humma LM. Pharmacogenetics of cardiovascular drugs. (Invited review). Brief Funct Genomic Proteomic 2002;1:66-79. PMID:15251067.
43. Keltai M, **Johnson JA**, Kowey PR, Ried LD, Tueth M. INVEST substudies: design and patient characteristics. Clin Cardiol. 2001;24(11 Suppl):V9-11. PMID:11712776.
44. Humma LM, Richardson HE, Lewis JF, McGorray SP, Pepine CJ, **Johnson JA**. Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of β -blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study. Pharmacotherapy 2002;22:939-946. PMID:12173796.
45. Andrisin TE, Humma LM, **Johnson JA**. Collection of genomic DNA by noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 2002;22:954-960. PMID:12173798.
46. Terra SG, **Johnson JA**. Pharmacogenetics, pharmacogenomics and cardiovascular therapeutics: the way forward (Invited review) Am J Cardiovasc Drugs 2002;2:287-296. PMID:14727958.
47. **Johnson JA**, Evans WE. Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. (Invited review) Trends Mol Med 2002;8:300-305. PMID:12067617.
48. **Johnson JA**, Terra SG. β -adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics (Invited review). Pharm Res 2002;19:1779-1787. PMID:12523655.
49. **Johnson JA**, Bootman JL, Evans WE, Hudson RA, Knoell D, Simmons L, Straubinger RM, Meyer SM. Pharmacogenomics: A scientific revolution in pharmaceutical sciences and pharmacy practice. Report of the 2001/02 Academic Affairs Committee. Am J Pharmaceut Ed 2002;66:12S-15S.
50. Lou X-Y, Casella G, Littell RC, Yang MCK, **Johnson JA**, Wu R. A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis. Genetics 2003;163:1533-1548. PMID:12702696.
51. **Johnson JA**, Zineh I, Puckett BJ, McGorray SP, Pauly DF. β_1 -adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003;74:44-52. PMID:12844134.
52. Zineh I, Schofield RS, **Johnson JA**. The evolving role of nesiritide in advanced or decompensated heart failure. Pharmacotherapy 2003;23:1266-1280. PMID:14594345.
53. **Johnson JA**, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. (Invited review) Pharmacogenetics. 2003;13:525-534. PMID:12972951.

54. **Johnson JA.** Pharmacogenetics: potential for individualized drug therapy through genetics. (Invited review) Trends Genet 2003;19:660-666. PMID:14585618.
55. Aquilante CL, Lobmeyer MT, Langaee TY, **Johnson JA.** Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004;24:720-726. PMID:15222661.
56. Gong Y, Zhu Y, Wang Z, Zhao W, **Johnson JA,** Wu R. A statistical model for functional mapping of quantitative trait loci regulating drug response. Pharmacogenomics J 2004;4:315-321. PMID:15263889.
57. **Johnson JA,** Langaee TY, Zineh I, Beitelshees AL. Caution with β_1 -adrenergic receptor genotyping (Letter). Clin Pharmacol Ther 2004;76:186.
58. Aquilante CL, Humma LM, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, **Johnson JA.** The influence of sex and race on pharmacodynamics response to dobutamine during dobutamine stress echocardiography. Am J Cardiol 2004;94:535-538.
59. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004;44:1083-1105. PMID:15342610.
60. Liu T, **Johnson JA,** Casella G, Wu R. Sequencing complex diseases with HapMap. Genetics 2004;168:503-511. PMID:15454560, PMC1448119.
61. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Leeder JS, Phillips MS, Gelfand CA, **Johnson JA.** Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004;76:536-544. PMID:15592325.
62. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN, **Johnson JA.** β -adrenergic receptor polymorphisms and responses during the titration of metoprolol CR/XL in patients with heart failure. Clin Pharmacol Ther 2005;77:127-137. PMID:15735607.
63. Lima JJ, Beasley BNT, Parker RB, **Johnson JA.** A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24 hour ambulatory blood pressure. Int J Clin Pharmacol Ther 2005;43:187-194. PMID:15966465.
64. Lin M, Aquilante CL, **Johnson JA,** Wu R. Sequencing drug response with HapMap. Pharmacogenomics J 2005;5:149-156. PMID:15782224.
65. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, **Johnson JA.** β_1 -adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β -blocker therapy. Pharmacogenet Genomics 2005;15:227-234. PMID:15864115.
66. **Johnson JA,** Cavallari LH. Cardiovascular pharmacogenomics. (Invited review). Exp Physiol 2005;90:283-289. PMID:15778411.
67. Terra SG, McGorray SP, McNamara DM, Cavallari LH, Wu R, Walker J, Wallace MR, Johnson BD, Bairey Merz CN, Sopko G, Pepine CJ, **Johnson JA.** Association between β -adrenergic receptor polymorphisms and their G-protein coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes 2005;29:746-754. PMID:15917856.
68. **Johnson JA,** Turner ST. Hypertension Pharmacogenomics: current status and future directions. (Invited review) Curr Opin Mol Ther 2005;7:218-225. PMID:15977418.

69. Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, **Johnson JA**. Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail 2006;12:171-176. PMID:16624680.
70. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, **Johnson JA**. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1 and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006;79:291-302, Epub Feb 28. PMID:16580898.
71. Beitelshes AL, Zineh I, Puckett BJ, Yarandi HN, Pauly DF, **Johnson JA**. Genetic determinants of β -blocker response: influence of phenotype and pharmacokinetics on drug target pharmacogenetics. Pharmacogenom J 2006;6:174-178.
72. Lin M, Wu R, **Johnson JA**. A bivariate functional mapping model for identifying haplotypes that control drug response for systolic and diastolic blood pressures. Pac Symp Biocomput 2006;572-583. PMID:17094270.
73. Beitelshes AL, Zineh I, Puckett BJ, Yarandi HN, Pauly DF, **Johnson JA**. Discordant β -blocker effects on clinic, ambulatory, resting and exercise hemodynamics in patients with hypertension. Pharmacotherapy 2006;26:1247-1254. PMID:16945046.
74. Zineh I, **Johnson JA**. Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Expert Opin Pharmacother 2006;7:1417-1427. PMID:16859425.
75. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring H, Shuldiner AR, Weinshilboum RM, Weiss ST, for the Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-757. PMID:17116919, PMC5006954.
76. Wang D, Papp AC, Binkley PF, **Johnson JA**, Sadee W. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1c (*CACNA1C*) in human heart tissues. Pharmacogenet Genomics 2006;16:735-745. PMID:17001293, PMC2688811.
77. Gong Y, Beitelshes AL, Wessel J, Langaee TY, Schork NJ, **Johnson JA**. Single nucleotide polymorphism discovery and haplotype analysis of Ca^{2+} -dependent K^{+} channel beta-1 subunit. Pharmacogenet Genomics 2007;17:267-75. PMID:17496725, PMC2713575.
78. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi HN, Schofield RS, Aranda JM, Hill JA, Pauly DF, **Johnson JA**. Relation of β_2 -adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 2007;99:250-55.
79. Lobmeyer MT, Gong Y, Terra SG, Beitelshes AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Patterson JH, Adams KF, Hill JA, Aranda JM, **Johnson JA**. Synergistic polymorphisms of β_1 - and α_{2c} -adrenergic receptors and the influence on left ventricular ejection fraction response to β -blocker therapy in heart failure. Pharmacogenet Genomics 2007;17:277-282. PMID:17496726.
80. Wu R, Li H Lin M, Terra SG, Pepine CJ, McGorray SP, Johnson DB, **Johnson JA**. Epistatic control of human obesity as revealed by linkage disequilibrium mapping: a report from the NHLBI-sponsored WISE Study. Curr Genom 2007;7:463-468.
81. Langaee TY, Gong Y, Yarandi H, Katz D, Cooper-DeHoff RM, Pepine CJ, **Johnson JA**. Association of *CYP3A5* polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007;81:386-391. PMID:17339868.

82. Gaedigk A, Ndjountsche L, Divakaran K, Bradford LD, Zineh I, Oberlander TF, Brousseau DC, McCarver G, **Johnson JA**, Alander SW, Riggs W, Leeder JS. Cytochrome P4502D6 (*CYP2D6*) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007;81:242-251. PMID:17259947.
83. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan EM, Flockhart DA, **Johnson JA**, Krauss RM, Kroetz DL, McLeod HL, Ratain MJ, Relling MV, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tyndale RF, Weinshilboum RM, Weiss ST, Zineh I for the Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007;81:328-345. PMID:17339863.
84. Beitelshes AL, Gong Y, Wang D, Schork NJ, Cooper-DeHoff RM, Langaee TY, Shriver MJ, Sadee W, Knot HJ, Pepine CJ, Johnson JA, for the INVEST Investigators. *KCNMB1* genotype influences response to verapamil SR and adverse outcomes in the International Verapamil SR/Trandolapril Study (INVEST). Pharmacogenet Genomics 2007;17:719-729. PMID:17700361, PMC2713584.
85. Shin J, **Johnson JA**. Pharmacogenetics of beta-blockers. (Invited review). Pharmacotherapy 2007;27:874-887. PMID:17542770, PMC2735790.
86. Brunner M, Cooper-DeHoff RM, Gong Y, Karnes JH, Langaee TY, Pepine CJ, **Johnson JA**. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril Study [INVEST]). Am J Cardiol 2007;99:1549-54, Epub Apr 16. PMID:17531579, PMC2720593.
87. Pacanowski MA, **Johnson JA**. PharmGKB submission update: IX. *ADRB1* gene summary. Pharmacol Rev 2007;59:2-4. PMID:17329544.
88. Lin M, Hou W, Li HY, **Johnson JA** and Wu RL. Modeling sequence-sequence interactions of drug response. Bioinformatics 2007;23:1251-1257, Epub Mar 28. PMID:17392331.
89. Levin GM, Bowles TM, Ehret MJ, Langaee TY, Tan JY, **Johnson JA**, Millard WJ. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 2007;11:155-160. PMID:17570737.
90. Shin J, Kline S, Moore M, Gong Y, Bhandari V, Schmalfuss CM, **Johnson JA**, Schofield RS. Association of diurnal blood pressure pattern with risk for hospitalization or death in men with heart failure. J Card Fail 2007;13:656-662. PMID:17923358, PMC2655230.
91. Aquilante CL, Cavallari LH, Yarandi HN, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, **Johnson JA**. Beta-adrenergic receptor polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. Pharmacogenomics J. 2008;8:408-415, Epub Feb 5. PMID:18253135.
92. **Johnson JA**, Moore MJ, Shin J, Frye RF. A summer research training program to foster PharmD students' interest in research. Am J Pharm Educ 2008;72:23. PMID:18483591, PMC2384198.
93. Shin J, **Johnson JA**. Beta-blocker pharmacogenetics in heart failure. (Invited Review) Heart Fail Rev 2010;15:187-196, Epub Apr 24. PMID:18437562, PMC2851851.
94. Hassan M, York KM, Li H, Li Q, Gong Y, Langaee TY, Fillingham RB, **Johnson JA**, Sheps DS. Association of B1-adrenergic receptor polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease. Arch Intern Med 2008;168:763-770. PMID:18413560.
95. Gage BF, Eby C, **Johnson JA**, Rieder MJ, Ridker PM, Rettie AE, Aquilante CL, Milligan PE, Deych E, Grosso L, Marsh S, Langaee TY, Farnett LE, Voora D, Veenstra DL, Glynn R, McLeod HL. Use

- of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-331, Epub Feb 27. PMID:18305455, PMC2683977.
96. Lima JJ, Mohapatra S, Feng H, Lockey R, Jones A, Castro M, Irvin C, **Johnson JA**, Wang J, Sylvester JE. A polymorphism in the *NPPA* gene associates with asthma. Clin Exp Allergy 2008;38:1117-1123, Epub Feb 20. PMID: 18294255.
97. Caldwell MD, Awad T, **Johnson JA**, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King C, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Zhang KQ, Berg RL, Burmester JK. *CYP4F2* genetic variant alters required warfarin dose. Blood 2008;111:4106-4112, Epub Feb 4. PMID:18250228, PMC2288721.
98. Kamdem LK; Hamilton L; Cheng C; Liu W; Yang W; **Johnson JA**; Pui CH, Relling MV. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2008;18:507-514. PMID:18496130.
99. Pacanowski MA, Zineh I, Li H, Johnson BD, Cooper-DeHoff RM, Bittner V, McNamara DM, Sharaf BL, Bairey Merz CN, Pepine CJ, **Johnson JA**. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. J Transl Med 2008;6:11, Epub Mar 10. PMID:18331634, PMC23295991.
100. Gerhard T, Gong Y, Beitelshes AL, Lobmeyer M, Cooper-DeHoff RM, Langaee TY, Shriver MD, Schork NJ, Pepine CJ, **Johnson JA**, for the INVEST Investigators. α -adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENETic Substudy of the INternational VErapamil SR-trandolapril Study (INVEST-GENES). Am Heart J 2008;156:397-404, Epub Jun 20. PMID:18657677, PMC2547143.
101. **Johnson JA**. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. (Invited review). Circulation 2008;118:1383-1393. PMID:18809808, PMC2730023.
102. Weiss ST, McLeod HL, Flockhart DA, Dolan E, Benowitz NL, **Johnson JA**, Ratain MJ, Giacomini KM on behalf of the Pharmacogenetics Research Network Investigators. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008;7:568-574, Epub Jun 20. PMID:18587383, PMC2682785.
103. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, **Johnson JA**, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS. Two *CES1* gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008;82:1241-1248, Epub May 15. PMID:18485328, PMC2427248.
104. Oner Ozgon G, Langaee TY, Feng H, Buyru N, Ulutin T, Ozbek U, Hatemi AC, Siva A, Saip S, **Johnson JA**. *VKORC1* and *CYP2C9* polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 2008;64:889-894, Epub June 10. PMID:18542936.
105. Wang D, Chen H, Momary KM, Cavallari LH, **Johnson JA**, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (*VKORC1*) affects gene expression and warfarin dose requirement. Blood 2008;112:1013-1021, Epub Jun 3. PMID:18523153, PMC2515137.
106. Cooper GM, **Johnson JA**, Langaee TY, Feng H, Stanaway IB, Schwarz U, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Reider MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008 Aug;112:1022-10277, Epub Jun 5. PMID:18535201; PMC2515139.

107. Shin J, Pauly DF, **Johnson JA**, Frye RF. Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;871:130-134, Epub Jul 5. PMID:18639501, PMC3832059.
108. Pacanowski MA, Gong Y, Cooper-DeHoff RM, Schork NJ, Shriver MD, Langae TY, Pepine CJ, **Johnson JA** for the INVEST Investigators. β -adrenergic receptor gene polymorphisms and β -blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008;84:715-721, Epub July 9. PMID:18615004, PMC2675574.
109. Johnson AD, Gong Y, Wang D, Langae TY, Shin J, Cooper-DeHoff RM, Schork NJ, Binkley P, Pepine CJ, **Johnson JA**, Sadee W. Promoter polymorphisms in *ACE* (angiotensin-I converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther 2009;85:36-44, Epub 2008 Oct 22. PMID:18946466, PMC2709290.
110. Dungan JR, Conley YP, Langae TY, **Johnson JA**, Kneipp SM, Hess PJ, Yucha CB. Altered beta-2 adrenergic receptor gene expression in human clinical hypertension. Biol Res Nurs 2009;11:17-26, Epub Mar 1. PMID:19254913, PMC2805083.
111. **Johnson JA**, Boerwinkle E, Zineh I, Chapman AB, Bailey KR, Cooper-DeHoff RM, Gums JG, Curry RW, Gong Y, Beitelshes AL, Schwartz GL, Turner ST. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Am Heart J 2009;157:442-449. PMID:19249413, PMC2671287.
112. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, **Johnson JA** for the International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009 ;360:753-764. PMID:19228618, PMC2722908.
113. Zhu HJ, Appel DI, **Johnson JA**, Chavin KD, Markwitz JS. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol 2009;77:1266-1272, Epub Jan 6. PMID:19185566.
114. Schentrup AM, Allayee H, Lima JJ, **Johnson JA**, Langae TY. Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (*ALOX5*) by pyrosequencing assay. Genet Test Mol Biomarkers 2009;13:361-365. PMID:19473080, PMC2998028.
115. Pacanowski MA, Zineh I, Cooper-DeHoff RM, Pepine CJ, **Johnson JA**. Genetic and pharmacogenetic associations between *NOS3* polymorphisms, blood pressure, and cardiovascular events in hypertension. Am J Hypertens 2009;22:748-753, Epub Apr 30. PMID:19407804, PMC2803093.
116. Beitelshes AL, Navare H, Wang D, Gong Y, Wessel J, Moss J, Langae TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, **Johnson JA**. *CACNA1C* gene polymorphisms, cardiovascular disease outcomes and treatment response. Circ Cardiovasc Genet 2009;2:362-370, Epub Jun 3. PMID: 20031608, PMC2761685. **Selected as top paper from issue (see Circulation 2011;124:e179)**
117. **Johnson JA**, Gong Y, Bailey K, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshes AL, Boerwinkle E, Gums JG. Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clin Pharmacol Ther 2009;86:533-539, Epub July 1. PMID:19571804, PMC2765524.

118. Gong Y, Handberg EM, Gerhard T, Cooper-DeHoff RM, Ried DL, **Johnson JA**, Pepine CJ. Systolic blood pressure and subjective well-being in patients with coronary artery disease. Clin Cardiol 2009;32:627-632, Epub Aug 26. PMID:19711440, PMC2810952.
119. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-DeHoff RM, Schwartz GL, Bailey K, Chapman AB, Hall KL, Feng H, Boerwinkle E, **Johnson JA**, Gums JG. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Pharmacotherapy 2009;29:1157-1165. PMID:19792989, PMC2777624.
120. Cooper-DeHoff RM, Wen S, Beitelshes AM, Zineh I, Gums JG, Turner ST, Gong Y, Hall KL, Parekh V, Chapman AB, Boerwinkle E, **Johnson JA**. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010;55:61-68, Epub 2009 Nov 18. PMID:19917874, PMC2811061. **Selected as journal's top paper in population science for 2010.**
121. Beitelshes AL, Gong Y, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, **Johnson JA**. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorothiazide. J Clin Hypertens 2010;12:14;-21. PMID:20047624, PMC2841560.
122. Cavallari LH, Langae TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MAG, Patel SR, **Johnson JA**. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010;87:459-464, Epub Jan 13. PMID:20072124.
123. Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, **Johnson JA**, Klein TE, Altman RB. Very Important Pharmacogene Summary *ADRB2*. Pharmacogenet Genom 2010;20:64-69, Epub Nov 18. PMID:19927042, PMC3098753.
124. Limdi NA, Wadelius M, Cavallari LH, Eriksson N, Crawford DC, Lee MTM, Chen CH, Motsinger-Reif A, Sagreya H, Liu N, Wu AHB, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, **Johnson JA**, Klein TE and Wagner MJ on behalf of the IWPC. Warfarin Pharmacogenetics: a single *VKORC1* polymorphism is predictive of dose across three racial groups. Blood 2010;115:3827-3834, Epub Mar 4. PMID:20203262, PMC2865873.
125. Turner ST, Schwartz GL, Chapman AB, Beitelshes AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, **Johnson JA**, Bailey KR. Plasma renin activity predicts blood pressure responses to β -blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010;23:1014-1022, Epub Aug 19. PMID:20725057, PMC2941699.
126. Navare HA, Frye RF, Cooper-DeHoff RM, Shuster JJ, Hall K, Schmidt SO, Turner ST, **Johnson JA**. Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. Pharmacotherapy 2010;30:872-878. PMID:20795842, PMC2999810.
127. Duarte JD, Lobmeyer MT, Wang Z, Chapman AB, Gums JG, Langae TY, Boerwinkle E, Turner ST, **Johnson JA**. Lack of association between polymorphisms in *STK39*, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics 2010;20:516-19, Epub Jun 15. PMID:20555294, PMC2922977.
128. Niu Y, Gong Y, Langae TY, Moss JI, Beitelshes AL, Rhonda M. Cooper-Dehoff RM, Pepine CJ, **Johnson JA** for INVEST investigators. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the International Verapamil SR-trandolapril Study-GENETic Substudy (INVEST-GENES). Circ Cardiovasc Genet 2010;3:548-555. PMID:21156931, PMC3060561. **Selected as top paper from issue (see Circulation 2011;124:e179).**

129. Beitelshes AL, **Johnson JA**, Hames M, Gong Y, Cooper-DeHoff RM, Cresci S, Wu J, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS ONE 2010;5:e15180. PMID:21170323, PMC3000815.
130. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, **Johnson JA**, Ellenberg JH, Anticoagulation through genetics investigators CC. Statistical design of personalized medicine interventions: the clarification of optimal anticoagulation through genetics (COAG) trial. Trials 2010;11:108, Epub Nov 17. PMID:21083927, PMC3000386.
131. Finkelman BS, Gage, BF, **Johnson JA**, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011;57:612-618. PMID:21272753, PMC3107000.
132. Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, Cooper-DeHoff RM, Beitelshes AL, Bailey KR, Boerwinkle A, Pepine CJ, **Johnson JA**. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genom 2011;21:42-49, Epub Nov 30 2010. PMID:21127457, PMC3028503.
133. Shahin MH, Khalifa SI, Gong Y, Sallam TH, Hammad LN, El Shafey M, Mohamed MEF, Langaee TY, **Johnson JA**. Genetic and non genetic factors associated with warfarin dose requirements in Egyptian Patients. Pharmacogenet Genomics 2011;21(3):130-135, Epub Jan 11. PMID:21228733, PMC3038469.
134. Lanktree MB, Gui Y, Murtaza M, Bailey SD, Onland NC, Glessner JT, Ongen H, Rajagopalan R, Johnson T, Shen H, Lettre G, Nelson CP, Klopp N, Baumert J, Padmanabhan S, Pankratz N, Pankow J, Shah S, Taylor K, Barnard J, Maloney C, Lobmeyer MT, Stanton A, Zafarmand MH, Romaine S, Mehta A, van Iperen EPA, Gong Y, Price T, Smith E, Kim CE, Atwood LD, Bailey KM, Bhatt D, Bauer F, Behr ER, Bhangale T, Boer JMA, Bohm BO, Bradfield JP, Brown M, Braund PS, Burton PR, Carty C, Chandrupatla HR, Connell J, Dalgeorgou C, Drenos F, Elbers CC, Fang JC, Fox CS, Frackelton EC, Fuchs B, Gibson Q, Geiger C, Hastie C, Howard PH, Huang GH, Johnson WC, Kleber M, Kimmel SE, Kooperberg C, Ky B, LaCroix A, Lanken P, Lathrop M, Li M, Marshall V, Melander O, Mentch FD, Meyer N, Monda KL, Montpetit A, Murugesan G, Nakayama K, Nondahl D, Onipinla A, Rafelt S, Newhouse SJ, Otieno FG, Patel S, Putt ME, Rodriquez S, Safa RN, Sawyer DB, Schreiner PJ, Sweitzer NK, Thomas KA, Thorand B, Tischfield S, Tobin M, Tomaszewski M, Verschuren WMM, Wallace C, Winkelmann B, Zhang H, Zheng D, Zhang L, Zmuda JM, Balmforth AJ, Danish J, Day IN, de Bakker PIW, Delles C, Duggan D, Hingorani AD, Hirschhorn JN, Hofker MH, Farrall M, Humphries SE, Klein BEK, Klein R, Kivimaki M, Lawlor DA, Marchant K, Mega JL, Mitchell BD, Morrow DA, Palmieri J, Redline S, Shields DC, Shuldiner AR, Sleiman PM, Smith GD, Lange LA, Jamshidi Y, Christiani DC, Hall A, Doevendans PA, Christie J, Illig T, Dorn II GW, Cappola TP, Boerwinkle E, Sever P, Rader DJ, Reilly MP, Schadt E, Caulfield M, Talmud PJ, Topol E, Peden J, Engert JC, Wang K, Dominiczak A, Silverstein RL, Sabatine MS, Wijmenga C, Marz W, Trip M, Saleheen D, Chuickshanks KJ, O'Connell JR, **Johnson JA**, Jarvik GP, Samani NJ, Papanicolaou GJ, Watkins H on behalf of PROCARDIS, Grant SFA, Munroe PB, Koenig W, North KE, Gaunt TR, Anand SS, van der Schouw YT, Kumari M on behalf of the Whitehall II Study and the WHII 50K group, Soranzo N, FitzGerald GA, Reiner A, Hegele R, Hakonarson H, Keating BJ. Meta-analysis of dense gene-centric association studies reveals common and uncommon variants associated with height. Am J Hum Genet 2011;88:6-18, Epub 2010 Dec 30. PMID:21194676, PMC3014369.
135. Gong Y, Beitelshes AL, Langaee TY, Cooper-DeHoff RM, Wu J, Spertus JA, Province MA, **Johnson JA**. Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet 2011;4:169-178, Epub Mar 3. PMID:21372283, PMC3101633. **Included in Circulation editors Top Articles in Genetic Epidemiology – CV Risk Factors. (Circ Cardiovasc Genet 2012;5:e38-e47.)**

136. **Johnson JA**, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. (Invited State of the Art review) Clin Pharmacol Ther 2011;89(3):366-378, Epub Feb 2. PMID:21289619, PMC3110683.
137. Price ET, Pacanowski MA, Martin MA, Cooper-DeHoff RM, Pepine CJ, Zineh I, **Johnson JA**. Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics 2011;21:333-340. PMID:21562465, PMC3093636.
138. Davis HM, **Johnson JA**. Heart failure pharmacogenetics: past, present and future. (Invited review). Curr Cardiol Rep 2011;13:175-184, Epub Mar 18. PMID:21416259, PMC3086976.
139. Shin J, Pauly DF, Pacanowski MA, Frye RF, **Johnson JA**. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy 2011;31 (10):942-950. PMID:21950641, PMC3712822.
140. Shroads AL, Langaee TY, Coats BS, Kurtz TL, Bullock JR, Weithorn D, Gong Y, Wagner DA, Ostrov DA, **Johnson JA**, Stacpoole PW. Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 2012; 52:837-849; Epub 2011 Jun 3. PMID:21642471, PMC3786668.
141. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, **Johnson JA**, Roden DM, Klein TE, Shuldiner AR. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for cytochrome P450-2C19 (*CYP2C19*) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-332, Epub Jun 29. PMID:21716271, PMC3234301.
142. Roden DM, **Johnson JA**, Kimmel SE, Krauss RM, Wong Medina M, Shuldiner AR, Wilke RA. Cardiovascular pharmacogenomics. (Invited review) Circ Res 2011;109:807-820. PMID:21921273, PMC3201825.
143. Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P, **Johnson JA**, Epstein BJ. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens 2011;13:917-924, Epub Nov 7. PMID:22142351
144. **Johnson JA**, Cavallari LH, Beitelshes AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. (Invited review) Clin Pharmacol Ther 2011;90:519-531, Epub Sept 14. PMID:21918509, PMC3190669.
145. **Johnson JA**, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MTM, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for *CYP2C9* and *VKORC1* genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-629, Epub Sept 7. PMID:21900891, PMC3187550.
146. Nelson DR, Conlon M, Baralt C, Johnson JA, Clare-Salzler MJ, Rawley-Payne M. University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine. Clin Transl Sci 2011;4:400-402, Epub Nov 9. PMID:22212220, PMC3666095.
147. Smith SM, Gong Y, Turner ST, Cooper-DeHoff RM, Beitelshes AL, Chapman AB, Boerwinkle E, Bailey K, **Johnson JA**, Gums JG. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens 2012;25:359-365, Epub 2011 Nov 17. PMID:22089105, PMC3288583.
148. Duarte JD, Turner ST, Tran BA, Chapman AB, Bailey KR, Gong Y, Gums JG, Langaee TY, Beitelshes AL, Cooper-DeHoff RM, Boerwinkle E, **Johnson JA**. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential *YEATS4*

- expression. Pharmacogenomics J 2013;13(3):257-263, Epub 2012 Feb 12. PMID:22350108, PMC3360116.
149. Wang D, Sun X, Gong Y, Gawronski BE, Langaee TY, Shahin MHS, Khalifa SI, **Johnson JA**. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers. Drug Metab Dispos 2012;40:884-891, Epub Jan 30. PMID:22289258, PMC3336799.
150. **Johnson JA**, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012;91:774-776. PMID:22513313, PMC3382015.
151. Le MT, Frye RF, Rivard CJ, Cheng J, McFann KK, Segal MS, Johnson RJ, **Johnson JA**. Effects of high fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism 2012;61:641-651, Epub Dec 5 2011. PMID:22152650, PMC3306467.
152. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-Dehoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuys-Pederson LA, Glessner JT, Goel A, Gong Y, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langaee TY, Lawlor DA, Li M, Lobbmeyer MT, Maitland-van der Zee AH, Meijis MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolffenbuttel BH, Young T, Zafarmand MH, Zmuda JM; the Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Caulfield M, Dominiczak A, Shields DC, Bhatt D, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW 2nd, Farrall M, Fitzgerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, **Johnson JA**, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs F, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012;90:410-425, Epub Feb 9. PMID:22325160, PMC3309185.
153. Shafiu M, Johnson RJ, Turner ST, Langaee T, Gong Y, Chapman AB, Gums JG, **Johnson JA**. Urate transporter gene *SLC22A12* polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res 2012;35:477-482, Epub Jun 8. PMID:22688828, PMC3480975.
154. Papp AC, Pinsonneault JK, Wang D, Newman LC, Gong Y, **Johnson JA**, Pepine CJ, Kumari M, Hingorani AD, Talmud PJ, Shah S, Humphries SE, Sadee W. Cholesteryl ester transfer protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One 2012;7:e31930, Epub Mar 5. PMID: 22403620, PMC3293889.
155. Ashley E, Hershberger RE, Caleshu C, Ellinor PT, Garcia JGN, Herrington D, Ho C, **Johnson JA**, Kittner S, MacRae CA, Mudd G, Rader DJ, Roden DM, Scholes D, Seilke F, Towbin J, Vaneyk J, Worrall BB. Genetics and cardiovascular disease: A policy statement from the American Heart Association. Circulation 2012;126:142-157, Epub May 29. PMID:22645291, PMC3721666.

156. **Johnson JA.** Advancing management of hypertension through pharmacogenomics. (Invited mini-review). Ann Med 2012;44:s17-22. PMID:22713143, PMC3686275.
157. Turner ST, Schwartz GL, Chapman AB, Beitelshes AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, **Johnson JA**, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med 2012;10:47. PMID:22413836, PMC3342146.
158. Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Beitelshes AL, Bailey KR, Fillingim R, Kone BC, **Johnson JA.** Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure response to hydrochlorothiazide. J Transl Med 2012;10:56, Epub Mar 22. PMID:22440088, PMC3320544.
159. **Johnson JA** Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012;92:437-439, Epub Aug 22. PMID: 22910441, PMC3454443.
160. Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Del-Aguila J, Boerwinkle EA, Pepine CJ, Turner ST, **Johnson JA**, Cooper-DeHoff RM. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J 2013;13:430-436, Epub Aug 21, 2012. PMID:22907731, PMC3529742.
161. Gerhard T, Delaney JAC, Shuster J, Brumback B, **Johnson JA**, Pepine C, Winterstein AG. Comparing marginal structure models to standard methods for estimating treatment effects of antihypertensive combination therapy. BMC Med Res Methodol 2012;12:119. PMID:22866767, PMC3573973.
162. Vandell AG, Lobmeyer MT, Gawronski BT, Langaee TY, Gong Y, Gums JG, Beitelshes AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, **Johnson JA.** G protein receptor kinase 4 polymorphisms: beta-blocker pharmacogenetics and treatment related outcomes in hypertension. Hypertension 2012;60:957-964, Epub Sept 4. PMID:22949529, PMC3462355.
163. Lesko LJ, **Johnson JA.** Academia at the crossroads: Education and training in pharmacogenomics. Personalized Medicine 2012;9:497-506.
164. Asselbergs FW, Guo Y, van Iperen EPA, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera Castillo B, Appelman YE, Barnard J, Baumert J, Beitelshes AL, Bhangale TR, Ida Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, Liu K, McDonough CW, Meijs MFL, Middelberg RPS, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SPR, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JMA, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, Cooper-DeHoff RM, Cupples LA, deJong JS, Delles C, Duggan D, Fornage M, Furlong CE, Glazer N, Gums JG, Hastie C, Holmes MV, Illig T, Kirkland SA, Kivimaki M, Klein R, Klein BE, Kooperberg C, Kottke-Marchant K, Kumari M, LaCroix AZ, Mallela L, Murugesan G, Ordovas J, Ouwehand WH, Post W, Saxena R, Scharnagl H, Schreiner PJ, Shah T, Shields DC, Shimbo D, Srinivasan SR, Stolk RP, Swerdlow DI, Taylor Jr. HA, Topol EJ, Toskala E, van Pelt JL, van Setten J, Yusuf S, Whittaker JC, Zwinderman AH, LifeLines Cohort Study, Anand SS, Balmforth AJ, Berenson GS, Bezzina CR, Boehm BO, Boerwinkle E, Casas JP, Caulfield MJ, Clarke R, Connell JM, Cruickshanks KJ, DavidsonKW, Day INM, de Bakker PIW, Doevendans PA, Dominiczak AF, Hall AS, Hartman CA, Hengstenberg C, Hillege HL, Hofker MH, Humphries SE, Jarvik GP, **Johnson JA**, Kaess BM, Kathiresan S, Koenig W, Lawlor DA, März W, Melander O, Mitchell BD, Montgomery GW, Munroe PB, Murray SS, Newhouse SJ, Onland-Moret NC, Poulter

- N, Psaty B, Redline S, Rich SS, Rotter JI, Schunkert H, Sever P, Shuldiner AR, Silverstein RL, Stanton A, Thorand B, Trip MD, Tsai MY, van der Harst P, Van Der Schoot E, van der Schouw YT, Monique Verschuren WM, Watkins H, Wilde AAM, Wolffenbuttel BHR, Whitfield JB, Hovingh HK, Ballantyne CM, Wijmenga C, Reilly MP, Martin NG, Wilson JG, Rader DJ, Samani NJ, Reiner AP, Hegele RA, Kastelein JJP, Hingorani AD, Talmud PJ, Hakonarson H, Elbers HC, Keating BJ, Drenos F. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet* 2012;91:823-838, Epub Oct 11. PMID:23063622, PMC3487124.
165. Danese E, Montagnana M, **Johnson JA**, Rettie A, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Rieder MJ, Halperin JL, Langaee T, Siguret V, Lorient MA, Sagreya H, Altman RB, Shahin MHA, Khalifa SI, Chowbay B, Suriapranata IV, Teichert M, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MTM, Pengo V, Guidi GC, Minuz P, Fava C. Impact of the *CYP4F2* p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. *Clin Pharmacol Ther* 2012;92:746-756, Epub Nov 7. PMID:23132553, PMC3731755.
166. Gong Y, McDonough CW, Wang Z, Cooper-DeHoff RM, Langaee TY, Beitelshes AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, **Johnson JA**. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Circ Cardiovasc Genet* 2012;5:686-691, Epub Oct 19. PMID:23087401, PMC3529147.
167. Chan KN, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, Gong Y, Pepine C, Laxton RC, Wittaker JC, Wilson Tang WH, **Johnson JA**, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye S. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden – a collaborative meta-analysis. *J Am Coll Cardiol* 2013;61:957-70, Epub Jan 23. PMID:23352782, PMC3653306.
168. Guo Y, Lanktree MB, Taylor KC, Fairfax BP, Elbers CC, Barnard J, Farrall M, Padmanabhan S, Baumert J, Castillo BA, Gaunt TR, Gong Y, Rajagopalan R, Romaine SP, Kumari M, Rafelt S, Smith EN, Li YR, Sivapalaratnam S, van Iperen EP, Speliotes EK, Toskala E, Zhang L, Ochs-Balcom HM, Bhangale TR, Chandrupatla HR, Drenos F, Gieger C, Gupta J, Johnson T, Kleber ME, Makino S, Mangino M, Meng Y, Nelson CP, Pankow JS, Pankratz N, Price TS, Shaffer J, Shen H, Tischfield S, Tomaszewski M, Atwood LD, Bailey KM, Balasubramanyam A, Baldwin CT, Basart H, Bauer F, Behr ER, Beitelshes AL, Berenson GS, Beresford SA, Bezzina CR, Bhatt DL, Boer JM, Braund PS, Burke GL, Burkley B, Carty C, Chen W, Clarke R, Cooper-DeHoff RM, Curtis SP, de Bakker PI, de Jong JS, Delles C, Dominiczak AF, Duggan D, Feldman HI, Furlong CE, Gorski MM, Gums JG, Hardwick R, Hastie C, Heid IM, Huang GH, Huggins GS, Humphries SE, Kirkland SA, Kivimaki M, Klein R, Klein BE, Knowler WC, Kottke-Marchant K, LaCroix AZ, Langaee TY, Li M, Lyon HN, Maiwald S, Marshall JK, Mehta A, Meijs MF, Melander O, Meyer N, Mitra N, Molony CM, Morrow DA, Murugesan G, Newhouse SJ, Nieto JF, Onland-Moret NC, Ouwehand WH, Palmen J, Pepine CJ, Ranchalis J, Rosas SE, Rosenthal EA, Scharnagl H, Schork NJ, Schreiner PJ, Shah T, Shashaty M, Shimbo D, Srinivasan SR, Thomas F, Tobin MD, Tsai MY, Verschuren WM, Wagenknecht LE, Winkelmann BR, Young T, Yusuf S, Zafarmand MH, Zmuda JM, Zwinderman AH, Anand SS, Balmforth AJ, Boehm BO, Boerwinkle E, Burton PR, Cappola TP, Casas JP, Caulfield MJ, Christiani DC, Christie J, Cruickshanks KJ, Davey-Smith G, Davidson KW, Day IN, Doevendans PA, Dorn GW 2nd, FitzGerald GA, Hall AS, Hingorani AD, Hirschhorn JN, Hofker MH, Hovingh KG, Illig T, Jamshidi Y, Jarvik GP, **Johnson JA**, Kanetsky PA, Kastelein JJ, Koenig W, Lawlor DA, März W, McCaffery J, Mega JL, Mitchell BD, Murray SS, O'Connell JR, Patel SR, Peters A, Pettinger M, Rader DJ, Redline S, Reilly MP, Sabatine MS, Schadt EE, Shuldiner AR, Silverstein RL, Spector TD, Taylor HA, Thorand B, Trip MD, Watkins H, Wichmann HE, Fox CS,

- Grant SF, Peter I, Talmud PJ, Munroe PB, Wilson JG, Knight JC, Samani NJ, Hegele RA, Asselbergs FW, Monda KL, van der Schouw YT, Demerath EW, Wijmenga C, Timpson NJ, Reiner AP, North KE, Papanicolaou GJ, Hakonarson H, Lange LA, Keating BJ. Gene-centric meta-analyses of 108,912 individuals confirm known body mass index loci and reveal three novel signals. Hum Mol Genet 2013;22:184-201, Epub Sep 21. PMID:23001569, PMC3522401.
169. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JM, Gieger C, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Most PJ, Van Iperen EP, van Setten J, Vonk JM, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Boer JM, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, Cooper-Dehoff RM, Curtis SP, Dreisbach A, Duggan D, Ehret GB, Fabsitz RR, Fornage M, Fox E, Furlong CE, Gansevoort RT, Hofker MH, Hovingh GK, Kirkland SA, Kottke-Marchant K, Kutlar A, Lacroix AZ, Langae TY, Li YR, Lin H, Liu K, Maiwald S, Malik R; METASTROKE, Murugesan G, Newton-Cheh C, O'Connell JR, Onland-Moret NC, Ouwehand WH, Palmas W, Penninx BW, Pepine CJ, Pettinger M, Polak JF, Ramachandran VS, Ranchalis J, Redline S, Ridker PM, Rose LM, Scharnag H, Schork NJ, Shimbo D, Shuldiner AR, Srinivasan SR, Stolk RP, Taylor HA, Thorand B, Trip MD, van Duijn CM, Verschuren WM, Wijmenga C, Winkelmann BR, Wyatt S, Young JH, Boehm BO, Caulfield MJ, Chasman DI, Davidson KW, Doevendans PA, Fitzgerald GA, Gums JG, Hakonarson H, Hillege HL, Illig T, Jarvik GP, **Johnson JA**, Kastelein JJ, Koenig W; LifeLines Cohort Study, März W, Mitchell BD, Murray SS, Oldehinkel AJ, Rader DJ, Reilly MP, Reiner AP, Schadt EE, Silverstein RL, Snieder H, Stanton AV, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Johnson AD, Munroe PB, de Bakker PI, Zhu X, Levy D, Keating BJ, Asselbergs FW. Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet 2013;22:1663-1678, Epub Jan 8. PMID:23303523, PMC3657476.
170. Wikoff WR, Frye RF, Zhu H, Boyle S, Churchill E, Gong Y, Cooper-DeHoff RM, Beitelshes AL, Lane A, Chapman AB, Fiehn O, **Johnson JA**, Kaddurah-Daouk. Pharmacometabolomics reveals race differences in response to atenolol treatment. PLoS One 2013;8:e57639, Epub Mar 11. PMID:23536766, PMC3594230.
171. Le MT, Lobbmeyer MT, Campbell M, Cheng J, Wang Z, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Gong Y, Johnson RJ, **Johnson JA**. Impact of genetic polymorphisms of *SLC2A2*, *SLC2A5* and *KHK* on metabolic and phenotypes in hypertensive individuals. PLoS One 2013;8:e52062, Epub Jan 14. PMID:23341889, PMC3544854.
172. Lewis JP, Ryan K, O'Connell JR, Horenstein RD, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshes AL, Pakzy R, Tanner K, Parsa, Tantry US, Bliden KP, Post WS, Faraday N, Herzog W, Gong Y, Pepine CJ, **Johnson JA**, Gurbel PA, Shuldiner AR. Genetic variation in *PEAR1* is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet 2013;6:184-192, Epub Feb 7. PMID:23392654, PMC3715320.
173. Karnes JH, Langae TY, McDonough CW, Chang SW, Ramos M, Catlin Jr JR, Casanova O, Gong Y, Pepine CJ, **Johnson JA**, Cooper-DeHoff RM. Lack of association of the *HMGA1* IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. J Transl Med 2013;11:12, Epub Jan 9. PMID:23302499, PMC3558451.
174. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langae TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshes AL, Boerwinkle E, Pepine CJ, Cooper-DeHoff RM, **Johnson JA**. Association of variants in *NEDD4L* with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens 2013;31:698-704, Epub Jan 30. PMID:23353631, PMC3756535.
175. Del-Aguila JL, Beitelshes AL, Cooper-DeHoff RM, Chapman AB, Gums JG, Bailey K, Gong Y, Turner ST, **Johnson JA**, Boerwinkle E. Genome-wide association analyses suggest nll1

- influences adverse metabolic response to HCTZ in African-Americans. Pharmacogenomics J 2014;14:35-40, Epub Feb 12, 2013. PMID:23400010, PMC3812324.
176. **Johnson JA**, Klein TE, Relling MV. Clinical implementation of pharmacogenetics: more than one gene at a time. Clin Pharmacol Ther 2013;93:384-385. PMID:23598455; PMC3716458.
177. Shuldiner AR, Relling MV, Peterson JF, Hicks K, Freimuth RR, Sadee W, Pereira NL, Roden DM, **Johnson JA**, Klein TE for the Pharmacogenomics Research Network Translational Pharmacogenetics Project Group. The Pharmacogenomics Research Network Translational Pharmacogenetics Program (TPP): overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013;94:207-210, Epub Mar 19. PMID:23588301, PMC3720847.
178. Shahin MH, **Johnson JA**. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice (invited review). Curr Opin Cardiol 2013;28:305-314, Epub Mar 8. PMID:23478884, PMC3731766.
179. Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, Patel S, Perry K, Meltzer DO, McLeod HL, **Johnson JA**. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirement in Egyptians. Thromb Haemost 2013;109:1045-1050, Epub Mar 21. PMID:23571513, PMC3712827.
180. **Johnson JA**. Pharmacogenetics in clinical practice: how far have we come and where are we going? (Invited review) Pharmacogenomics 2013;14:835-843. PMID:23651030, PMC3697735.
181. **Johnson JA**, Elsey AR, Clare-Salzler MJ, Nessler D, Conlon M, Nelson DR. Institutional profile: University of Florida & Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 2013;14:723-726. PMID:23651020, PMC3684075.
182. Kimmel SE, French B, Anderson JL, Gage BF, **Johnson JA**, Rosenberg YD, Geller NL, Kasner S, Eby CS, Joo J, Caldwell MD, Goldhaber SZ, Hart RG, Cifelli D, Madigan R, Brensinger CM, Golderber S, Califf RM, Ellenberg JH for the COAG Investigators. Rationale and design of the clarification of optimal anticoagulation through genetics (COAG) trial. Am Heart J 2013;166:435-441, Epub Jul 12. PMID:24016491, PMC4415273.
183. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AHB, Burmester JK, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, **Johnson JA**. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013;382:790-796, Epub Jun 5. PMID:23755828, PMC3759580.
184. **Johnson JA**, Cavallari LH. Pharmacogenetics and cardiovascular disease – implications for personalized medicine (invited review). Pharmacol Rev 2013;65:987-1009. PMID:23686351, PMC3698938.
185. McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O, Pepine CJ, Dominiczak AF, Cooper-DeHoff RM, **Johnson JA**. Pharmacogenomic association of non-synonymous SNPs in *SIGLEC12*, *A1BG*, and the selectin region and cardiovascular outcomes. Hypertension 2013;62:48-54, Epub May 20. PMID:23690342, PMC3686553.
186. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshes AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstrand B, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, **Johnson JA**. Genomic association analysis of common

- variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013;62:391-397, Epub June 10. PMID: 23753411, PMC3780966.
187. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, **Johnson JA**, Shuldiner AS. Clinical pharmacogenetics implementation consortium (CIPIC) guidelines for *CYP2C19* genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94:317-323, Epub May 22. PMID:23698643, PMC3748366.
188. Daneshjou R, Tatonetti N, Karczewski KJ, Sagreiya H, Bourgeois S, Drozda K, Burmester JK, Tsunoda T, Nakamura Y, Kubo M, Tector M, Limdi NA, Cavallari LH, Perera M, **Johnson JA**, Klein TE, Altman RB. Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics 2013;14(Suppl 3):S11, Epub May 28. PMID:23819817, PMC3829086.
189. Theofilogiannakos EK, Boudoulas KD, Gawronski BE, Langae TY, Kelpis TG, Pitsis AA, **Johnson JA**, Boudoulas H. Beta-Adrenergic receptor polymorphisms: A basis for pharmacogenetics. World J Cardiovasc Dis. 2013;3:406-411.
190. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood M, Langae TY, Pepine CJ, **Johnson JA**, Cooper-DeHoff RM. Impact of *TCF7L2* single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet Genomics 2013;23:697-705. PMID:24128935, PMC3893755.
191. Chapman AB, Cotsonis G, Parekh V, Schwartz GL, Gong Y, Bailey KR, Turner ST, Gums JG, Beitelshes AL, Cooper-DeHoff RM, Boerwinkle E, **Johnson JA**. Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens 2014;27:546-554, Epub 2013 July 25. PMID:23886594, PMC3958600.
192. Meschia JF, Arnett DK, Ay H, Brown RD Jr, Benavente OR, Cole JW, de Bakker PI, Dichgans M, Doheny KF, Fornage M, Grewal RP, Gwinn K, Jern C, Conde JJ, **Johnson JA**, Jood K, Laurie CC, Lee JM, Lindgren A, Markus HS, McArdle PF, McClure LA, Mitchell BD, Schmidt R, Rexrode KM, Rich SS, Rosand J, Rothwell PM, Rundek T, Sacco RL, Sharma P, Shuldiner AR, Slowik A, Wassertheil-Smoller S, Sudlow C, Thijs VN, Woo D, Worrall BB, Wu O, Kittner SJ; on behalf of the NINDS SiGN Study. Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke 2013;44:2694-2702, Epub Sep 10. PMID:24021684, PMC4056331.
193. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MHA, Buford TW, El Rouby NM, Sá ACC, Langae TY, Gums JG, Chapman AB, Cooper-DeHoff RM, Turner ST, Gong Y, **Johnson JA**. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) Study. PLoS One 2013;8:e76984. PMID:24116192, PMC3792156.
194. Gong Y, McDonough CW, Beitelshes AL, O'Connell JR, Karnes JH, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, **Johnson JA**, Cooper-DeHoff RM. *PROX1* gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy 2014;34:123-130, Epub 2013 Oct 9. PMID:24122840, PMC3945213.
195. Kimmel SE, French B, Kasner SE, **Johnson JA**, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JAS, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billet HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, on behalf of the COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369:2283-2293, Epub Nov 19. PMID: 24251361, PMC3942158.
196. Ganesh S, Arnett D, Assimes T, Basson C, Chakravarti A, Ellinor P, Engler M, Goldmuntz E, Herrington D, Hong Y, **Johnson JA**, Kittner S, McDermott D, Meschia J, O'Donnell C, Psaty B,

- Vasan R, Ruel M, Shen WK. Genetics and genomics for the prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2013;128:2813-2851. PMID:24297835.
197. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshes A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, Cooper-Dehoff RM, Gaunt TR, Gieger C, Gong Y, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP, O'Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Verschuren WM, Anand SS, Dominiczak A, Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T, **Johnson JA**, Kirkland S; the Look AHEAD Research Group, König W, Langae TY, McCaffery J, Melander O, Mitchell BD, Munroe P, Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, van der Schouw YT, Shimbo D, Shuldiner AR, Tobin MD, Wijmenga C, Yusuf S; the GIANT Consortium; the CARE IBC Consortium, Hakonarson H, Lange LA, Demerath EW, Fox CS, North KE, Reiner AP, Keating B, Taylor KC. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet* 2014;23:2498-2510, Epub 2013 Dec 17. PMID:24345515, PMC3988452.
 198. Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, **Johnson JA**. *CYP2C19* polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? *Pharmacotherapy* 2014;34:703-718, Epub Feb 7. PMID:24510446, PMC4082739.
 199. Perera MA, Cavallari LH, **Johnson JA**. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. *Clin Pharmacol Ther* 2014;95:242-244, PMID:24548987, PMC4131541.
 200. Vandell AG, McDonough CW, Gong Y, Langae TY, Lucas AM, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Hydrochlorothiazide-induced hyperuricemia in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *J Intern Med* 2014;276:486-497, Epub Feb 28. PMID:24612202, PMC4130802.
 201. Rosenwasser R, Shah NK, Smith SM, Wen X, Gong Y, Gums JG, Nichols WW, Chapman AB, Boerwinkle E, **Johnson JA**, Epstein B. Baseline predictors of central aortic blood pressure: a PEAR substudy. *J Am Soc Hypertens* 2014;8:152-158, Epub Jan 3. PMID:24629400, PMC3959656.
 202. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith E N, Johnson T, Holmes M V, Karczewski KJ, Almoguera B, Barnard J, Baumert J, Chang YC, Elbers CC, Farrall M, Fischer ME, Gaunt TR, Gho JM, Gieger C, Goel A, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Mellander O, Nelson CP, Nolte IM, Padmanabhan S, Pankratz N, Price TS, Shaffer J, Shah S, Tomaszewski M, van der Most PJ, Van Iperen EP, Vonk JM, Witkowska K, Wong C, Zhang L, Berenson GS, Bhatt DL, Brown M, Burt A, Cooper-DeHoff RM, Cruickshanks KJ, Curtis SP, Gansevoort RT, Guo X, Haiqing S, Hastie CE, Hofker MH, Hovingh GK, Kim D, Kirkland SA, Klein B E, Klein R, Li YR, Newton-Cheh C, Onland-Moret NC, Palmas W, Parsa A, Penninx BW, Pettinger M, Vasan RS, Ridker PM, Shimbo D, Steele L, Stolk RP, Thorand B, Trip MD, van Duijn CM, Verschuren CM, Wijmenga62, Wyatt S, Young JH, Zwinderman AH, Bezzina CR, Boerwinkle E, Casas JP, Caulfield MJ, Chakravarti A, Chasman DI, Davidson KW, Doevendans PA, FitzGerald GA, Fornage M, Hakonarson H, Halder I, Hillege HL, Illig T, Jarvik GP, **Johnson JA**, Kastelein JJ, Koenig W, März W, Murray SS, O'Connell JR, Oldehinkel AJ, Rader DJ, Redline S, Reilly MP, Schadt EE, Silverstein RL, Snieder H, Snyder M, Stanton AV, Tobin MD, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Johnson AD, Reiner AP, Zhu X, de Bakker PI, Levy D, Asselbergs FW, Munroe PB, Keating BJ. Gene-centric meta-analysis in 87,736

- individuals of European ancestry identifies multiple blood pressure related loci. Am J Hum Genet 2014;94:349-360. PMID:24560520, PMC3951943.
203. Buford T, Hsu FC, Brinkley T, Carter C, Church T, Dodson J, Goodpaster B, McDERMOTT MM, Nicklas B, Yank V, **Johnson JA**, Pahor M. Genetic influence on exercise-induced changes in physical function among mobility-limited older adults. Physiol Genomics 2014;46:149-58, Epub Jan 14. PMID: 24423970, PMC3949106.
204. Weitzel KW, Eelsey AR, Langaee TY, Burkley BM, Nessler DR, Owusu Obeng A, Staley, Hui-Dong HJ, Allan RW, Liu JF, Cooper-DeHoff RM, Anderson RD, Conlon M, Clare-Salzler MJ, Nelson DR, **Johnson JA**. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 2014;166:56-67, Epub Mar 10. PMID:24616371, PMC4076109.
205. Langaee TY, Zhu H, Wang X, El Rouby N, Markowitz J, Goldstein J, **Johnson JA**. The influence of the *CYP2C19*10* allele on clopidogrel activation and *CYP2C19*2* genotyping. Pharmacogenet Genomics 2014;24:381-386, Epub June 18. PMID:24945780, PMC4090277.
206. Hamadeh IS, Langaee TY, Dwevedi R, Garcia S, Burkley BM, Chapman AB, Gums JG, Turner ST, Gong Y, Cooper-DeHoff RM, **Johnson JA**. Impact of *CYP2D6* polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther 2014;96:175-181, Epub Mar 17. PMID:24637943, PMC4111800.
207. Cooper-DeHoff RM, Hou W, Weng L, Baillie RA, Beitelshes AL, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, Frye RF, Kaddurah-Daouk R, **Johnson JA**. Is a diabetes mellitus-linked amino acid signature associated with beta blocker-induced impaired fasting glucose? Circ Cardiovasc Genet 2014;7:199-205, Epub Mar 13. PMID:24627569, PMC4050976.
208. Karnes JH, Gong Y, Arwood MJ, Gums JG, Hall K, Limacher MC, **Johnson JA**, and Cooper-DeHoff RM. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Res Clin Pract 2014;104:363-369, Epub Apr 13. PMID:24794890, PMC4074403.
209. Daneshjou R, Gamazon, E, Burkley B, Cavallari LH, **Johnson JA**, Klein TE, Limdi N, Hillenmyer S, Percha B, Karczewski K, Langaee TY, Patel SR, Bustamante CD, Altman RB, Perera MA. Genetic variant in folate homeostasis associated with lower warfarin dose in African Americans. Blood 2014;124:2298-2305, Epub Jul 30. PMID:25079360, PMC4183989.
210. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Gums JG, Beitelshes AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums, JG, Cooper-DeHoff RM, **Johnson JA**. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy 2014;34:1132-1140, Epub Sept 9. PMID:25202885, PMC4227953.
211. Owusu Obeng A, Weitzel KW, Hatton RA, Staley BJ, Ashton J, Cooper-DeHoff RM, **Johnson JA**. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy 2014;34:1102-1112, Epub Sep 15. PMID:25220280, PMC4188772.
212. **Johnson JA**, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med 2015;25:33-41, Epub 2014 Sept 6. PMID:25282448, PMC4278947.
213. Fontana V, McDonough CW, Gong Y, El Rouby NM, Sá ACC, Taylor KD, Chen Y-D I, Gums JG, Chapman AB, Turner ST, Pepine CJ, **Johnson JA**, Cooper-DeHoff RM. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc 2014;3:e001398. PMID:25385345, PMC4338734.

214. Del-Aguila JL, Cooper-DeHoff RM, Chapman AB, Beitelshes AL, Gums JG, Bailey K, Turner ST, **Johnson JA**, Boerwinkle E. Transethnic meta analyses suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. Pharmacogenomics J 2015;15:153-157. Epub 2014 Sept 9. PMID:25201287, PMC4362777.
215. Theofilogiannakos EK, Boudoulas KD, Gawronski BA, Langaee TY, Dardas PS, Ninios V, Kelpis TG, **Johnson JA**, Pitsis AA, Boudoulas H. (MD). Floppy mitral valve/mitral valve prolapse syndrome: beta-adrenergic receptor polymorphism may contribute to the pathogenesis of symptoms. J Cardiol 2015;65:434-438, Epub 2014 Sep 22. PMID:25172623.
216. Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatt S, Chapman AB, Gums JG, Gong Y, Cooper-DeHoff RM, Frau F, Glorioso V, Zaninello R, Salvi E, Gloriso N, Boerwinkle E, Turner ST, **Johnson JA**, Kontula KK. Pharmacogenomics of hypertension: a genome-wide placebo-controlled cross-over study, using four class of antihypertensive drugs. J Am Heart Assoc 2015;4:e001521. PMID:25622599; PMC4330076.
217. Langaee TY, Hamadeh IS, Chapman AB, Gums JG, **Johnson JA**. A novel simple method for determining *CYP2D6* gene copy number and identifying allele(s) with duplication/multiplication. PLoS One 2015;10:e0113808. PMID:25625348, PMC4308104.
218. Weng L, Quinlivan E, Gong Y, Beitelshes AL, Shahin MH, Turner S Chapman A, Gums J, **Johnson JA**, Frye RF, Garrett TJ and Cooper-DeHoff RM. Association of Branched and Aromatic Amino Acid Levels with Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients. Metab Syndr Relat Disord 2015;13:195-202, Epub Feb 9. PMID:25664967, PMC4519105.
219. Chittani M, Zaninello R, Lanzani C, Frau F, Ortu M, Salvi E, Fresu G, Cittero L, Braga D, Piras D, Carpini SD, Velayutham D, Simonini M, Argiolas G, Pozzoli S, Troffa C, Glorioso V, Kontula K, Hiltunen T, Donner, KM, Turner ST, Boerwinkle E, Chapman A, Padmanabhan S, Dominiczak, AF, Melander O, **Johnson JA**, Cooper-DeHoff RM, Gong Y, Manunta P, Cusi D, Glorioso N, Barlassina C. TET2 and CSMD1 genes affect SPB response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens 2015;33:1301-09. PMID:25695618, PMC4484731.
220. McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR. CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. J Am Heart Assoc 2015;4:e001652, Epub May 27. PMID:26019129, PMC4599525.
221. Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, **Johnson JA**, Hutz MA, Suarez-Kurtz G. Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics 2015;16:1253-1263, Epub Aug 12. PMID: 26265036, PMC4573240.
222. Fox CS, Hall JL, Arnett DK, Ashley EA, Delles C, Engler MB, Freeman MW, **Johnson JA**, Lanfear DE, Liggett SB, Lusic AJ, Loscalzo J, MacRae CA, Musunuru K, Newby LK, O'Donnell CJ, Rich SS, Terzic A. Future translational applications from the contemporary genomics era: A scientific statement from the American Heart Association. Circulation 2015;131:1715-1736, Epub Apr 16. PMID: 25882488. PMC4825323.
223. Gong Y, McDonough CW, Beitelshes AL, El Roubay N, Hiltunen TP, O'Connell JR, Padmanabhan S, Langaee TY, Schmidt SO, Curry RW, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Chapman AB, Turner ST, Cooper-DeHoff RM, **Johnson JA**. *PTPRD* Gene Associated with Blood Pressure Response to Atenolol and Resistant Hypertension in Hypertensive Individuals. J Hypertens 2015;33(11):2278-2285. PMID:26425837. PMC4788379.

224. Biel NM, Santostefano KE, DiVita BB, El Rouby N, Carrasquilla SD, Simmons C, Nakanishi M, Cooper-DeHoff RM, **Johnson JA**, Terada N. Vascular smooth muscle cells from hypertensive patient-derived induced pluripotent stem cells to advance hypertension pharmacogenomics. Stem Cells Transl Med 2015;4:1380-1390, Epub Oct 22. PMID:26494780, PMC4675511.
225. Hoh BL, Gong Y, McDonough CW, Waters MF, Royster AJ, Sheehan TO, Burkley B, Langae TY, Mocco J, Zuckerman SL, Mummareddy N, Stephens ML II, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, Roden DM, **Johnson JA**. CYP2C19 and CES1 Polymorphisms and Efficacy of Clopidogrel and Aspirin Dual Antiplatelet Therapy in Patients with Symptomatic Intracranial Atherosclerotic Disease. J Neurosurg 2016;124:1746-1751, Epub 2015 Nov 20. PMID:26587656, PMC4915569.
226. Cooper-DeHoff RM, **Johnson JA**. Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches. (Invited review) Nat Rev Nephrol 2016;12:110-122, Epub 2015 Nov 23. PMID:26592190, PMC4778736.
227. Pulit SL*, McArdle PF*, Wong Q*, Malik R*, Gwinn K, Achterberg S, Algra A, Amouyel P, Anderson CD, Arnett DK, Arsava EM, Attia J, Ay H, Bartz TM, Battey T, Benavente OR, Bevan S, Biffi A, Bis JC, Blanton SH, Boncoraglio GB, Brown Jr. RD, Burgess AI, Carrera C, Chapman Smith SN, Chasman DI, Chauhan G, Chen WM, Cheng YC, Chong M, Cloonan LK, Cole JW, Cotlarciuc I, Cruchaga C, Cuadrado-Godia E, Tushar D, Dawson J, Debette S, Delavaran H, Dell CA, Dichgans M, Doheny KF, Dong C, Duggan DJ, Engström G, Evans MK, Pallejà XE, Faul JD, Fernández-Cadenas I, Fornage M, Frossard PM, Furie KJ, Gamble DM, Gieger C, Giese AK, Giralto-Steinhauer E, González HM, Goris A, Gretarsdottir S, Grewal RP, Grittner U, Gustafsson S, Han B, Hankey GJ, Heitsch L, Higgins P, Hochberg MC, Holliday E, Hopewell JC, Horenstein RB, Howard G, Ikram MA, Ilinca A, Ingelsson E, Irvin MR, Jackson RD, Jern C, Jiménez Conde J, **Johnson JA**, Jood K, Kahn MS, Kaplan R, Kappelle LJ, Kardia SLR, Keene KL, Kissela BM, Kleindorfer DO, Koblar S, Labovitz D, Launer LJ, Laurie CC, Laurie CA, Lee CH, Lee JM, Lehm M, Lemmens R, Levi C, Leys D, Lindgren A, Longstreth Jr. WT, Maguire J, Manichaikul A, Markus HS, McClure LA, McDonough CW, Meisinger C, Melander O, Meschia JF, Mola-Caminal M, Montaner J, Mosley TH, Müller-Nurasyid M, Nalls MA, O'Connell JR, O'Donnell M, Ois A, Papanicolaou GJ, Paré G, Peddareddygar LR, Pedersén A, Pera J, Peters A, Poole D, Psaty BM, Rabionet R, Raffeld MR, Rannikmäe K, Rasheed A, Redfors P, Reiner AP, Rexrode K, Ribasés M, Rich SS, Robberecht W, Rodriguez-Campello A, Rolfs A, Roquer J, Rose LM, Rosenbaum D, Rost NS, Rothwell PM, Rundek T, Ryan KA, Sacco RL, Sale ML, Saleheen D, Salomaa V, Sánchez-Mora C, CO Schmidt, Schmidt H, Schmidt R, Schürks M, Scott R, Segal HC, Seiler S, Seshadri S, Sharma P, Shuldiner AR, Silver B, Slowik A, Smith JA, Söderholm M, Soriano C, Sparks MJ, Stanne T, Stefansson K, Stine OC, Strauch K, Sturm J, Sudlow CLM, Tajuddin SM, Talbert RL, Tatlisumak T, Thijs V, Thorleifsson G, Thorsteindottir U, Tiedt S, Traylor M, Trompet S, Valant V, Waldenberger M, Walters M, Wang L, Wassertheil-Smoller S, Weir DR, Wiggins KL, Williams SR, Wloch-Kopec D, Woo D, Woodfield R, Wu O, Xu H, Zonderman AB, Australian Stroke Genetics Consortium, Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) study, Cohorts of Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, Consortium of Minority Population genome-wide Association Studies of Stroke (COMPASS), METASTROKE consortium, Wellcome Trust Case-Control Consortium, Worrall BB*, de Bakker PIW*, Kittner SJ*, Mitchell BD*, Rosand J*. Loci associated with ischemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurol 2016;15:174-184. Epub 2015 Dec 19. PMID:26708676, PMC4912948.
228. Rotroff DM, Shahin MH, Gurley SB, Zhu H, Motsinger-Reif A, Meisner M, Beitelshes AL, Fiehn O, **Johnson JA**, Eldadawi-Dishu M, Frye RF, Gong Y, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk R. Pharmacometabolomic assessments of atenolol and hydrochlorothiazide treatment reveal novel drug response phenotypes. CPT Pharmacometrics Syst Pharmacol 2015;4:669-679, Epub Oct 29. PMID:26783503, PMC4716583.

229. Weitzel KW, Alexander M, Bernhardt BA, Calman N, Carey DJ, Cavallari LH, Field JR, Hauser D, Junkins HA, Levin PA, Levy K, Madden EB, Manolio TA, Odgis J, Orlando LA, Pyeritz R, Wu RR, Shuldiner AR, Bottinger EP, Denny JC, Dexter PR, Flockhart DA, Horowitz CR, **Johnson JA**, Kimmell SE, Levy MA, Polin TI, Gindsburg GS on behalf of the IGNITE Network. The IGNITE Network: a model for genomic medicine implementation and research. BMC Med Genomics 2016;9:1, Epub Jan 5. PMID:26729011, PMC4700677.
230. Khalil BM, Shahin MH, Solayman MH, Langaee TY, Taimour Langaee, Schaalán, MF, Gong Y, Hammad LN, Al-Mesallamy HL, Hamdy NM, El-Hammady WA, **Johnson JA**. Genetic and Non-Genetic Factors Affecting Clopidogrel Efficacy in Egyptian Population. Clin Transl Sci 2016;9:23-28; Epub Jan 12. PMID:26757134, PMC4760893.
231. Gong Y, Beitelshes AL, Wang Z, McDonough CW, Langaee TY, Hall K, Schmidt SOF, Curry Jr RW, Gums JG, Bailey KR, Boerwinkle E, PhD³, Chapman AB, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. Hypertension 2016;67:556-563. Epub Jan 4. PMID:26729753, PMC4752391.
232. Solayman M, Langaee TY, Patel A, El-Wakeel L, El-Hamamsy M, Badary O, **Johnson JA**. Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Mol Biotechnol 2016;58:179-87; Epub Jan 21. PMID:26798072, PMC4758859.
233. Hamadeh IS, Shahin MH, Lima SM, Oliveira F, Wilson L, Khalifa SI, Langaee TY, Cooper-DeHoff RM, Cavallari LH, **Johnson JA**. Impact of GGCX, STX1B, and FPGS Polymorphisms on Warfarin Dose Requirements in European Americans and Egyptians. Clin Transl Sci 2016;9:36-42. Epub Jan 19. PMID:26751406, PMC4760888.
234. Chang SW, Gong Y, McDonough CW, Langaee TY, Nasiri Kenari N, Beitelshes AM, Gums JG, Chapman AB, Turner ST, **Johnson JA**, Cooper-DeHoff RM. Melatonin Pathway and Atenolol-Related Glucose Dysregulation- Is There a Correlation?" Clin Transl Sci 2016;9:114-122, Epub Mar 7. PMID:26946962, PMC4915567.
235. Zhu H-J, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS. Zhu H-J, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, Markowitz JS. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. Eur J Clin Pharmacol 2016;72:681-687, Epub Feb 26. PMID:26915813, PMC4865408.
236. Shahin MH, **Johnson JA**. Mechanisms and pharmacogenetics signals underlying thiazide diuretics blood pressure response. Curr Opin Pharmacol 2016;27:31-37, Epub Feb 10. PMID:26874237, PMC4915478.
237. The Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Stroke Genetics Network (SiGN), and the International Stroke Genetics Consortium (ISGC). Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome wide association studies. Lancet Neurol 2016;15:695-707, Epub Apr 7. PMID:27068588, PMC49943223.
238. Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, Perera MA, **Johnson JA**, Klein TE, Bustamante CD, Roden DM, Shaffer C, Denny JC, Zehnder JL, Altman RB. Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Mol Genet Genomic Med 2016;4:513-520, eCollection Sep. PMID: 27652279, PMC5023936.

239. Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshes AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, **Johnson JA**. A genetic response score for hydrochlorothiazide use: insights from genomics and metabolomics integration. Hypertension 2016;68:621-629, Epub July 5. PMID:27381900, PMC4982802.
240. Gharaibeh KA, Turner ST, Hamadah AM, Chapman AB, Cooper-Dehoff RM, **Johnson JA**, Bailey KR, Schwartz GL. Comparison of Blood Pressure Control Rates among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. Am J Hypertens 2016;29:1186-1194. Epub Jun 30. PMID:27365079, PMC5863787.
241. de Oliveira F, Shahin MH, Gong Y, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, **Johnson JA**, Cooper-DeHoff RM. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics 2016;12:129. Epub Jul 13. PMID:28217400, PMC5310671.
242. Weitzel KW, McDonough CW, Elsey AR, Burkley B, Cavallari LH, **Johnson JA**. Effects of using personal genotype data on student learning and attitudes in a pharmacogenomics course. Am J Pharm Educ 2016;80:122. PMID:27756930, PMC5066925.
243. Salvi E, Wang Z, Rizzi F, Gong Y, McDonough CW, Padmanabhan S, Hiltunen TP, Lanzani C, Zaninello R, Chittani M, Bailey KR, Barcella M, Melander O, Chapman AB, Kontula KK, Manunta P, **Johnson JA**, Glorioso N, Cusi D, Dominiczak AF, Barlassina C, Boerwinkle E, Cooper-DeHoff RM, Turner ST. Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide. Hypertension 2017;69:51-59, Epub 2016 Oct 31. PMID:27802415, PMC5145728.
244. Cavallari LH, Lee CR, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, **Johnson JA**. Implementation of inpatient models of Pharmacogenetics programs. Am J Health Syst Pharm 2016;73:1944-1954. PMID:27864202, PMC5359627.
245. Weng L, Gong Y, Culver J, Gardell S, Petucci C, Morse AM, Frye RF, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Beitelshes AL, Borum PR, **Johnson JA**, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic response in hypertensive patients treated with atenolol. Metabolomics 2016;12:160, Epub Sept 15. PMID:28217401, PMC5313050.
246. Traylor M, Malik R, Nalls MA, Cotlarciuc I, Radmanesh F, Thorleifsson G, Hanscombe KB, Langefeld C, Saleheen D, Rost NS, Yet I, Spector TD, Bell JT, Hannon E, Mill J, Chauhan G, Debette S, Bis JC, Longstreth Jr. WT, Ikram MA, Launer LJ, Seshadri S, METASTROKE, UK Young Lacunar DNA Study, NINDS Stroke Genetics Network, Neurology Working Group of the CHARGE Consortium, Hamilton-Bruce MA, Jimenez-Conde J, Cole JW, Schmidt R, Slowik A, Lemmens R, Lindgren A, Melander O, Grewal RP, Sacco RL, Rundek T, Rexrode K, Arnett DK, Johnson JA, Benavente OR, Wassertheil-Smoller S, Lee JM, Pulit SL, Wong Q, Rich SS, de Bakker PIW, McArdle PF, Woo D, Anderson CD, Xu H, Heitsch L, Fornage M, Jern C, Stefansson K, Thorsteinsdottir U, Gretarsdottir S, Lewis CM, Sharma P, Sudlow CLM, Rothwell PM, Boncoraglio GB, Thijs V, Levi C, Meschia JF, Rosand J, Kittner SJ, Mitchell BD, Dichgans M, Worrall BB, Markus HS, on behalf of the International Stroke Genetics Consortium. Genetic Variation at 16q24.2 is associated with small vessel stroke. Ann Neurol 2017;81:383-394, Epub 2016 Dec 20. PMID:27997041, PMC5366092.
247. Shahin MH, Sa AC, Webb A, Gong Y, Langae TY, McDonough CW, Riva A, Beitelshes AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Scherer SE, Sadee W, Cooper-DeHoff RM, **Johnson JA**. Genome-Wide Prioritization and Genomics-Transcriptomics Integration Reveal Novel

- Signatures Associated with Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet 2017;10:001404, Epub Jan 23. PMID:28115488, PMC5298887.
248. Luzum JA, PakyzRE, Eley AR, Haidar CE, PetersonJF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JS, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, **Johnson JA**, Relling MV, Wang L, Weinshilboun RM, Shuldiner AR, Freimuth RR, for the Pharmacogenomics_Research Network Translational Pharmacogenetics Program. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes_and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther 2017;102:502-510, Epub Jun 9. PMID:28090649, PMC5511786.
249. Dumitrescu L, Ritchie MD, Denny JC, El Roubay NM, McDonough CW, Bradford Y, Ramirez AH, Bielinski SJ, Basford MA, Chai SH, Peissig P, Carrell D, Pathak J, Rasmussen LV, Wang X, Pacheco JA, Kho AN, Hayes MG, Matsumoto M, Smith ME, Li R, Gong Y, Kullo IJ, Chute CG, Chisholm RL, Jarvik GP, Larson EB, Carey D, McCarty CA, Williams MS, Roden DM, Bottinger E, **Johnson JA**, de Andrade M, Crawford DC. Genome-wide study of resistant hypertension identified from electronic health records. PLoS One 2017;12:e0171745, Epub Feb 21. PMID:28222112, PMC5319785.
250. Cavallari LH, Beitelshes A, Blake K, Dressler L, Duarte J, Eley A, Eichmeyer J, Empey P, Franciosi J, Hicks J, Holmes A, Jeng L, Lee C, Lima J, Limdi N, Modlin J, Obeng A, Petry N, Pratt V, Skaar T, Tuteja S, Voora D, Wagner M, Weitzel K, Wilke R, Peterson J, **Johnson JA**. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. Clin Transl Sci 2017;10:143-146, Epub Mar 14. PMID: 28294551, PMC5421730.
251. Cavallari LH, Weitzel KW, Eley AR, Liu X, Mosley S, Smith DM, Staley B, Winterstein AG, Mathews CA, Franchi F, Rollini F, Angiolillo DJ, Starostik P, Clare-Salzler MJ, Nelson DR, **Johnson JA**. Institutional Profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics 2017;18:421-26, Epub Mar 27. PMID:28346068, PMC5558508.
252. **Johnson JA**, Caudle KE, Gong L, Whirl-Carrillo MW, Stein CM, Scott SA, Lee MTM, Gage BF, Kimmel SE, Perera M, Anderson JL, Pirmohamed M, Klein TE, Limbi NA, Cavallari LH, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther 2017;102:397-404. Epub Apr 4. PMID:28198005, PMC5546947.
253. Magvanjav O, McDonough CW, Gong Y, McClure LA, Talbert RL, Horenstein RB, Shuldiner AR, Benavente OR, Mitchell BD, **Johnson JA**, NINDS Stroke Genetics Network (SiGN). Pharmacogenetic associations of β 1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 trial. Stroke 2017;48:1337-1343, Epub Mar 28. PMID:28351962, PMC5404951.
254. Hamadeh IS, Klinker KP, Borgert SJ, Richards AM, Li W, Mangal N, Hiemenz JW, Schmidt S, Langaee TY, Peloquin CA, **Johnson JA**, Cavallari LH. Impact of the CYP2C19 Genotype on Voriconazole Exposure in Adults with Invasive Fungal Infections. Pharmacogenet Genom 2017;27:190-196, Epub Mar 16. PMID:28306618, PMC5391994.
255. Howson JMM, Zhao W, Barnes DR, Ho WK, Young R, Paul DS, Waite LL, Freitag DF, EB Fauman, Salfati EL, Sun BB, Eicher JD, Johnson AD, Sheu WHH, Nielsen SF, Lin WY, S Praveen, Malarstig A, Wilk JB, Tybjærg-Hansen A, Rasmussen KL, Kamstrup PR, Deloukas P, Erdmann J, Kathiresan S, Samani NJ, Schunkert H, Watkins H, Do R, Radar DJ, **Johnson JA**, Hazen S, Quyyumi A, Spertus J, Pepine C, Franceschini N, Justice A, Reiner AP, Buyske S, Hindorff LA, Carty CL, North KE, Kooperberg C, Boerwinkle E, Young K, Graff M, Peters U, Absher D, Hsiung CA, Lee WJ,

- Taylor KD, Chen YH, Lee IT, Guo X, Chung RH, Hung YJ, Rotter JI, Juang JM, Quertermous T, Wang TD, Rasheed A, Frossard P, Alam DS, Majumder AS, Angelantonio ED, Chowdhury R, Chen YDI, Nordestgaard BG, Assimes TL, Danesh J, Butterworth AS, Saleheen. Fifteen new risk loci for coronary artery disease highlight arterial wall-specific mechanisms. *Nat Genet* 2017;49:1113-1119. Epub May 22. PMID:28530674; PMC5555387.
256. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, **Johnson JA**, Scholz M, Beutner F, Thiery J, Smith JG, Vilmondarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leisher A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hofer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium., Krämer BK, Scharnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol* 2017;5:534-543. Epub May 26. PMID:28566218; PMC5651679.
257. Sa ACC, Sadee W, **Johnson JA**. Whole Transcriptome Profiling: An RNA-Seq Primer and Implications for Pharmacogenomics Research. *Clin Trans Sci* 2018;11:153-161, Epub Oct 23. PMID:28945944, PMC5866981.
258. Mehanna M, Gong Y, McDonough CM, ; Beitelshes AL, Gums, JG, Chapman AB, Schwartz G, **Johnson JA**, Turner ST, Cooper-DeHoff RM. Blood Pressure Response to Metoprolol and Chlorthalidone in Hypertensive European and African Americans. *J Clin Hypertens* 2017;19:1301-1308, Epub Sept 21. PMID:28940643, PMC5722670.
259. Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshes AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, **Johnson JA**. Genetic variants associated with uncontrolled blood pressure on combination therapy with a thiazide diuretic/beta-blocker in the PEAR and INVEST trials. *J Am Heart Assoc* 2017;6:e006522. PMID:29097388, PMC5721751.
260. Cavallari LH, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elseey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, **Johnson JA** on behalf of the IGNITE Network. *JACC Cardiovasc Interv* 2018; 11: 181-191, Epub Nov 1. PMID:29102571, PMC5775044.
261. Sá ACC, Webb A, Gong Y, McDonough CW, Datta S, Langae TY, Turner ST, Beitelshes AL, Chapman AB, Gums JG, Boerwinkle E, Scherer SE, Cooper-DeHoff RM, Sadee W, **Johnson JA**. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. *Sci Rep* 2017;7:16068. PMID:29167564, PMC5700078.

262. Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJ, **Johnson JA**, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther* 2018;104:664-674. Epub Jan 30. PMID:29280137, PMC6019555.
263. Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshes AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. Shingolipid metabolic pathway impacts thiazide diuretics blood pressure response: Insights from genomics, metabolomics and lipidomics. *J Am Heart Assoc* 2018;7:e006656, Epub Dec 29, 2017. PMID:29288159, PMC5778957.
264. Weitzel KW, Smith DM, Eley AR, Duong BQ, Burkley B, Clare-Salzler MJ, McCabe TH, Kong B, Langae TY, Staley B, Vo T, Wake D, Cavallari LH, **Johnson JA**. Development and Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Unique Challenges and Lessons Learned. *Clin Transl Sci* 2018;11:175-181, Epub Jan 19. PMID:29351371, PMC5867028.
265. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, Benavente OR, Bevan S, Boncoraglio GB, Brown, Jr. RD, Butterworth AS, Carrera C, Carty CL, Chasman DI, Chen WM, Cole JW, Correa A, Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, den Hoed M, Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Grewal RP, Gudnason V, Gustafsson S, Haessler J, Harris TB, Hassan A, Havulinna AS, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, Irvin MR, Jian X, Jiménez-Conde J, **Johnson JA**, Jukema JW, Kanai M, Keene KL, Kissela BM, Kleindorfer DO, Kooperberg C, Kubo M, Lange L, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, McArdle PF, Meschia JF, Mitchell BD, Mosley TH, Nalls MA, Ninomiya T, O'Donnell MJ, Psaty BM, Pulit SL, Rannikmäe K, Reiner AP, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale MM, Salomaa V, Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, Tanislav C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, van Duijn CM, Walters M, Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KL, Yang Q, Yusuf S, AFGen consortium, Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, International Genomics of Blood Pressure (iGEN-BP) Consortium, INVENT consortium, STARNET, Bis JC, Pastinen T, Ruusalepp A, Schadt EE, Koplev S, Björkegren JLM, Codoni V, Civelek M, Smith N, Trégouët DA, Christophersen IE, Roselli C, Lubitz SA, Ellinor PT, Tai ES, Kooner JS, Kato N, He J, van der Harst P, Elliott P, Chambers JC, Takeuchi F, BioBank Japan Cooperative Hospital Group, COMPASS consortium, EPIC-CVD consortium, EPIC-InterAct consortium, International Stroke Genetics Consortium (ISGC), METASTROKE Consortium, Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, NINDS Stroke Genetics Network (SiGN), UK Young Lacunar DNA Study, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, Longstreth, Jr WT, Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, Saleheen D, Stefansson K, Worrall BB, Kittner SJ, Seshadri S, Fornage M, Markus HS, Howson JM, Kamatani Y, Dichgans DS. Multi-ancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* 2018;50:524-537, Epub Mar 12. PMID:29531354, PMC5968830.
266. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobbmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Genome-wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to Beta-blockers. *J Am Heart Assoc* 2018;7:e006443, Epub Feb 24. PMID:29478026, PMC5778957.

267. Singh S, McDonough CW, Gong Y, Alghamdi W, Arwood M, Bargal S, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira F, Fredette N, Shahin M, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Genome Wide Association Study to Identify Genomic Variants Associated with Chlorthalidone-Induced Glucose Change. J Am Heart Assoc 2018;7:e007339, Epub Mar 9. PMID:29523524, PMC5907544.
268. Volpi S, Bult C, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Lyman Rodriguez L, Aronson S, Cavallari LH, Denny JC, Dressler L, **Johnson JA**, Klein TE, Steven Leeder J, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV. Research directions in the clinical implementation of pharmacogenomics - An Overview of US programs and projects. Clin Pharmacol Ther 2018;103:778-786, Epub Mar 30. PMID:29460415, PMC5902434.
269. McDonough CW, Magvanjav O, Sa ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, **Johnson JA**. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Circ Genom Precis Med 2018;11:e001854, Epub Apr 12. PMID:29650764, PMC5901893.
270. Cavallari LH, Franchi F, Rollini, Been L, Rivas A, Agarwal M, Smith DM, Newsome K, Gong Y, Elsey AR, Starostik P, **Johnson JA**, Angiolillo D. Clinical Implementation of Rapid *CYP2C19* Genotyping to Guide Antiplatelet Therapy after Percutaneous Coronary Intervention. J Transl Med 2018;16:92. Epub Apr 11. PMID:29642909; PMC5896099.
271. El Rouby N, Lima JJ, **Johnson JA**. Proton pump inhibitors: From *CYP2C19* pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol 2018;14:447-460, Epub Apr 12. PMID:29620484; PMC5942154.
272. Sa ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshes AL, Chapman AB, Eric Boerwinkle, Gums JG, Scherer SA, Cooper-DeHoff RM, Sadee W, **Johnson JA**. Blood Pressure Signature Genes and Blood Pressure Response to Thiazide Diuretics: Results from the PEAR and PEAR-2 Studies. BMC Med Genomics 2018;11:55. PMID:29925376, PMC6011347.
273. Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, Turner ST, Chapman AB, Gums JG, McDonough CM, Bailey KR, Beitelshes AL, Cooper-DeHoff RM, Scherer SE, Boerwinkle E, **Johnson JA**. Targeted sequencing identifies missense variant in the *BEST3* gene associated with anti-hypertensive response to hydrochlorothiazide. Pharmacogenet Genom 2018;28:251-255. PMID:30289819, PMC6262886.
274. Cicali EJ, Blake K, Gong Y, Mougey EB, Al-Atrash H, Chambers N, Denham J, Evans J, George Gomez R, Palomo P, Taufiq S, **Johnson JA**, Lima JJ, Franciosi JP. Novel implementation of genotype-guided proton pump inhibitor medication therapy in children: A pilot, randomized, multi-site pragmatic trial. Clin Transl Sci. 2019;12:172-179, Epub 2018 Nov. PMID:30341969, PMC6440564.
275. El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Crawford DC; eMERGE network, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Benavente OR, Shuldiner AR, **Johnson JA**. Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics J 2019;19:295-304, Epub 2018 Sept 20. PMID:30237584, PMC6426691.

276. Danese E, Raimondi S, Montagnana M, Tagetti A, Langae T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Rodrigues Botton M, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kristiansen Kringen M, Foss Haug KB,²⁵ Gwak HS, Lee KE, Minuz P, Michael Lee MT, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Lorient MA, Kumar Kutala V, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Singh Rathore S, Sagreiya H, Altman RB, Shaheen MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Federico Zambon C, Pengo V, Zhang JE, Pirmohamed M, **Johnson JA**, Fava C. The effect of *CYP4F2*, *VKORC1* and *CYP2C9* in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals. *Clin Pharmacol Ther* 2019;105:1477-1491, Epub Feb 17, PMID:30506689, PMC6542461.
277. Magvanjav O, Cooper-DeHoff RM, McDonough CW, Gong Y, Segal MS, Hogan WR, **Johnson JA**. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among real-world hypertensive patients with chronic kidney disease. *J Clin Hypertens* 2019;21:91-101, Epub 2018 Nov 14. PMID:30427124, PMC6329007.
278. Thorn C, Whirl-Carrillo M, Hachad H, Johnson JA, McDonagh E, Ratain MA, Relling MV, Scott S, Altman RB, and Klein TE. Essential characteristics of pharmacogenomics study publications. *Clin Pharmacol Ther* 2019;105:86-91, Epub 2018 Nov 8. PMID:30406943, PMC6449845.
279. Zebrowski AM, Ellis DE, Barg FK, Sperber NR, Bernhardt BA, Denny JC, Dexter PR, Ginsburg GS, Horowitz CR, **Johnson JA**, Levy MA, Orlando LA, Pollin TI, Skaar TC, Kimmel SE MD. Qualitative study of system level factors related to genomic implementation. *Genet Med* 2019;21:1534-1540, Epub 2018 Nov 23. PMID:30467402, PMC6533158.
280. Chauhan G, Adams HHH, Satizabal CL, Bis JC, Teumer A, Sargurupremraj M, Hofer E, Trompet S, Hilal S, Vernon A, Jian X, Malik R, Traylor M, Pulit SL, Amouyel P, Mazoyer B, Zhu YC, Kaffashian S, Schilling S, Beecham GW, Montine TJ, Schellenberg GD, Kjartansson O, Gudnason V., Knopman DS, Griswold ME, Windham BG, Gottesman RF, Mosley TH, Schmidt R, Saba Y, Schmidt H, Takeuchi F, Yamaguchi S, Nabika T, Kato N, Rajan KB, Aggarwal NT, De Jager PL, Evans DA, Psaty BM, Rotter JI, Rice K, Lopez OL, Liao J, Chen CPLH, Cheng CY, Wong TY, Ikram MK, van der Lee SJ, Amin N, Chouraki V, DeStefano A, Aparicio HJ, Romero JR, Maillard P, DeCarli CS, Wardlaw, Valdés Hernández M del C, Luciano M, Liewald D, Deary IJ, Starr JM, Bastin ME, Muñoz Maniega S, Slagboom PE, Beekman M, Deelen J, Uh HW, Lemmens R, Brodaty H, Wright MJ, Ames D, Boncoraglio GB, Hopewell JC, Beecham AH, Halloran Blanton S, Wright CB, Sacco RL, Wen W, Thalamuthu A, Armstrong NJ, Chong E, Schofield PR, Kwok JB, van der Grond J, Stott DJ, Ford I, Jukema JW, Vernooij MW, Hofman A, Uitterlinden AG, van der Lugt A, Wittfeld K, Grabe HJ, Hosten N, von Sarnowski B, Völker U, Levi CR, Jimenez-Conde J, Sharma P, Sudlow CLM, Rosand J, Woo D, Cole JW, Meschia JF, Stowik A, Thijs V, Lindgren A, Melander O, Grewal RP, Rundek T, Rexrode K, Rothwell PM, Arnett DK, Jern C, **Johnson JA**, Benavente OR, Wassertheil-Smoller S, Lee JM, Wong Q, Mitchell BD, Rich SS, McArdle PF, Geerlings MI, van der Graaf Y, de Bakker PIW, Asselbergs FW, Srikanth VK, Thomson R, McWhirter R, Moran C, Callisaya ML, Phan TG, Rutten-Jacobs LCA, Bevan S, Tzourio C, Mather KA, Sachdev PS, van Duijn CM, Worrall BB, Dichgans M, Kittner SJ, Markus HS, Ikram MA, Fornage M, Launer LJ, Seshadri S, Longstreth, Jr. WT, and Dobbie S. Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. *Neurology* 2019;92:486-503, Epub Jan 16. PMID:30651383, PMC6369905.
281. Smith DM, Weitzel KW, Elsey AR, Langae T, Gong Y, Wake DT, Duong BQ, Hagan M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, **Johnson JA**, Cavallari LH. CYP2D6-guided opioid therapy improves pain control

- in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med 2019;21:1842-1850, Epub Jan 23. PMID:30670877, PMC6650382.
282. Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, **Johnson JA**, Turner ST, Cooper-DeHoff RM. Plasma Renin Activity Is a Useful Predictive Biomarker of Blood Pressure in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens 2019;32:668-675, Epub Feb 9. PMID:30753254, PMC6558666.
283. Solayman MH, Langae TY, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshes AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff RM, Badary OA, **Johnson JA**. Effect of Plasma MicroRNA on the Antihypertensive Response to Beta Blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Studies. Eur J Pharm Sci 2019;131:93-98, Epub Feb 10. PMID:30753892, PMC6467266.
284. Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Owusu Obeng A, Beitelshes AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, **Johnson JA**, Peterson JF, Empey PE, Skaar TC. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med 2019;21:2255-2263, Epub Mar 21. PMID:30894703, PMC6754805.
285. Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe L, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Anselmi CV, Vlachopoulou E, Ali LA, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge P, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki JL, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha C, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Brenner H, Bruggs JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Jabbari R, **Johnson JA**, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kilizek M, Klungel OH, Lagerqvist Bo, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani A, Asselbergs FW. Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. Circ Genom Precis Med 2019;12:e002470, Epub Mar 21. PMID:30896328, PMC6629546.
286. Patel R, Schmidt A, Tragante V, McCubrey R, Holmes M, Howe L, Direk K, Åkerblom A, Leander K, Virani S, Kaminski K, Muehlschlegel J, Dubé MP, Allayee H, Almgren P, Alver M, Baranova E, Behloui H, Boeckx B, Braund P, Breitling L, Delgado G, Duarte N, Dufresne L, Eriksson N, Foco L, Gijsberts C, Gong Y, Hartiala J, Heydarpour M, Hubacek J, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini P, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson C, Nikus K, Pilbrow A, Ploski R, Sun Y, Tanck M, Tang WH, Trompet S, van der Laan S, van Setten J, Vilmundarson R, Anselmi CV, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist J, Carruthers K,

- Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo P, Marziliano N, Mordi I, Muhlestein J, Newton-Cheh C, Pitha J, Saely C, Samman-Tahhan A, Sandesara P, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde A, Ford I, Stott D, Algra A, Andreassi M, Ardissino D, Arsenault B, Ballantyne C, Bergmeijer TO, Bezzina C, Body S, Bogaty P, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty R, Drexel H, Engert JC, Fox K, Girelli D, Hagström E, Hazen S, Held C, Hemingway H, Hofer I, Hovingh GK, **Johnson JA**, Jukema JW, Kaczor M, Kähönen M, Kettner J, Kiliszek M, Klungel O, Lagerqvist B, Lambrechts D, Laurikka J, Lehtimäki T, Lindholm D, Mahmoodi B, Maitland-van der Zee A, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer C, Pasterkamp G, Pepine C, Pereira A, Pilote L, Quyyumi A, Richards A, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus J, Stewart A, Szczeklik W, Szpakowicz A, ten Berg J, Thanassoulis G, Thiery J, van der Graaf Y, Visseren F, Waltenberger J, van der Harst P, Tardif JC, Sattar N, Paré LC, Brophy J, Anderson J, März W, Wallentin L, Cameron V, Horne B, Samani N, Hingorani A, and Asselbergs F. Association of Chromosome 9p21 with Subsequent Coronary Heart Disease events: A GENIUS-CHD study of individual participant data. Circ Genom Precis Med 2019;12:e002471, Epub Mar 21. PMID:30897348, PMC6625876.
287. Cicali EJ, Wiisanen Weitzel K, Elsey ER, Orlando FA, Vinson M, Scott Mosley S, Smith DM, Davis R, Lori Drum L, Estores D, Franciosi JP, Hagen MG, Jerkins GJ, Mercado ES, Nainaparampil J, Padron A, Rosenberg EI, Wright A, Schmidt SO, Mathews CA, Cavallari LH, **Johnson JA**. Challenges and Lessons Learned from Clinical Pharmacogenetic Implementation of Multiple Gene-Drug Pairs Across Ambulatory Care Settings. Genet Med 2019;21:2264-2274, Epub Mar 30. PMID:30926959, PMC6768772.
288. Singh S, El Rouby N, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Genomic Association Analysis Reveals Variants Associated with Blood Pressure Response to Beta-Blockers in European Americans. Clin Transl Sci 2019;12:497-504, Epub Jun 4. PMID:31033190, PMC6742943.
289. Snyder SR, Hao J, Cavallari LH, Geng Z, Elsey A, **Johnson JA**, Mohamed Z, Chaiyakunapruk N, Chong HY, Dahlui M, Shabaruddin FH, Patrinos GP, Mitropoulou C, Williams MS. Generic Cost Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-making for Public Health Precision Medicine. Public Health Genomics 2018;21:217-227, Epub 2019 Jun 12. PMID:31189173, PMC6762029.
290. Shahin MH, El Rouby N, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, **Johnson JA**. Beta2-Adrenergic Receptor Gene Affects the Heart Rate Response of Beta-Blockers: Evidence from Three Clinical Studies. J Clin Pharmacol 2019;59:1462-1470, Epub May 14. PMID:31090079, PMC6773496.
291. Singh S, Warren HR, Hiltunen TP, McDonough CW, El Rouby N, Salvi E, Wang Z, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Turner ST, Chapman AB, Boerwinkle E, **Johnson JA**, Gong Y, Cooper-DeHoff RM. Genome Wide Meta-Analysis of Blood Pressure (BP) Response to β_1 -Blockers: Results from the International Consortium of Antihypertensive Pharmacogenomics Studies (ICAPS). J Am Heart Assoc 2019;8:16:e0131115, Epub Aug 19. PMID:31423876, PMC6759913.
292. Singh S, McDonough CW, Gong Y, Bailey K, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep 2019;9:1, Epub Nov 21. PMID:31754133, PMC6872535.
293. Iniesta R, Campbell D, Venturini C, Singh S, Irvin MR, Cooper-DeHoff RM, **Johnson JA**, Turner ST, Arnett DK, Weale ME, Warren H, Munroe PB, Padmanabhan S, Lewis C, Chowienczyk P. Gene variants at loci related to blood pressure account for ethnic variation in response to anti-

- hypertensive drugs: genomic precision medicine may dispense with “ethnicity”. Hypertension 2019;74:614-622, Epub Jul 22. PMID:31327267.
294. Cunningham PN, Wang Z, Grove-Gaona ML, Cooper-DeHoff RM, Beitelshes AL, Gong Y, Gums JG, **Johnson JA**, Turner ST, Boerwinkle E, Chapman AB. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade. PLoS One. 2019;14:e0221957. PMID:31532792, PMC6750571.
295. El Rouby N, Alrwisan A, Langae TY, Riva A, Elsey AE, **Johnson JA**, Cavallari LH, Winterstein AG. Clinical utility of pharmacogene panel-based testing in patients undergoing percutaneous coronary intervention (PCI). Clin Transl Sci 2020;13:473-481. Epub Jan 16. PMID:31758664, PMC7214641.
296. Magvanjav O, Cooper-DeHoff RM, McDonough CW, Gong Y, Hogan WR, **Johnson JA**. Combination antihypertensive therapy prescribing and blood pressure control in a real-world setting. Am J Hypertens 2020;33:316-324, Epub Dec 19, 2019. PMID:31853537.
297. Cicali EJ, Smith DM, Duong BQ, Kovar LG, Cavallari LH, **Johnson JA**. A scoping review of the evidence behind CYP2D6 inhibitor classifications. Clin Pharmacol Ther 2020;108:116-125. Epub Jan 7. PMID:31910286, NIHMS1067435.
298. Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar T, Pisu M, Dillon C, Beitelshes AL, Empey PE, Duarte JD, Diaby V, Gong Y, **Johnson JA**, Graves J, Garbett S, Zhou Z, Peterson JF on behalf of Implementing GeNomics In pracTicE (IGNITE) Network Pharmacogenetic Working Group. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by realworld data. Pharmacogenomics J. 2020;20:724-735. Epub Feb 11. PMID:32042096.
299. Yang J, Asico LD, Beitelshes AL, Feranil JB, Wang X, Jones JE, Armando I, Cuevas SG, Schwartz GL, Gums JG, Chapman AB, Turner ST, Boerwinkle E, Cooper-DeHoff RM, **Johnson JA**, Felder RA, Weinman EJ, Zeng C, Jose PA, Villar VAM. Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB J. 2020;34:7941-7957. Epub Apr 15. PMID 32293069, PMC7643053.
300. Marrero RJ, Cicali EJ, Arwood MJ, Eddy E, DeRemer D, Ramnarain BH, Daily KC, Jones D Jr, Cavallari LH, Wiisanen KW, Langae T, Newsom KJ, Starostik P, Clare-Salzer MJ, **Johnson JA**, George TJ, Cooper-DeHoff RM. How to Transition from Single Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. Clin Pharmacol Ther 2020;108(3):557-565. Epub July 6. PMID 32460360. PMC7704727.
301. Beitelshes AL, Stevenson JM, El Rouby N, Dillon C, Empey PE, Fielstein EM, **Johnson JA**, Limdi NA, Ong HH, Peterson JF, Rosenman MB, Skaar TC, Tuteja S, Cavallari LH, on behalf of the IGNITE Pharmacogenetics Working Group. Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. Genet Med 2020;22(11):1898-1902. Epub July 17. PMID32678355. PMC7606808.
302. Mahmoodi BK, Tragante V, Kleber V, Holmes MV, Schmidt AF, McCubrey RO, Howe LJ, Direk K, Allayee H, Baranova EV, Braund PS, Delgado G, Eriksson N, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Pasterkamp G, Kotti S, Kuukasjärvi P, Lenzini PA, Levin D, Lyytikäinen LP, Muehlschlegel JD, Nelson CP, Nikus K, Pilbrow AP, Wilson Tang WH, van der Laan SW, van Setten J, Vilmundarson RO, Deanfield J, Deloukas P, Dudbridge F, James F, Mordi IR, Teren A, Bergmeijer BO, Body SC, Bots M, Burkhardt R, Cooper-DeHoff RM, Cresci S, Danchin N, Doughty RN, Grobbee DE, Hagström E, Hazen SL, Held C, Hofer IO, Hovingh GK, **Johnson JA**, Kaczor MP, Kähönen M, Klungel OH, Laurikka JO, Lehtimäki T, Lindholm D, MD, Maitland-van der Zee AH, McPherson R, Palmer CN, Kraaijeveld AO, Pepine CJ, Sanak M, Sattar N, Scholz M, Simon T, Spertus JA, Stewart AFR, Szczeklik W, Thiery J, Visseren FLJ, Waltenberger J, Richards AM, Lang

- CC, Cameron VA, Åkerblom A, Pare G, März W, Samani NJ, Hingorani AD, ten Berg JM, Wallentin L*, Asselbergs* FW, Patel* R. Association of Factor V Leiden with Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. Circulation 2020;142(6):546-555. Epub July 13. PMID32654539. PMC7493828.
303. Thomas CD, **Johnson JA**. Pharmacogenetic factors affecting beta-blocker metabolism and response (Invited Review). Exp Opin Drug Metab Toxicol 2020;16(10):953-964. Epub Sept 9. PMID 32726152. PMC7606773.
304. Arwood MJ, Dietrich EA, Duong BQ, Smith DM, Cook K, Elchynski A, Rosenberg EI, Huber KN, Nagoshi YL, Wright A, Budd JT, Holland NP, Maska E, Panna D, Eley AR, Cavallari LH, Weitzel KW, **Johnson JA**, Gums JG. Design and early implementation successes and challenges of a pharmacogenetics consult clinic. J Clin Med 2020;9:E2274. Epub July 17. PMID32708920, PMC7408871.
305. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther 2021;109(6):1417-1423. Epub Sep 20. PMID 32770672. PMC7868475.
306. Lee CR, Thomas CD, Beitelshes AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, **Johnson JA**, Stouffer GA, Cavallari LH on behalf of the IGNITE Network Pharmacogenetics Working Group. Impact of the *CYP2C19*17* allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. Clin Pharmacol Ther 2021;Mar;109:705-715. Epub Oct 2020. PMID 3897581. PMC7902344.
307. Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langae TY, Gong Y, Wang D, Schmidt SO, Binkley P, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman AB, Cooper-DeHoff RM, Gums JG, Hamadeh IS, Zhao L, Schmidt S, Frye RF, **Johnson JA***, Cavallari LH*. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics across *CYP2D6* Genotype-derived Activity Scores. *co-senior authors. CPT: Pharmacometr Syst Pharmacol 2020;9:678-685. PMID33067866. PMC7762806.
308. Schunk SJ, Kleber ME, März W, Pang S, Zewinger S, Triem S, Ege P, Reichert MC, Krawczyk M, Weber SN, Jaumann I, Schmit D, Sarakpi T, Wagenpfeil S, Kramann R, Boerwinkle E, Ballantyne CM, Grove ML, Tragante V, Pilbrow AP, Richards AM, Cameron VA, Doughty RN, Dubé MP, Tardif JC, Feroz-Zada Y, Sun M, Liu C, Ko YA, Quyyumi AA, Hartiala JA, Tang WHW, Hazen SL, Allayee H, McDonough CW, Gong Y, Cooper-DeHoff RM, **Johnson JA**, Scholz M, Teren A, Burkhardt R, Martinsson A, Smith JG, Wallentin L, James SK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Campbell H, Tierling S, Walter J, Ampofo E, Niemeyer BA, Lipp P, Schunkert H, Böhm M, Koenig W, Fliser D, Laufs U, Speer T; eQTLGen consortium; BIOS consortium. Genetically determined NLRP3 inflammasome activation associates with system inflammation and cardiovascular mortality. Eur Heart J 2021;42:1742-1756. Epub May 7. PMID 33748830.
309. Thomas CD, Parvataneni HK, Gray CF, Deen JT, Prieto HA, Pulido LF, Eley AR, Elwood EN, Starostik P, Gong Y, Fillingim RB, **Johnson JA**, Cavallari LH. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genet Med, 2021;23:621-628. Epub Jan 28. PMID 33420349.
310. Chekka LMS, Chapman AB, Gums JG, Cooper-DeHoff RM, **Johnson JA**. Race specific comparisons of antihypertensive and metabolic effects of hydrochlorothiazide and chlorthalidone. Submitted for publication, 2020. Am J Med 2021; Epub Jan 9. PMID 33434556.

311. Ginsburg GS, Cavallari LH, Chakraborty H, Cooper-DeHoff RM, Dexter PR, Eadon MT, Ferket BS, Horowitz CR, **Johnson JA**, Kannry J, Kucher N, Madden EB, Orlando LA, Parker W, Peterson J, Pratt VM, Rakhra-Burris TK, Ramos MA, Skaar TC, Sperber N, Steen-Burrell KA, Van Driest SL, Voora D, Wiisanen K, Winterstein AG, Volpi S for the IGNITE Pragmatic Trials Network. Establishing the Value of Genomics in Medicine – The IGNITE Pragmatic Trials Network. Genet Med 2021; Epub Mar 29. PMID 33782552
312. Arwood MJ, McDonough CW, Cavallari LH, Elsey AR, Frye RF, Gong Y, Langae T, **Johnson JA**, Wiisanen K. Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. J Am Coll Clin Pharm 2021;4:343-351.
313. Elchynski AL, Cicali EJ, Ferrer M, Hamilton A, Chang KL, Schmidt S, Weiner B, Davis, Estores D, Smith DS, Wiisanen K, **Johnson JA**, Cavallari LH. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease. Pharmacogenom J 2021 Epub Jun 1. PMID 34075203.
314. McDonough CW, Warren HR, Jack JR, Motsinger-Reif AA, Armstrong ND, Bis JC, House JS, Singh S, El Rouby NM, Gong Y, Mychaleckyj JC, Rotroff DM, Benavente OR, Caulfield MJ, Doria A, Pepine CJ, Psaty BM, Glorioso VP, Glorioso N, Hiltunen TP, Kontula KK, Arnett DK, Buse JB, Irvin MR, **Johnson JA**, Munroe PB, Wagner MJ, Cooper-DeHoff RM. Adverse Cardiovascular Outcomes and Antihypertensive treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS). Clin Pharmacol Ther 2021;110:723-32. Epub Aug 15. PMID 34282303.
315. Cicali EJ, Elchynski AL, Cook KJ, Houdier JT, Thomas CD, Smith DM, Elsey A, **Johnson JA**, Cavallari LH, Wiisanen K. How to Integrate CYP2D6 Phenoconversion into Clinical Pharmacogenetics: A Tutorial. Clin Pharmacol Ther 2021;110:677-687. E pub July 28. PMID 34231197.
316. Sperber NR, Dong OM, Roberts MC, Dexter P, Elsey AR, Ginsburg GS, Horowitz CR, Johnson JA, Levy KD, Ong H, Peterson J, Pollin TI, Rakhra-Burris T, Ramos MA, Skaar T, Orlando L. Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE network. J Prec Med 2021 Epub July 8. PMID34357114. PMC8306482.
317. Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshes AL, Empey PE, Johnson JA, Owusu Obeng A, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH; IGNITE Network Pharmacogenetics Working Group. Multi-site investigation of strategies for the clinical implementation of preemptive pharmacogenetic testing. Genet Med. 2021 Jul 19 Epub. PMID 34282303.
318. Zewinger S, März W, Kleber MK, Schunk SJ, Schmit D, Triem S, Wagenpfeil S, Kramann R, Gergei I, Boerwinkle E, Ballantyne CM, Grove-Gaona ML, Richards AM, Cameron VA, Doughty RN, Pilbrow AP, Dubé MP, Tardif JC, Feroz-Zada Y, Liu C, Ko YI, Quyyumi A, Hartiala JA, Tang WHW, Hazen SL, Allayee H, McDonough CW, Gong Y, Cooper-DeHoff RM, **Johnson JA**, Scholz M, Teren A, Burkhardt R, Thiery J, Martinsson A, Smith JG, Melander O, Orho-Melander M, Schulz CA, Engström G, Wallentin L, James SK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Lenzini PA, Koenig W, Fliser D, Laufs U, Speer T. A common variant in the NLRP3 inflammasome locus associates with mortality. 2021. Submitted for publication.
319. Beitelshes AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Skaar TC, Coons JC, Giri J, McDonough CW, Rowland R, Stevenson JM, Thai T, Wellen JT, **Johnson JA**, Winterstein AG, Cavallari LH, Lee CR, on behalf of the IGNITE

Network Pharmacogenetics Working Group. Real-world outcomes with CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. 2021, submitted for publication.

Editorials, Letters to the Editor and Commentaries

320. **Johnson JA.** Improving cardiovascular drug therapy through pharmacogenomics? Hellenic J Cardiol 2002;43:16-19.
321. **Johnson JA.** β -blockers in heart failure: Will we someday select therapy based on genetics? Pharmacogenetics 2003;13:375-77.
322. **Johnson JA.** Use of pharmacogenetics in clinical medicine: Hype or hope? Personalized Med 2005;2:279-282.
323. Gerhard T, Beitelshes AL, **Johnson JA.** Letter to the Editor RE: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost effectiveness analysis. Pharmacogenet Genom 2006;16:613.
324. Altman RD, Benowitz N, Gurwitz D, Lunshof J, Relling MV, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, **Johnson JA**, McLeod HL, Flockhart D, Weinshilboum R, Shuldiner AR, Roden DM, Krauss RM, Ratain M. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics 2007;8:519. PMID: 17465717.
325. **Johnson JA.** Warfarin: An old drug but still interesting. Pharmacotherapy 2008;28:1081-83. PMID: 18752378
326. Klein TE, Kimmel SE, **Johnson JA.** Warfarin pharmacogenetics (letters to the editor, author reply). N Engl J Med 2009;360:2475.
327. **Johnson JA.** Pharmacogenomics of antihypertensive drugs: Past, present and future. Pharmacogenomics 2010;11:487-91. PMID: 20350127. PMCID: PMC4867543.
328. Gums JG, **Johnson JA.** Combination antihypertensive treatment: Is initiation order important? J Clin Hypertension 2010;12:565-67. PMID: 20695931
329. Gong Y, Beitelshes AL, Cooper-DeHoff RM, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, **Johnson JA.** Response to Letter Regarding Article "Chromosome 9p21 Haplotypes and Prognosis in white and Black Patients with Coronary Artery Disease". Circ Cardiovasc Genet. 2011;4 (4): e12. PMID: 21846865. PMCID: PMC3101633
330. **Johnson JA.** Warfarin pharmacogenetics: A rising tide for its clinical value. Circulation 2012;125:1964-6. Epub Mar 19. PMID 22431866. PMCID: PMC3337679.
331. Ratain M, **Johnson JA.** Meaningful use of pharmacogenetics. (Invited Commentary). Clin Pharmacol Ther 2014;96:650-52. PMID 25399712.
332. **Johnson JA**, Hamadeh IS, Langaee TY. Loss of heterozygosity at the *CYP2D6* locus in breast cancer: implications for tamoxifen pharmacogenetic studies. (Invited editorial) J Natl Cancer Inst 2015;107, Jan 31. PMID 25638249.
333. **Johnson JA**, Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: How, where and who? (Invited Commentary) Clin Pharmacol Ther 2016;99:154-6. Epub 2015 Oct 6. PMID26440500. PMC4724232.

334. **Johnson JA.** Pharmacists should jump onto the clinical pharmacogenetics train (Invited commentary). Am J Health Syst Pharm 2016 Dec 1;73(23):2013-16. PMID 27864209. PMC5359626.
335. Cavallari LH, **Johnson JA.** A case for genotype-guided pain management (Invited Commentary). Pharmacogenomics 2019;10:705-7018. Epub Aug 1. PMID: 31368851. PMC
336. Brouwer KLR, Schmidt S, Floren LC, **Johnson JA.** Clinical pharmacology education: The decade ahead. Clin Pharmacol Ther 2020;107:37-39. Epub Nov 10, 2019. PMID: 31709518. PMC6937203.
337. Shahin MH, Abdel-Rahman S, Hartman D, **Johnson JA**, Mitchel D, Reynolds KS, Wagner JA, Morrissey KM. A Perspective on the Future of Clinical Pharmacology. Clin Pharmacol Ther 2020;107:72-75. Epub Nov 21, 2019. PMID 31751490.
338. **Johnson JA.** What will be your legacy in pharmacy? How will you be a Paul Parker? J Am Coll Clin Pharm 2020;3:6-7.
339. **Johnson JA**, Schmidt S. Tribute to Professor Hartmut Derendorf (1953-2020): Driving force in clinical pharmacology and mentor extraordinaire. Clin Pharmacol Ther 2021;109:805-809. Epub Mar 5. PMID 33667324.

Public data deposits

340. Johnson JA, et al. Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR and PEAR-2) dbGaP data deposit. Accession # phs000649.v2.p2.
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000649.v2.p2.

Peer-reviewed electronic publications

341. Pacanowski MA, **Johnson JA.** Annotated pharmacogenetic gene information for the β_1 -adrenergic receptor gene (*ADRB1*). <http://www.pharmgkb.org/search/annotatedGene/adrb1/> and <http://www.pharmgkb.org/search/annotatedGene/adrb1/>.
342. Litonjua A, Shin J, **Johnson JA**, Weiss ST. Annotated pharmacogenetic gene information for the β_2 -adrenergic receptor gene (*ADRB2*). <http://www.pharmgkb.org/search/annotatedGene/adrb2/> and <http://www.pharmgkb.org/search/annotatedGene/adrb2/variant.jsp>.
343. Schentrup AM, Lima JJ, **Johnson JA.** Annotated pharmacogenetic gene information for the arachidonate 5-lipoxygenase gene (*ALOX5*). <http://www.pharmgkb.org/search/annotatedGene/alox5/index.jsp> and <http://www.pharmgkb.org/search/annotatedGene/alox5/variant.jsp>.
344. Bushwitz J, Pacanowski MA, **Johnson JA.** Annotated pharmacogenetic gene information for the coagulation factor 5 gene (*F5*). <http://www.pharmgkb.org/search/annotatedGene/f5/index.jsp> and <http://www.pharmgkb.org/search/annotatedGene/f5/ImportantVariantInformationforF5.jsp>.
345. Gonzales D, Pacanowski MA, **Johnson JA.** Annotated pharmacogenetic gene information for the potassium inwardly-rectifying channel, subfamily J, member 11 (*KCNJ11*). <http://www.pharmgkb.org/search/annotatedGene/kcnj11/index.jsp> and <http://www.pharmgkb.org/search/annotatedGene/kcnj11/ImportantVariantInformationforKCNJ11.jsp>

Other electronic publications

1. **Johnson JA.** How your genes influence what medicines are right for you. The Conversation. <http://theconversation.com/how-your-genes-influence-what-medicines-are-right-for-you-46904>

Books Edited

1. Allen WL, **Johnson JA**, Knoell DL, Kolesar JM, McInerney JD, McLeod HL, Spencer HT, Tami JA. Pharmacogenomics – Applications to Patient Care ACCP: Kansas City, Missouri, 2004.
2. McLeod HL, DeVane CL, **Johnson JA**, Knoell DL, Kolesar JM, McInerney JD, Rogers PD, Walker JR. Pharmacogenomics – Applications to Patient Care, 2nd Ed ACCP: Kansas City, Missouri, 2009.
3. **Johnson JA**, Ellingrod V, Kroetz DL, Kuo GM. Pharmacogenomics: Applications to Patient Care, 3rd Ed. ACCP: Lenexa, Kansas. 2015.

Book chapters

1. **Johnson JA**, Lalonde RL. Congestive Heart Failure. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Posey LM (eds). Pharmacotherapy A Pathophysiologic Approach, 2nd Edition. Appleton & Lange: Norwalk, Connecticut. 1992, pp. 160-193.
2. Sowinski KM, **Johnson JA**. Angina Pectoris. In Herfindal ET, Gourley DR (eds). Textbook of Therapeutics, 6th Edition. Williams & Wilkins: Baltimore, Maryland. 1996:811-828.
3. **Johnson JA**, Lalonde RL. Congestive Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy A Pathophysiologic Approach, 3rd Edition. Appleton & Lange: Norwalk, Connecticut. 1997, pp. 219-256.
4. **Johnson JA**, Parker RB, Geraci SA. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy A Pathophysiologic Approach, 4th Edition. Appleton & Lange: Norwalk, Connecticut, 1999, pp.153-181.
5. **Johnson JA**, Parker RB, Patterson JH. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy A Pathophysiologic Approach, 5th Edition. McGraw Hill: New York, New York, 2002, pp.185-218.
6. **Johnson JA**. Drug target pharmacogenetics. In: Pharmacogenomics – Applications to Patient Care. ACCP: Kansas City, Missouri, 2004, pp. 337-376.
7. **Johnson JA**, Cavallari LH. Cardiovascular pharmacogenomics. In: Raizada MK, Paton JFR, Kasparov S, Katovich MJ (eds). Cardiovascular Genomics. Humana Press, Inc: Totowa, NJ, 2005, pp. 71-93.
8. Parker RB, Patterson JH, **Johnson JA**. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy A Pathophysiologic Approach, 6th Edition. McGraw Hill: New York, New York, 2005, pp. 219-260.
9. **Johnson JA**, Zineh I. Cardiovascular Pharmacogenomics and Personalized Medicine. In: Liew CC, Dzau V (eds). Cardiovascular Genetics and Genomics for the Cardiologist. Blackwell Publishing: Oxford, England. 2007, pp. 250-276.
10. **Johnson JA**, Zineh I, Pacanowski MA. Pharmacogenetics and Pharmacogenomics. In: Roden DM (ed). Cardiovascular Genetics and Genomics. Blackwell Publishing: Oxford, England. 2009, pp. 211-230.
11. **Johnson JA**. Drug target pharmacogenetics. In: McLeod HL, DeVane CL, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, Rogers PD, Walker JR. Pharmacogenomics – Applications to Patient Care, 2nd Ed. ACCP: Kansas City, Missouri, 2009, pp 90-106.

12. Gong Y, McDonough CW, Padmanabhan S, **Johnson JA**. Hypertension Pharmacogenomics. In: Padmanabhan S. Handbook of Pharmacogenomics and Stratified Medicine. Elsevier: London, UK, 2014, pp 747-778.
13. Cavallari LH, Mosley SA, **Johnson JA**. Pharmacogenetics. In: Wecker L, Taylor DA, Theobald Jr RJ (eds). *Brody's Human Pharmacology: Mechanism-Based Therapeutics*. Elsevier: Philadelphia, PA, 2019, pp. 39-46.
14. **Johnson JA**. Reflections on Clinical Pharmacy: Evolution of Pharmacogenetics into Clinical Practice. In: Elenbaas RM, Worthen DB, Webb CE (eds). *Clinical Pharmacy in the United States: Transformation of a Profession 2nd Ed*. American College of Clinical Pharmacy: Lenexa, KS, 2019, pp. 148-149.

Abstracts (since 2010)

87. HM Davis, B Allen, Y Gong, RM Cooper-DeHoff, CJ Pepine, JA Johnson. Clinical Association of Variation in the CACNB2 Regulatory Subunit of the Voltage-Gated Calcium Channel (CACNB2) With Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* (2010) 87, S2. Presented as an oral abstract at the 2010 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Atlanta, Georgia, March 2010. Winner of the Jason Morrow Best Trainee Award (for highest graded trainee abstract), and Presidential Trainee Award.
88. MJ Moore, VPW Chik, Y Gong, T Langae, AB Chapman, GL Schwartz, ST Turner, JG Gums, RM Cooper-DeHoff, AL Beitelshes, JA Johnson. Association between melatonin receptor 1B single nucleotide polymorphisms (SNPs) and response to antihypertensive drugs. *Clin Pharmacol Ther*. 2010;87(1):S45. Presented at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA, March 2010. Duarte JD, Welder GJ, Schofield RS, Johnson JA, Zineh I. Sirtuin-1 Gene Expression Correlates with Systemic Cytokine Concentrations in Atorvastatin-Treated Healthy Subjects. *Clin Pharmacol Ther* 2010;87(S1):S46. Presented at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA, March 2010.
89. Duarte JD, Tran B, Langae TY, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Johnson JA. YEATS4 Gene Region Polymorphisms Associate with Antihypertensive Response to Hydrochlorothiazide in African Americans. *Clin Pharmacol Ther* 2010;87(S1):S46. Presented at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA, March 2010.
90. Karnes JH, George AM, Gong Y, Langae TY, Stauffer LA, Burkley BM, Pepine CJ, Johnson JA, Cooper-DeHoff RM. New onset diabetes risk associated with antihypertensive therapy in hypertensive coronary artery disease patients is modified by a single nucleotide polymorphism in the L-type calcium channel alpha 1c subunit (*CACNA1C*). *Clin Pharmacol Ther* 2010;87(S1):S45. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA. March 2010
91. Gong Y, Beitelshes AL, Lobmeyer MT, Langae TY, Cooper-DeHoff RM, Wu J, Spertus JA, Province MA, Pepine CJ, Johnson JA. Chromosome 9p21 SNP haplotypes are associated with cardiovascular outcomes in patients with coronary artery diseases. *Circulation* 2010;122:A16925. Presented as a platform presentation at the 2010 American Heart Association Scientific Sessions, Chicago, Illinois.
92. Davis HM, Gong Y, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Genetic Variation in the Calcium Signaling Pathway and Association with Outcomes in Hypertensive Coronary Artery Disease Patients. *Clinical Pharmacology & Therapeutics* (2011) 89 S1: S20. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Dallas, Texas, March 2011.
93. Vandell AG, Lobmeyer MT, Gawronski B, Langae TY, Gong Y, Beitelshes AL, Gums JG, Turner ST, Chapman AB, Cooper-DeHoff RM, Liggett SB, Johnson JA. Influence of g protein receptor kinase 4 (grk4) polymorphisms on blood pressure response to the β -blocker atenolol. *Clin Pharmacol Ther* 2011;89:S74. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Dallas, Texas, March 2011.
94. Karnes JH, Vo TT, Gong Y, Langae TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Pepine CJ, Johnson JA, Cooper-DeHoff, RM. KCNJ1 SNPs Are Associated With Increased

- Fasting Glucose And Risk of New Onset Diabetes During HCTZ Therapy. *Clin Pharmacol Ther* 2011;89(S1):S46. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Dallas, Texas, March 2011.
95. CW McDonough, B Burkely, Y Gong, TY Langaee, CJ Pepine, RM Cooper-DeHoff, JA Johnson. Non-synonymous SNPs in *SELE*, *SELP*, and *SIGLEC12* associate with Cardiovascular (CV) Outcomes in the International Verapamil SR-Trandolapril Study Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2012;91 (suppl 1):S20. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington DC, March 2012.
 96. Karnes JH, McDonough CW, Gong Y, Langaee TY, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Alpha adducin-1 (*ADD1*) single nucleotide polymorphism (SNP) associated with new onset diabetes risk with hydrochlorothiazide (HCTZ) therapy in the International Verapamil SR Trandolapril Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2012; 91 (S1): S21. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington DC, March 2012.
 97. Gong Y, McDonough CW, Wang Z, Cooper-DeHoff RM, Langaee TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S16. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington DC, March 2012.
 98. Moore MJ, Gong Y, Schmidt S, Hall K, Chapman AB, Langaee TY, Gums JG, Coop-DeHoff RM, Johnson JA. Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose., *Clin Pharmacol Ther* 2012; 91 (S1): S25. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington DC, March 2012.
 99. Moore MJ, Gong Y, Hou W, Chapman AB, Langaee TY, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. Clinical Predictors of Dysglycemic Effects Associated with Use of Beta Blockers and Thiazide Diuretics. *Clin Pharmacol Ther*. 2012;91(1):S24-25. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington DC, March 2012.
 100. Vandell AG, McDonough CW, Langaee TY, Burkley B, Gong Y, Turner ST, Gums JG, Chapman AB, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. Association of *FTO* with Hydrochlorothiazide (HCTZ)-induced elevation in uric acid (UA) in African American (AA) hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S59. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington DC, March 2012.
 101. Cooper-DeHoff RM, Hou W, Baillie R, Beitelshes AL, Gong Y, Chapman AB, Gums JG, Turner ST, Boyle SH, Zhu H, Wikoff WR, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. *Circulation*. 2012;126:A11088. Presented at the 2012 American Heart Association Scientific Sessions, Los Angeles, California.
 102. M. H. Shahin, S. I. Khalifa, A. Dvorak, T. Langaee, S. Patel, K. Perry, M. Perera, L. H. Cavallari, H. L. McLeod, J. A. Johnson. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Clin Pharmacol Ther* 2013; 93 (S1): S8. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Indianapolis, Indiana, March 2013. ***Awarded the ASCPT Presidential Trainee Award for outstanding trainee abstract.**
 103. Gong Y, Moore MJ, Karnes JH, McDonough CW, Wang Z, Langaee TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. Fasting Glucose Loci Associated with Glucose Response to Antihypertensives-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). *Clin Pharmacol Ther* 2013; 93 (S1): S28. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Indianapolis, Indiana, March 2013.
 104. Gamazon ER, Daneshjou R, Cavallari LH, Limdi NA, Wadelius M, Johnson JA, Klein TE, Scott S, Tsunoda T, Deloukas P, Altman RB, Cox NJ, Perera MA. Expression quantitative trait loci analysis of stable warfarin dose identifies novel associations: Finding signal within the noise. *Clin Pharmacol Ther* 2013; 93 (S1): S27.

- Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Indianapolis, Indiana, March 2013.
105. Gong Y, McDonough CW, Wang Z, Langaee TY, Beitelshes AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study. *Clin Pharmacol Ther* 2014; 95 (S1): S16. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting. Atlanta, GA. March 2014.
 106. Chang S, McDonough CW, Gong Y, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Pharmacogenomic genome-wide association study (GWAS) for new onset diabetes (NOD) in the international verapamil sr-trandolapril study (INVEST). Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting. Atlanta, GA. March 2014.
 107. Fontana V, McDonough CW, Gong Y, El Rouby NM, Sa AC, Pepine CJ, Cooper-Dehoff RM, Johnson JA. ATP2B1 locus is associated with resistant hypertension in the international verapamil sr tandolapril study-genetic substudy (INVEST-GENES). Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting. Atlanta, GA. March 2014.
 108. Hamadeh IS, Langaee TY, Chapman AB, Turner ST, Gums JG, **Johnson JA**. A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting. Atlanta, GA. March 2014.
 109. McDonough CW, Gong Y, Langaee TY, Pepine CJ, Cooper-DeHoff RM, Johnson JA. A pharmacogenomics genome-wide association study for adverse cardiovascular outcomes in the international verapamil sr-trandolapril study (INVEST). Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting. Atlanta, GA. March 2014.
 110. Chang S, McDonough CW, Gong Y, Pepine CJ, **Johnson JA**, Cooper-DeHoff RM. Pharmacogenomic genome-wide association study (GWAS) for new onset diabetes (NOD) in the international verapamil sr-trandolapril study (INVEST). Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting. Atlanta, GA. March 2014.
 111. Sa AC, Webb A, Gong Y, Langaee T, Turner S, Chapman A, Gums J, Scherer S, Cooper-DeHoff RM, Sadee W, **Johnson JA**. Identifying Genes Differentially Expressed Associated with Extreme Blood Pressure Response to Hydrochlorothiazide monotherapy. Abstract/Program 732M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October, 2014, San Diego, CA.
 112. Shahin MH, Gong Y, Langaee T, Beitelshes AL, Rotroff DM, Chapman, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Fiehn O, **Johnson JA**, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R. Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2015, 97: S30. Poster presentation at the 2015 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, Louisiana, March 2015.
 113. Shahin MH, Rotroff DM, Gong Y, Langaee T, McDonough CW, Beitelshes AL, Garrett TJ, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Scherer SE, Sadee W, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, **Johnson JA**. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. *Clin Pharmacol Ther* 2015, 97: S11. Presentation at the 2015 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, Louisiana, March 2015. **David Goldstein Trainee Award for top abstract and Presidential Trainee Award winner.**
 114. Cavallari LH, Magvanjav O, Anderson RD, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Elsey AR, Cooper-Dehoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, **Johnson JA**. Fewer cardiovascular events after percutaneous coronary intervention with genotype-guided antiplatelet therapy: results from the UF Health Personalized Medicine Program. Late-Breaking/Encore Abstract Poster Walk, American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting.
 115. Chang, Y. Gong, C.W. McDonough, N. Nasiri Kenari, T. Langaee, A.L. Beitelshes, J.G. Gums, A.B. Chapman, S.T. Turner, **J.A. Johnson**, R.M. Cooper-DeHoff. Correlating the melatonin pathway with atenolol

- associated glucose dysregulation in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Clin Pharmacol Ther 2015;97: S17. Presentation at the 2015 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, Louisiana, March 2015. **Presidential Trainee Award winner.**
116. Weitzel KW, Darwiche H, Elsey AR, Cavallari LH, Koroly MJ, **Johnson JA**, Nelson DR. Development of a pharmacogenomics curriculum for secondary teachers: Collaboration supports translational workforce development [abstract]. Clin Transl Sci. 2015;8(3):243. Presented at Association of Clinical and Translational Science 2015 Annual Meeting. April 17, 2015.
 117. Solyman MH, Langaee T, Gong Y, El-Hamamsy M, El-Wakeel L, Boerwinkle E, Chapman A, Turner S, Gums J, Beitelshes A, Cooper-DeHoff R, Badary O, **Johnson JA**. Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers. Clinical Pharmacology in Drug Development. 2105; 4(S1) 58-59. Presented at the 2015 Annual Meeting of the American College of Clinical Pharmacology, San Francisco, California. **Best Student Award finalist.**
 118. Sa AC, Webb A, Gong Y, McDonough CW, Langaee TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, SchererS, Cooper-DeHoff RM, Sadee W, **Johnson JA**. Molecular Markers of Blood Pressure Response to Thiazide Diuretics Identified Through Whole Transcriptome RNA-Seq Analysis, Program/Abstract #656. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 2015. Baltimore, MD.
 119. El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Benavente OR, Shuldiner AR, **Johnson JA**. Novel genetic loci for resistant hypertension discovered through a genome-wide association approach (GWAS) in the INternational VErapamil SR-Trandolapril STudy (INVEST) and the Secondary Prevention of Subcortical Strokes (SPS3) Study. Program/Abstract # 665. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 2015, Baltimore, MD.
 120. Shahin MH , Sa AC, Webb A, Gong Y, Langaee TY, McDonough CW, Beitelshes AL, Chapman AB, Gums JG , Turner ST, Frye RF, Scherer SE, Sadee W, Cooper-DeHoff RM, **Johnson JA**. Identifying a Novel Hypertension Genetic Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Program/Abstract #674. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 2015, Baltimore, MD.
 121. El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Benavente O, Shuldiner AR, **Johnson JA**. Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-Wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation. 2015;132:A15465. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 8, 2015. Orlando, FL.
 122. Cavallari LH, Magvanjav O, Anderson RD, Gong Y, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Elsey AR, Allan RW, Starostik P, Cooper-DeHoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, **Johnson JA**. Clinical implementation of *CYP2C19* genotype guided antiplatelet therapy reduces cardiovascular events after PCI. Circulation 2015;132:A11802. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL.
 123. Shahin MH, Rotroff DM, Webb A, Gong A, Langaee TY, McDonough CW, Beitelshes AL, Garrett T, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Scherer SE, Sadee W, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk RM, **Johnson JA**. Integrating Metabolomics and Genomics Uncovers Novel Pathways and Genetic Signatures Influencing Hydrochlorothiazide Blood Pressure Response: A Genetic Response Score for Hydrochlorothiazide Use. Circulation 2015;132:A13621. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 8, 2015. Orlando, FL.
 124. de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, **Johnson JA**, Cooper-DeHoff RM. Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers In DPYS Associated With Higher Glucose Change After Treatment With Atenolol. Circulation 2015;132:A18338. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 10, 2015. Orlando, FL.

125. Shahin MH, Sa AC, Webb A, Gong Y, Langae T, McDonough CW, Riva A, Beitelshes AL, Chapman AB, GumsJG, Turner ST, Frye RF, Scherer SE, Sadee W, Cooper-DeHoff RM, **Johnson JA**. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clin Pharmacol Ther* 2016, 99: S19. Presented at the 2016 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, California, March 2016. **Winner of the Presidential Trainee Award.**
126. Magvanjav O, McDonough CW, Gong Y, McClure LA, Talbert RL, Horenstein RB, Mitchell BD, Shuldiner AR, Benavente OR, **Johnson JA**. Pharmacogenetic association of β 1-adrenergic receptor Ser49Gly polymorphism with outcomes in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. *Clin Pharmacol Ther* 2016, 99: S19 (PT-17). Oral presentation at the 2016 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, California, March 2016. **Winner of the Presidential Trainee Award.**
127. Sa AC, Webb A, Gong Y, McDonough CW, Shahin MH, Langae TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, GumsJG, Scherer S, Cooper-DeHoff RM, Sadee W, Johnson JA. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. *Clinical Pharmacology & Therapeutics* 2016, 99: S19 (PT23). Oral presentation at the 2016 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, California, March 2016. **Winner of the Presidential Trainee Award.**
128. Lovato B, Weitzel W, Elsey A, McDonough C, Gong Y, Fillingim R, Schmidt S, Johnson J, Cavallari L. Factors influencing beliefs about pharmacogenetics testing in patients with chronic pain. *Pharmacotherapy* 2016;36(10):e144 (#455). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL
129. Mehanna M, Gong Y, McDonough CW, Beitelshes A, Gums J, Chapman AB, **Johnson JA**, Turner S, Cooper-DeHoff R. The role of plasma renin activity for improving precision of antihypertensive drug therapy in European Americans and African Americans. *Pharmacotherapy* 2016;36(12):e214 (#40). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.
130. Cavallari LH, Denny JC, Lee CR, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, **Johnson JA**, Peterson JF. Prospective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. *Circulation* 2016;134:e711-712 (abstract #21050). Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association's Scientific Sessions 2016. New Orleans, Louisiana. November 2016.
131. Costa Sa A, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langae TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, **Johnson JA**. RNA-Seq Analyses Identify Molecular Markers of Blood Pressure (BP) Response to Thiazide Diuretics (TD). *Clinical Pharmacology & Therapeutics* 2017; 101:S96 . (PWIV-001). Poster Walk presentation at the 2017 American Society of Clinical Pharmacology and Therapeutics Meeting, Washington DC. March 2017. **Winner of the Presidential Trainee Award.**
132. Singh S, Alghamdi W, Arwood MJ, Bargal SA, de Oliveira F, Dumeny L, Wen-Yi L, Mehanna M, Stockard B, Yang G, Fredette N, Shahin M, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Gong Y, McDonough CW, Cooper-DeHoff RM, **Johnson JA**. A Genome Wide Association Study to Identify Pharmacogenomic Variants Associated with Chlorhalidone Induced Glucose Change in African Americans. *American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics* 2017; 101:S9. (PT-019). Poster presentation at the 2017 American Society of Clinical Pharmacology and Therapeutics Meeting, Washington DC. March 2017. **Winner of the Presidential Trainee Award.**
133. El Roubi N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Bradford Y, Crawford DM, Ritchie MD, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Benavente OR, DeHoff RM, **Johnson JA**. A GWAS of Resistant Hypertension in the INternational VErapamil SR-trandolapril Study (INVEST) and Secondary Prevention of Small Subcortical Strokes (SPS3). *Clinical Pharmacology & Therapeutics* 2017; 101:S27. (PI 029). Poster presentation at 2017 Annual Meeting, Washington, DC, March 2017.

134. Shahin MH, Michailidis G, Gong Y, Beitelshes AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Thiazide-Induced Hyperuricemia: Novel Insights from Metabolomics and Genomics Integration in the Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR2) Study. *Clinical Pharmacology & Therapeutics* 2017; 101: S13. (PT-028). Poster presentation at the 2017 American Society of Clinical Pharmacology and Therapeutics Meeting, Washington DC. March 2017. **Winner of the Presidential Trainee Award.**
135. Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshes AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, **Johnson JA**. Towards precision therapy in hypertension: Genome-wide association study reveals genetic variants associated with uncontrolled blood pressure on thiazide diuretic/beta-blocker combination therapy. #PgmNr 2713/W. Poster presentation at the Annual Meeting of the American Society of Human Genetics. Orlando, Florida. October 2017.
136. El Rouby N, Alrwisn A, **Johnson JA**, Winterstein AG, Cavallari LH. Utilization of drugs with evidence for pharmacogenomic testing following percutaneous coronary intervention. PgmNr 2684/T. Poster presentation at the 67th Annual Meeting of The American Society of Human Genetics, Orlando, Florida. October 2017.
137. Shahin MH, Akoluk A, Singh S, McDonough CW, Gong Y, Chapman AB, Turner ST, Gums JG, Beitelshes AL, Boerwinkle E, Cooper-DeHoff RM, **Johnson JA**. A genome-wide association study identifies novel genetic signatures associated with thiazide diuretics adverse metabolic events. PgmNr 2678/T. Poster presentation at the 67th Annual Meeting of The American Society of Human Genetics, Orlando, Florida, October 2017.
138. Mosley S, Frye R, Langae T, Schmidt S.O.F., Schmidt S, Gong Y, Binkley P, **Johnson JA**, Cavallari LH. Determination of CYP2D6 phenotyping for metoprolol using the genotype-derived activity score. Poster presentation for ACCP Updates in Therapeutics 2018 meeting (F-42). Jacksonville, FL. February 2018.
139. Shahin MH, Balasubramanian DK, Lima ET, Mansoor H, Schmidt E, **Johnson JA**, Modave F. Mining electronic health records data unlocks novel insights about antihypertensive medication use and the risk of incident gout. *Clin Pharmacol Ther* 2018; 103: S16. Oral abstract presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018.
140. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Genome-wide meta-analyses reveal novel predictors of heart rate response to β -blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. *Clin Pharmacol Ther* 2018; 103: S15. Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018.
141. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, **Johnson JA**. β 2-adrenergic receptor gene affects the negative chronotropic effects of β -blockers in the PEAR and PEAR2 studies. *Clin Pharmacol Ther* 2018; 103: S15. Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018.
142. Singh S, Wang Z, Shahin MH, Langae TY, Gong Y, McDonough CW, Bailey KR, Turner, A. Chapman, J.G. Gums, A.L. Beitelshes, R.M. Cooper-DeHoff, S. Scherer, E. Boerwinkle, **J.A. Johnson**. Targeted sequencing identifies missense variant in the BEST3 gene associated with antihypertensive response to thiazide diuretics *Clin Pharmacol Ther* 2018;103:S5. Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018. **Winner of the David Goldstein Trainee Award for highest scoring abstract and Presidential Trainee Award winner.**
143. S. Singh, Y. Gong, C.W. McDonough, K.R. Bailey, A.L. Beitelshes, E. Boerwinkle, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, **Johnson JA**. Genome wide association study identifies novel pharmacogenetic variants associated with chlorthalidone blood pressure response in African Americans. *Clin Pharmacol Ther* 2018;103:S50. Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018.
144. El Rouby N, Mosley S, Wake DT, Liu X, Weitzel KW, Elsey AR, Riva R, LangaeTY, Winterstein AG, **Johnson JA**, Cavallari LH. Prevalence of actionable genotype and medication exposure for patients undergoing cardiac catheterization in University of Florida Personalized Medicine Program. *Clin Pharmacol Ther* 2018;103:S31. Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018

145. Schwartz EJ, Mougey EB, Chambers NA, Denham JM, Al-Atrash H, Gomez RA, Palomo PJ, Taufiq S, George DE, Evans J, Gong Y, Blake KV, **Johnson JA**, Lima JJ, Franciosi JP. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Therapy in Children: A Pilot, Randomized, Multi-Site Pragmatic Trial. *Clin Pharmacol Ther* 2018;103:S16. Presented as a Late Breaker poster at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018
146. Dumeny L, Chantra M, Langae TY, Duong BQ, Zambrano DH, Han FY, Humma JF, Dacosta JP, Lovato TB, Mei CH, **Johnson JA**, Bleiweis MS, Cavallari LH. Beta1 Adrenergic Receptor Genotype and Susceptibility to Junctional Ectopic Tachycardia after Congenital Heart Surgery. *Clin Pharmacol Ther* 2018;103:S1 (PI-0603). Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018.
147. Smith DM, Weitzel KW, Elsey AR, Wake DT, Gong Y, Duong BQ, Newsom K, Smith SM, Starostik P, Clare-Salzler MJ, Schmidt SO, **Johnson JA**, Fillingim R, Cavallari LH. Outpatient *CYP2D6* Genotype-Supported Opioid Therapy: A Prospective Trial. *Clin Pharmacol Ther* 2018; 103: S1. (PT-01). Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018. **Presidential Trainee Award winner.**
148. Magvanjav O, McDonough CW, Gong Y, Cooper-DeHoff RM, Hogan WR, **Johnson JA**. Combination Antihypertensive Therapy Prescribing Among Outpatients: Evidence from an Electronic Health Records Database. *Clin Pharmacol Ther* 2018, 103: S1 (PI-112). Poster presentation at the 2018 American Society of Clinical Pharmacology and Therapeutics Meeting, Orlando, Florida. March 2018.
149. Campbell D, Aman A, Iniesta R, Menni C, Gong Y, Cooper-DeHoff R, **Johnson J**, Burgess K, Barrett M, Lewis C, Chowienzyk P, Padmanabhan S, PEAR Investigators. Pharmacometabolomics of Blood Pressure Response to Beta-Blockers And Diuretics. *Hypertens J*. 2018;36:e124-e125. Presentation at the ESH 28th European Meeting on Hypertension and Cardiovascular Protection; June 10, 2018; Barcelona, Spain.
150. Smith DM, Cicali EJ, Duong BQ, Kovar L, Cavallari LH, **Johnson JA**. Assessing the evidence behind *CYP2D6* inhibitor classifications; a systematic review. *JACCP*. 2018;1(2):122-353. (#47411). Presented at the American College of Clinical Pharmacy Annual Conference. Seattle, Washington.
151. S. Singh, H.R. Warren, T.P. Hiltunen, E. Salvi, N. El Rouby, T. Garofalidou, F. Fyhrquist, K.K. Kontula, V. Glorioso, R. Zaninello, N. Glorioso, C.J. Pepine, P.B. Munroe, A.L. Beitelshes, S.T. Turner, A.B. Chapman, E. Boerwinkle, **J.A. Johnson**, Y. Gong, R.M. Cooper-DeHoff. Genome wide meta-analysis of blood pressure response to β -blockers: results from international consortium of antihypertensive pharmacogenomics studies. *Clin Pharmacol Ther* **2019**, 105 (S1), S27. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Washington DC. March 2019. **Presidential Trainee Award winner.**
152. N. El Rouby, T. Langae, A. Elsey, A. Riva, L.H. Cavallari, **J.A. Johnson**. Estimating the clinical value of a customized cardiovascular pharmacogenetics panel. American Society for Clinical Pharmacology and Therapeutics. *Clin Pharmacol Ther* 2019;105(S1):S93. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Washington DC. March 2019.
153. C.D. Thomas, S.A. Mosley, N. El Rouby, S. Kim, K. Lingineni, T. Langae, Y. Gong, **J.A. Johnson**, S.O. Schmidt, S. Schmidt, R.F. Frye, L.H. Cavallari. Determination of *CYP2D6* phenotyping for metoprolol using the *CYP2D6* genotype-derived activity score: results from a prospective, clinical trial. *Clin Pharmacol Ther* 2019;105 (S1):S40 (LB-028). Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Washington DC. March 2019.
154. L.M.S. Chekka, S. Singh, T.Y. Langae, A.B. Chapman, J.G. Gums, S.T. Turner, R.M. Cooper-DeHoff, **J.A. Johnson**. Systematic, Hypothesis-Driven Approach to Identify Circulating MicroRNAs That Predict Blood Pressure Response to Antihypertensive Drugs. American Society for Clinical Pharmacology and Therapeutics. *Clinical Pharmacology & Therapeutics* **2019**, 105 (S1), S89 (PIII-024; PGRN-011). Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Washington DC. March 2019.
155. Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Owusu Obeng A, Beitelshes AL, Bell GC, Blake K, Crona DJ, Dressler L, Empey PE, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Peterson JF, **Johnson JA**, Skaar TC. Multi-site Investigation of Strategies for the Clinical Implementation of *CYP2D6* Genotype-Guided Therapies. *Clin Pharmacol Ther* 2019;105(S1):S88 (PIII-023). Poster presentation at American Society of Clinical Pharmacology and Therapeutics 2019 Annual Meeting. Washington DC. March 2019.

156. Shahin MH, Gong Y, Singh S, Beitelshes AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, T.J. Garrett TJ, **Johnson JA**. Machine Learning Uncovers Novel Biomarkers of Antihypertensive Response in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Clinical Pharmacology & Therapeutics* 2019; 105: S27. (PT-013). Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Washington DC. March 2019. **Presidential Trainee Award winner.**
157. Thomas CD, Eley AR, Starostik P, Gong Y, Deen JT, Pulido LF, Prieto HA, Fillingim R, Gray CF, Parvataneni HK, **Johnson JA**, Cavallari LH. Precise Pain Control: Feasibility and Efficacy of a Preemptive CYP2D6-Genotype Guided Postoperative Pain Management Paradigm. *Clin Pharmacol Ther.* 2020;107(S1):S5-S121. **Presidential Trainee Award winner.**
158. Mehanna M, Gong Y, McDonough C, Gums JG, Chapman AB, Turner ST, **Johnson JA**, Cooper-DeHoff RM. Metabolomics Reveals Racial Difference in Blood Pressure Response to Metoprolol. *Clin Pharmacol Ther.* 2021;109(S1):S5-S88. Presented at the 2021 American Society for Pharmacology and Therapeutics Annual (Virtual) Meeting. **Presidential Trainee Award winner.**
159. Nahid N, Cicali E, McDonough C, Gong Y, **Johnson JA**. Impact of CYP2D6 Inhibitors on Opioid Therapy in Patients with Pain. *Clin Pharmacol Ther.* 2021;109(S1):S5-S88. Presented at the 2021 American Society for Pharmacology and Therapeutics Annual (Virtual) Meeting.
160. Cicali E, Elwood E, Elchynski A, Rattanasuwan T, Cook K, Alam B, Nguyen K, Eley A, Cavallari L, **Johnson JA**, Wiisanen K. The University of Florida Heath Precision Medicine Program: A 10-Year Look Back. *Clin Pharmacol Ther.* 2021;109(S1):S5-S88. Presented at the 2021 American Society for Pharmacology and Therapeutics Annual (Virtual) Meeting.
161. Cook K, Duong B, Singh D, Smith D, Dietrich E, **Johnson JA**, Wiisanen K, Gums JG, Arwood M. Patient Perceptions of Pharmacogenetic Testing in a Primary Care Setting. *Clin Pharmacol Ther.* 2021;109(S1):S5-S88. Presented at the 2021 American Society for Pharmacology and Therapeutics Annual (Virtual) Meeting.
162. Elchynski A, Hurst N, Del Busto MF, Hamilton A, Smith D, Chang K, Schmidt S, Weiner B, Davis R, Estores D, **Johnson JA**, Wiisanen K, Cavallari L, Cicali E. Comparison of Primary Care and Specialty Providers Prescribing Decisions When Pharmacogenetic Test Results are Available. *Clin Pharmacol Ther.* 2021;109(S1):S5-S88. Presented at the 2021 American Society for Pharmacology and Therapeutics Annual (Virtual) Meeting.

NATIONAL PODCASTS

Is Precision Medicine the Future of Healthcare? iHeart Radio, Spit podcast. Released March 30, 2020. https://podcasts.apple.com/us/podcast/spit/id1422827494?i=1000469952152&fbclid=IwAR3CpMS5TkVKH57cxFsoTFpQd34g2JSXIUAJJjDlgtJIW_8YJ07DI7InWs

INVITED PRESENTATIONS since 2012

121. "Translating pharmacogenetics to clinical practice: PGRN, CPIC and PharmGKB". 2nd Latin American Pharmacogenomics and Personalized Medicine Congress. Rio De Janeiro, Brazil. June 2012.
122. "Moving towards personalized care with clopidogrel and warfarin". 2nd Latin American Pharmacogenomics and Personalized Medicine Congress. Rio De Janeiro, Brazil. June 2012.
123. "Hypertension pharmacogenomics: Advancing the promises of personalized medicine". Fondazione Sigma Tau Progress in Medicine Series, San Rafeale Hospital, Milan, Italy. November, 2012
124. "Hypertension pharmacogenomics: Advancing the promises of personalized medicine". Fondazione Sigma Tau Progress in Medicine Series, University of Padua, Padua, Italy. November, 2012

125. "Clinical Implementation of Pharmacogenomics: Progress and Challenges". The Sebok Pharmacy Lecture, Raabe College of Pharmacy, Ohio Northern University, Ada, Ohio. January 2013.
126. "Clopidogrel and Warfarin Pharmacogenetics: Clinical Utilization and Ongoing Trials". 32nd Annual Perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology, Orlando, Florida, January 2013.
127. "Personalized Medicine: Translating Genetic Discoveries to Practice". 2013 Association of Pathology Chairs: Southeast Chairs and Administrators Regional Conference, Longboat Key, Florida, February 2013.
128. "Personalized Medicine: Translating Genetic Discoveries to Practice". University of Rochester, Department of Pathology Seminar Series. Rochester, New York, February 2013.
129. "Pharmacogenomics of antihypertensive drug responses". International Stroke Genetics Consortium meeting. Charlottesville, Virginia, April 2013.
130. "Warfarin pharmacogenetics". Federal Interagency Workgroup for Adverse Drug Events – Anticoagulants. National webinar. June 2013.
131. "Personalized Medicine and Pharmacogenomics: Horizons of discovery and clinical implementation". Science Plenary, American Association of Colleges of Pharmacy Annual Meeting, Chicago, Illinois, July 2013.
132. "Deciphering the drug-dosing instructions in your genome". Council for Advancement of Science Writing Annual Meeting. Gainesville, Florida, November 2013.
133. "Hypertension Pharmacogenomics: Discoveries and potential to guide hypertension therapy with genetics". State of the Art Plenary Lecture, American Society of Nephrology Kidney Week. Atlanta, Georgia, November 2013.
134. "Pharmacogenomics: Clinical Translation Leads to Improved Outcomes?". American Heart Association 2013 Scientific Sessions, Dallas, Texas, November 2013
135. "Genotyping hypertensive patients to improve outcomes". American Heart Association 2013 Scientific Sessions, Dallas, Texas, November 2013
136. "Novel discoveries in hypertension pharmacogenomics and potential implications for practice". University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award Lecture, Chapel Hill, North Carolina, December 2013.
137. "Implications for personalized medicine: Metabolic and cardiovascular diseases". Companion diagnostics: from biomarker identification to market entry". New York Academy of Sciences. New York, New York, April 2014.
138. "Hypertension pharmacogenomics: Discoveries and opportunities". American College of Clinical Pharmacology Honorary Fellow Award Lecture. Atlanta, Georgia, September 2014.
139. "Hypertension pharmacogenomics: Using 'omics technologies to advance discovery". Gerhard Levy Lecture, University of Buffalo College of Pharmacy. Buffalo, New York, October 2014.
140. "Pharmacogenomics focus on nephrology: Hypertension and Kidney Transplant". American Society of Nephrology Kidney Week 2014. Philadelphia, Pennsylvania, November 2014.

141. "Prospects for Pharmacogenomics for Patients and Populations". American Heart Association Scientific Sessions 2014. Chicago, Illinois, November 2014.
142. "Pharmacogenomics: From Randomized Trails to Populations". American Heart Association Scientific Sessions 2014. Chicago, Illinois, November 2014.
143. "Building for excellence in clinical pharmacology: an academic perspective". American Society for Clinical Pharmacology and Therapeutics Pre-meeting Symposium, New Orleans, Louisiana, March 2015.
144. "Pharmacogenomics: Discovery to Clinical Practice". American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Featured Speaker, New Orleans, Louisiana, March 2015.
145. "Cardiovascular Pharmacogenomics: Discovery to Clinical Implementation". Visiting Professor, Mt Sinai Charles Bronfman Institute for Personalized Medicine". May 2015.
146. "Pharmacogenomics: Translation to Clinical Practice - The UF Health Personalized Medicine Program". Global Gators 10th Symposium, Utrecht, The Netherlands. June 2015.
147. "Advancing understanding of drug response variability through coupling metabolomics, genomics and transcriptomics data". Pediatric Clinical Pharmacology T32 meeting, Bethesda, MD, September 2015
148. "Cardiovascular pharmacogenomics: From discovery to clinical practice". International Pharmaceutical Federation (FIP) 75th World Congress. Dusseldorf, Germany, October 2015.
149. "Pharmacogenetics in Your Clinical Practice". Special Session, 2015 Scientific Sessions of the American Heart Association, Orlando, Florida, November 2015.
150. "Improving Clinical Outcomes Through Pharmacogenomics" Pharmacogenomics Research Network Conference, American Society for Clinical Pharmacology and Therapeutics, San Diego, California, March 2016.
151. "Cardiovascular Pharmacogenomics: Discovery through Clinical Implementation". William B Abrams Lectureship Award, American Society for Clinical Pharmacology and Therapeutics and The US Food and Drug Administration. White Oak, Maryland, April 2016.
152. "Advancing Precision Medicine through Clinical Implementation and Research". Keynote Speaker, University of Florida Jacksonville Research Day. Jacksonville, Florida, May 2016
153. "Improving Clinical Outcomes Through Pharmacogenomics". Keynote Speaker, 17th Golden Helix Pharmacogenomics Day, Rotterdam, The Netherlands, May 2016.
154. "Research Leadership in Team-based Research". Academic Research Fellows Program, American Association of Colleges of Pharmacy Annual Meeting, July 2016.
155. "The UF Health Personalized Medicine Program: Improving Clinical Outcomes through Pharmacogenomics". Personalized and Genomic Medicine Program and School of Pharmacy Joint Seminar. Baltimore, Maryland. September 2016.
156. "Improving Clinical Outcomes through Pharmacogenomics – Focus on CYP2C19: the UF Health Personalized Medicine Program. Mayo Clinic 5th Annual Individualizing Medicine Conference Keynote Speaker. Rochester, Minnesota. October 2016
157. "Integrating Precision Medicine into Clinical Practice". American Heart Association 2016 Scientific Sessions. New Orleans, Louisiana. November 2016.

158. "Advancing Patient Care Through Pharmacogenomics". John I White Lecture, Washington State University School of Pharmacy, Spokane, Washington. March 2017.
159. "Pharmacogenetics in Patient Care: The Future is Now". Keynote Address. Precision Medicine Conference, University of Florida. Orlando, Florida. March 2017.
160. "Pharmacogenomics in Patient Care: The Future is Now". German Pharmacists Society Clinical Pharmacy Symposium. Munster, Germany. June 2017.
161. "Improving Patient Outcomes through Pharmacogenetics-Guided Therapy". Global Gators Symposium, Dusseldorf, Germany. June 2017.
162. "Advancing Patient Care through Pharmacogenomics". Grant Wilkinson Endowed Lectureship, Vanderbilt University College of Medicine. Nashville, Tennessee. June 2017
163. "Pharmacy and the Future of Precision Medicine". Keynote Speaker, Joint Commission of Pharmacy Practitioners. August 2017.
164. "Improving Clinical Outcomes through Precision Medicine". Keynote Speaker, American Conference on Pharmacometrics 8. Ft. Lauderdale, Florida. October 2017
165. "Advancing Patient Care through Genetically-Guided Drug Therapy: The UF Health Personalized Medicine Program". Florida Genetics Symposium. Gainesville, Florida. October 2017.
166. "Improving Patient Outcomes through Pharmacogenetics". Leon Goldberg Endowed Lecture, Medicine Grand Rounds, University of Chicago. October 2017.
167. "Improving Patient Outcomes through Pharmacogenetics". Varro Tyler Endowed Lecture, College of Pharmacy, Purdue University. West Lafayette, Indiana. November 2017.
168. "Precision Medicine: Is it Influenced by Continental Ancestry?". American Association of Pharmaceutical Scientists Annual Meeting. San Diego, California. November, 2017.
169. "Improving Patient Outcomes through Precision Medicine". Duke University Genomic and Precision Medicine Forum. Durham, North Carolina. February, 2018.
170. "Improving Clinical Outcomes with Pharmacogenomics". American Association for Advancement of Science Annual Meeting 2018, Austin, Texas. February, 2018.
171. "Improving Clinical Outcomes with Pharmacogenomics". National Health Service England: Pharmacogenomics in the NHS Workshop. London, England. February 2018.
172. "Improving Clinical Outcomes through Precision Medicine". Milap Nahata Distinguished Lecture, The Ohio State University College of Pharmacy. Columbus, Ohio, March 2018.
173. "Improving Care and Outcomes through Precision Medicine". UF Precision Medicine Conference. Orlando, Florida. March 2018
174. "Improving Clinical Outcomes through Pharmacogenetics". Charles M Gruber Distinguished Lecturer. Thomas Jefferson University Sidney Kimmel Medical College. Philadelphia, Pennsylvania. May 2018.
175. "Improving Patient Outcomes through Pharmacogenetics". University of Minnesota Pharmacogenomics Conference 2018. Minneapolis, Minnesota. June 2018.

176. "How Precision Medicine and Pharmacogenomics Are Changing Patient Care at University of Florida Health". Precision Medicine Institute Summit. Nashville, Tennessee. September, 2018
177. "Opportunities to improve clinical outcomes through pharmacogenetics". American College of Clinical Pharmacology Annual Meeting, Washington DC. September, 2018
178. "Improving clinical outcomes through pharmacogenetics". University of Illinois – Chicago Research Day Keynote Speaker. Chicago, Illinois. February 2019.
179. "Translational Pharmaceutical Scientists: Advancing Science and patient care". American Association of Colleges of Pharmacy Interim Meeting, Keynote speaker, Research pre-meeting symposium. Tampa, Florida. February 2019.
180. "Pharmacogenetics Implementation: Successes and Challenges". 4th Annual Precision Medicine Conference. University of Florida. Orlando, Florida. March 2019.
181. "Clinical outcomes and pharmacogenetics". United Health Group Pharmacogenomics Symposium Keynote presentation. Minneapolis, Minnesota. May 2019.
182. "Precision Medicine – The Future is Now: Evidence, practice and educating the future workforce". Plenary session. American Association of Colleges of Pharmacy Annual Conference. Chicago, Illinois. July 2019.
183. "Pharmacogenetics: Opportunities, implementation and improving clinical outcomes". Icahn Mt Sinai School of Medicine, Department of Family Medicine and Community Health Grand Rounds. New York, New York. October 2019.
184. "Precision Medicine: How will it change pharmacy and healthcare?". American College of Clinical Pharmacy Annual Meeting. New York, New York. October 2019.
185. "Research Leadership in Team-Based Research". American Association of Colleges of Pharmacy Annual Meeting. Virtual conference. August 2020.
186. "Improving Cancer Care through Pharmacogenomics". African Organization for Research and Training in Cancer (AORTIC) Cancer Genomics Conferences. Virtual conference. February 2021.
187. "Improving Clinical Outcomes through Pharmacogenomics". Rho Chi Lecture, Creighton University. Virtual seminar. March 2021.
188. "Using Clinical Pharmacology Tools to Improve Patient Outcomes". Rawls Palmer Progress in Medicine Award Lecture. American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Virtual conference. March 2021.
189. "Cardiovascular Pharmacogenomics". The Evolving Practice of Cardiovascular Precision Medicine. American College of Cardiology. Virtual Conference. April 2021.

INVITED PRESENTATIONS – UNIVERSITY OF FLORIDA (NON COLLEGE OF PHARMACY) since 2010

"Clopidogrel and Warfarin Pharmacogenetics: Current Status and Clinical Implications". Medicine Grand Rounds. February 2010.

"Hypertension Pharmacogenomics: An Update". Division of Nephrology Seminar Series, March 2011.

“Your DNA and You”. University of Florida Foundation Women’s Leadership Conference. April 2011.

“Moving toward personalized care with clopidogrel and warfarin”. Division of Cardiology Grand Rounds. April 2011.

“UF&Shands Personalized Medicine Program”. Center for Pharmacogenomics and Department of Pharmacotherapy and Translational Research Seminar Series. October 2011.

“Clopidogrel Pharmacogenomics and the UF&Shands Personalized Medicine Program”. Cardiology Grand Rounds, January 2012

“Hypertension Pharmacogenomics: An Update”. Division of Nephrology Research Seminar, February 2012.

“Update on the Personalized Medicine Program – Clopidogrel Pilot”. Cardiology Grand Rounds. August 2012.

“FDA safety warning on codeine and CYP2D6 genotype: Challenges with use of codeine in pediatrics”. Pediatric Grand Rounds. November 2012.

“Hypertension pharmacogenomics: Update on PEAR and INVEST”. Cardiology Grand Rounds. December 2012

“UF Health Personalized Medicine Program” Center for Pharmacogenomics and CTSI Seminar; and Cardiology Grand Rounds. August 2013

“UF Health Personalized Medicine Program”. 2013 UF Mini Medical School for high and middle school science teachers. November and December 2013

“Advancing genomic discoveries to patient care: the UF Health Personalized Medicine Program”. Department of Neuroscience Seminar Series, February 2015.

“Advancing Pharmacogenomics with iPSCs”. UF iPSC’s Symposium and Retreat. December 2015.

“Advancing Precision Medicine through Clinical Implementation and Research. UF Nursing Symposium. January 2017.

“Advancing Care through Precision Medicine”. UF Center for Vision Research Annual Symposium. November 2019.

COMMUNITY SERVICE PRESENTATIONS since 2010

“Pharmacogenomics – the promise of personalized medicine”. Gainesville Business Leaders luncheon. Gainesville, Florida. June 2010.

“Personalized Medicine: The future in healthcare?”. University of Florida Alpha Epsilon Delta Honor Society. Gainesville, Florida, February 2011.

“Personalized Medicine: The future in healthcare?”. University of Florida College of Pharmacy American Pharmaceutical Association Academy of Student Pharmacists. Gainesville, Florida, February, 2011.

“Your DNA and you”. University of Florida Inaugural Women’s Leadership Forum. Gainesville, Florida, April 2011.

“Your DNA, your medications and you”. Gainesville Kiwanis Club. Gainesville, Florida, August 2011.

“Your DNA, your medications and you”. Oak Hammock at University of Florida, Institute for Learning Cutting Edge Seminar Series. Gainesville, Florida, August 2011.

“Personalized Medicine”. US Naval Academy Alumni Luncheon. Gainesville, Florida, January 2014.

“Deciphering the drug-dosing instructions in your genome”. University of Florida Retired Faculty Association. Gainesville, Florida, January, 2015.

“Precision Medicine: What is it & how can it improve healthcare?”. UF/Gainesville Eye Openers Breakfast, Gainesville, Florida, April 2016.

“Precision Medicine: What is it & how can it improve healthcare?” Altrusa House, Gainesville, Florida, April 2017.

“Precision Medicine and How Will It Change Healthcare?” University Women’s Club 6 O’Clock Scholars. Gainesville, Florida, January 2018.

“Precision Medicine – What’s it All About?”. University of Florida College of Medicine Retired Faculty. Gainesville, Florida, September 2018.

“Improving Healthcare through Precision Medicine – And How UF is Leading the Way”. UF Orange and Blue Plate Luncheon. Tallahassee, Florida. November 2019.

“Improving Healthcare through Precision Medicine – And How UF is Leading the Way”. Shellpoint Medical Breakthroughs and Discoveries. Fort Meyers, Florida. February 2020.

POST-DOCTORAL FELLOWS

Kevin M. Sowinski, Pharm.D., BCPS (State University of New York at Buffalo). July 1992 to June 1995. Current position: Professor of Clinical Pharmacy, tenured, Purdue University.

Wendell Scott Akers, Pharm.D., BCPS (University of Tennessee). July 1992 to July 1994. Current position: Professor and Chair, David Lipscomb University.

Mohamad Haniki Nik Mohamed, Pharm.D. (University of Tennessee) July 1996 to October 1997. First position: Permanent Lecturer (equivalent to Assistant Professor), tenure track, School of Pharmaceutical Sciences, Universiti Sains Malaysia.

B. Nhi T. Nguyen, Pharm.D. (Philadelphia College of Pharmacy and Science). July 1997 to June 1999. Current position: Medical Reviewer, Cardio-Renal Division, Food and Drug Administration, Center for Drug Evaluation and Research.

Larisa M. Humma (Cavallari), Pharm.D., BCPS (University of Georgia). July 1998 to December 2000. First position: Assistant Professor, College of Pharmacy, University of Illinois, Chicago. Current position: Associate Professor (tenured), College of Pharmacy and Director, Center for Pharmacogenomics, University of Florida.

Brian J. Puckett, Pharm.D. (University of Texas). August 1999 to August 2001. First position: Assistant Professor of Clinical Pharmacy, tenure track, Medical College of Virginia – Virginia Commonwealth University. Current position: practicing physician.

Steven G. Terra, Pharm.D., BCPS (Northeastern University). July 2000 to June 2002. First and current position: Clinical Research Scientist, Cardiovascular/Metabolic Disease, Pfizer Global Research and Development.

Christina L. Aquilante, Pharm.D. (University of North Carolina at Chapel Hill). July 2001 to December 2003. Current position: Professor of Pharmaceutical Sciences, tenured, University of Colorado.

Issam Zineh, Pharm.D. (Northeastern University). July 2001 to December 2003. First position: Assistant Professor of Pharmacy Practice, tenure track, University of Florida College of Pharmacy. Current position: Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration.

Lauren Brum, Ph.D – Genetics (University of Florida). May 2003 to April 2004. Current position: Scientific Reviewer, Office of Clinical Pharmacology, Food and Drug Administration.

Amber Beitelshes, Pharm.D. (University of Florida). July 2002 to June 2005. Current position: Associate Professor, tenure track, University of Maryland.

Yan Gong, Ph.D. – Pharmaceutics (University of Florida). July 2004 to June 2005. Current position: Associate Professor, University of Florida College of Pharmacy.

Jaekyu Shin, Pharm.D. (University of Florida). July 2004 to August 2007. Current position: Professor, Department of Clinical Pharmacy, Division of Clinical Pharmacology and Experimental Therapeutics, School of Pharmacy, University of California, San Francisco.

Martin Brunner, M.D. (University of Vienna). January 2005 to June 2006. Current Position, Associate Professor, Department of Clinical Pharmacology, University of Vienna.

Michael Pacanowski, Pharm.D. (Philadelphia College of Pharmacy). July 2005 to July 2008. Current position: Associate Director for Genomics and Targeted Therapy, Office of Clinical Pharmacology and, Office of Translational Sciences, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA)

Mohamed Shafiu, M.D. UF Nephrology Fellow, co-mentored with Richard Johnson, MD, July 2007 to June 2009. Current: Private practice physician in underserved area, Bexar County, Texas.

Hazem Elewa, BS Pharmacy, PhD. (University of Georgia). July 2009 to July 2010. Current position: Clinical Assistant Professor, School of Pharmacy, Qatar University.

Maximilian Lobmeyer, BS Pharmacy, PhD (University of Florida) June 2009 to June 2010. First position: Research Scientist, Boehringer Ingelheim. Current position: Senior Pharmacokinetic Expert, Bayer Healthcare

Julio Duarte, Pharm.D. (University of Florida), Ph.D. (University of Florida). August 2010 to July 2011. First position: Assistant Professor (tenure track), Department of Clinical Pharmacy, University of Illinois, Chicago. Current position: Assistant Professor (tenure track), Department of Pharmacotherapy and Translational Research, University of Florida.

Alexander Vandell Pharm.D. (University of Georgia), Ph.D. (Mayo Graduate School). July 2010 to June 2012. Current position: Associate Director, Clinical Pharmacogenomics, Diachi Sankyo Incorporated.

Caitrin McDonough, Ph.D. (Wake Forest University). July 2010 to May 2013. Current position: Assistant Professor, tenure track. University of Florida College of Pharmacy.

Issam Hamadeh, Pharm.D. (Purdue University). January 2013 to 2016. Current position: Research Clinical Pharmacist, Johns Hopkins University Medical Center.

Sonal Singh, Ph.D. (University of Houston). September 2015 to September 2019. First Position: Scientist II, Takeda Pharmaceuticals.

Mohamed Shahin, Ph.D. (University of Florida). January 2016 to December 2018. First Position: Translational Scientist, Pfizer.

Emily Schwartz Cicali, PharmD (Philadelphia College of the Sciences). August 2017 to July 2018. First position: Clinical Assistant Professor, University of Florida College of Pharmacy.

GRADUATE STUDENTS

Major Professor - PhD

Maximilian Lobmeyer, BS. 2004 to 2009. PhD awarded May 2009. Dissertation title: "Genetic Variation of beta-adrenergic receptor kinase 1 and beta-arresting 1: Definition, functional consequences and clinical implications". Current position: Research Scientist, Boehringer Ingelheim.

Anzeela Schentrup, MS, Pharm.D., 2005 to August 2009. Dissertation title: "Leukotriene pathway and Cardiovascular disease". Current position: Informatic Team, Shands Hospital. University of Florida

Elvin Price, Pharm.D. 2006 to December 2009 (co-chair). Dissertation title: "Liver X Receptor-Alpha (LXRA) Gene Polymorphisms in Cardiovascular Disease and Fenofibrate Response". Current position: Associate Professor, tenure track, Medical College of Virginia

MyPhuong Le, BS, 2006 to May 2009. Dissertation title: "Factors Impacting Fructose Bioavailability and Adverse Metabolic Effects". Current position: Assistant Professor, College of Medicine, University of Colorado.

Julio Duarte, Pharm.D., 2007 to August 2010. Dissertation title: "The Role of the AF9/Dot1a/Sirt1 Candidate Pathway on Patient Variability in Blood Pressure and Cardiometabolic Responses to Hydrochlorothiazide". First position: Clinical Assistant Professor, Department of Clinical Pharmacy, University of Illinois, Chicago. Current position: Assistant Professor, College of Pharmacy, University of Florida.

Heather Davis, Pharm.D., 2008 to December 2011. Dissertation title: "Pharmacogenetic Assessment and Molecular Analysis of Calcium Signaling Pathway Variation". Current position: practicing pharmacist.

Jason Karnes, Pharm.D., 2009 to August 2012 (co-chair). Dissertation title: "Genetic, pharmacogenetic, and pharmacotherapeutic risk factors for thiazide-induced dysglycemia". Current position: Assistant Professor, College of Pharmacy, University of Arizona.

Mariellen Moore, Pharm.D, 2008 to December 2012. Dissertation title: "Adverse Metabolic Effects of Antihypertensive Medications: Clinical, Genetic, and Molecular Predictors". Current position: Research pharmacist, Veterans Administration Hospital, Orlando, Florida.

Mohamed Hossam Shahin, MS, 2011 to 2015. Dissertation title: "Pharmacogenomics, transcriptomics and metabolomics for the identification of novel biomarkers of blood pressure response to antihypertensive drugs". Current position: Translational Scientist, Pfizer.

Shin-Wen Chang, MS, 2011-2015 (co-chair). "Pharmacogenomics of antihypertensive treatment-related glucose dysregulation and potential underlying mechanism"

Carol Costa Sa, MS 2013 to 2017. Transcriptomics: Advancing hypertension pharmacogenomics.
First position: Computational Biologist, Janssen Pharmaceuticals.

Nihal El Rouby, PharmD, 2013 to 2017. "Identification of genetic predictors of resistant hypertension through genome-wide association analysis coupled with induced pluripotent stem cells". First position: Assistant Professor, University of Cincinnati College of Pharmacy.

Oyunbileg Magvanjav, MS (MD/PhD student, University of Florida) 2014 to 2018. "Genetic and non-genetic determinants of uncontrolled blood pressure on combination antihypertensive therapy". Continued MD education after PhD graduation. Internal Medicine Residency – Vanderbilt University.

Manasa Chekka, PharmD. 2017-present. "Personalizing thiazide therapy through clinical and microRNA biomarkers of response to thiazides"

Noor Nahid, Pharm.D. 2019-present.

PhD awarded at another institution – dissertation research conducted in my laboratory

Mohamed Solayman, MS, 2014-2016. "Applications of Personalized Medicine in the Field of Clinical Pharmacy". Degree awarded by Ain Shams University, Cairo, Egypt.

Committee Member - PhD

Jennifer Dungan, RN. UF College of Nursing, February 2006.

Tobias Gerhard, BS. Department of Pharmacy Healthcare Administration, February 2007

Laurie Duckworth, MSN, ARNP. College of Nursing. August 2007

Hongying Li, MS. Department of Statistics, College of Liberal Arts and Sciences, July 2007.

Major Professor – MS

Hrishikesh Navare, BS, MS. MS awarded May 2009. Thesis title: "Atenolol exposure and risk for development of adverse metabolic effects on glucose and lipids".

Committee Member – MS

Margarete Ribeiro Dasilva, DMD, MS. MS awarded May 2010. Thesis title: "Sex related influences on pain sensitivity and inflammation in temporomandibular joint disorder"

Mohamed Shahin, Ph.D. MS Biomedical Informatics Awarded December 2018. "Using a systems pharmacology approach to identify novel signatures associated with thiazide-induced change in uric acid levels".

CLINICAL RESIDENTS

B. Nhi Nguyen (Beasley) – Cardiology Residency, Audie Murphy Veterans Administration Medical Center, Memphis, TN. PharmD – Philadelphia College of the Sciences. July 1996-June 1997

Larisa Humma (Cavallari) - Cardiology Residency, Audie Murphy Veterans Administration Medical Center, Memphis, TN. PharmD – University of Georgia. July 1997-June 1998.

Aniwaa Owusu Obeng – Pharmacogenomics PGY2 Residency, UF Health, University of Florida. PharmD – Albany College of Pharmacy. July 2012-June 2013.

PHARM.D. HONORS THESIS MENTOR

2008

Daniel Gonzalez, Pharm.D.

2009

Stephanie Roberts, Pharm.D.

Marcus Campbell, Pharm.D.

2010

Ryan Rodriguez, Pharm.D.

2011

Veronica Chik, Pharm.D.

2012

Kristina Lee, Pharm.D.

Nicholas Carris, Pharm.D.

BaoAhn Tran, Pharm.D.

Milena Wong, Pharm.D.

2013

Sarah Burbage, Pharm.D.

2014

Ruti Dwevedi, Pharm.D.

2016

Wenhui Li, Pharm.D.

2019

Amy Yagi, Pharm.D.

VISITING SCIENTISTS

Robert Straka, University of Minnesota, Visiting Professor. September 2006 – March 2007.

Gulay Oner-Ozgon, University of Istanbul, Istanbul, Turkey. Visiting Professor, November – December 2006.

Mohamed Shahin, Visiting Masters of Science student, Misr International University, Egypt. January – February 2010.

Vanessa Fontana, State University of Campinas - UNICAMP – Brazil. Visiting post-doctoral fellow. March-May 2013.

Mohamed Solayman, Visiting PhD student, Ain Shams University, Egypt. October 2013 to present.

PROFESSIONAL SERVICE

National Academy of Medicine

Membership Committee:

- Vice-chair, Section 10: 2016-2018
- Chair, Section 10: 2018-2020

National Institutes of Health

Council activities:

- NIGMS National Advisory Council, ad hoc, January 2006

Study Section/Grant Review activities:

- XNDA Study Section chartered member, July 2007 to June 2012
- Pediatric Heart Disease Clinical Research Network, Protocol Review Committee member, January 2002 to December 2012.
- Special Emphasis Panel member, February 2002, May 2002, April 2004, November 2004
- XNDA Study Section, ad hoc member, February 2006, October 2006
- NHLBI Heart Failure Network Data Safety Monitoring Board member, June 2008 to July 2013.
- ARG1 DKUS-C ((*)) Grand Opportunity Special Emphasis Panel Chairperson; September 2009.
- ZRG1 HDM-W52. RFA Panel: Economics of Personalized Health Care; May 2013.
- ZHG1-HGR-L (M1). RFA Panel: eMERGE Genome Sequencing and Genotyping Center. March 2015
- ZHG1 HGR-M (J2). RFA SEP: Clinical Sequencing Evidence-generating Research (CSER2), November 2016.
- ZDA HXO-H (15) R. Pharmacogenomics of anti-retroviral therapy in people who inject drugs. Study section Chair. February 2018.

Workshops/Other activities

- Workshop on Genetic Determinants of Response to Drug Therapies in Heart Failure, NHLBI, participant/speaker, September 2002
- Working Group on Polymorphisms of the β -adrenergic Receptor Gene: Implications for the Pharmacotherapy of Asthma, NHLBI, participant/speaker, June 2003.
- Working Group on Behavioral Genetics and Cardiovascular Disease, NHLBI, participant/speaker, August 2005
- NHLBI Advisory Group – Genotype-Guided Trial of Warfarin Therapy, NHLBI, November, 2006.

NIH Clinical Trial: “Clarification of Optimal Anticoagulation through Genetics (COAG)”

- Protocol planning Committee, April-December 2008
- Steering Committee, June 2008 to present
- Executive Committee, Vice Chair, December 2008 to present
- Clinical trial site Principal Investigator

NIH Pharmacogenetics Research Network (PGRN)

- Coordinating Committee member, 2005 to 2010
- Heart Lung Action Group, Chair, 2006 to present

- International Warfarin Pharmacogenetics Consortium, leadership team, 2007 to present
- NIH-supported Pharmacogenomics Knowledge Base (PharmGKB)
 - Scientific Advisory Board, 2010 to 2015.
- NIH - National Human Genome Research Institute Implementing Genomics in Practice (IGNITE) Network
 - Inaugural Chair, Steering Committee, 2013-2014

National Science Foundation

- SBIR grant review committee, May 2002

Food and Drug Administration

- Nonprescription Drugs Advisory Committee member, June 2000 – May 2004.
 - Special Government Employee available for service to Nonprescription Drugs Advisory Committee, 2004-2009; 2009-2014; 2014-2019.

Centers for Disease Control

- Evaluation of Genomic Applications in Practice and Prevention Stakeholder's Group, 2008

American Society for Clinical Pharmacology and Therapeutics

- Membership Committee member, 1995 to 1998
- Scientific Program Committee member, 2004 to 2007
 - Vice Chair, 2004-05
 - Chair, 2005-06
 - Past-chair, 2006-07
- Scientific Awards Selection Task Force
 - Member - 2008, 2009
 - Chair – 2010, 2011, 2012
- **Presidential officer**
 - President-elect – 2015-16
 - President – 2016-17
 - Past-president – 2017-18

American Heart Association

Committee on Scientific Sessions Program (CSSP): Functional Genomics and Translational Biology Council representative; Dec 2007- Nov 2011

2009 International Congress on Genetics and Genomics of Cardiovascular Disease, co-chair.

Distinguished Scientist Selection Committee – December 2008 to November 2011

Functional Genomics and Translational Biology Interdisciplinary Working Group

- Steering Committee, July 2006 to June 2008
- Program Committee, Co-chair: July 2006 to Nov 2007; Chair: Dec 2007-2010

Review Committee Activities:

- AHA Southern/Ohio Valley Research Consortium Peer Review Committee 3A, Committee member 2004
- AHA Southern/Ohio Valley Research Consortium Peer Review Committee 3A, Committee Co-chair, 2005
- AHA Southern/Ohio Valley Research Consortium Peer Review Committee 3B, Committee Chair, 2006-2007

Research Affiliate/Consortium Service

- AHA Florida/Puerto Rico Affiliate Research Committee, member 2004-2006
- AHA Research Consortium II Steering Committee member, 2007 to 2012

Other Service

- UT-AHA High School Research Seminar - speaker, pharmacy representative and judge for summer research positions. 1996, 1997
- Mended Hearts - Organization of post-open heart surgery patients. Invited speaker - 1993, 1996.
- Memphis Area AHA Speakers Bureau - speaker for AHA to schools, lay and civic organizations, 1997-98.

American College of Clinical Pharmacy

- Research Affairs Committee member, 1989-90
- Public and Professional Relations Committee member, 1990-91
- Publications Committee member, 1991-92
- Educational Affairs Committee member, 1993, 1994
- Abstract Reviewer, 1992,1993, 1994, 1995, 1996, 1997, 1998
- 1994 Pharmacotherapy Exam Preparatory Course Planning Committee
- 1993 Strategic Planning Conference, participant
- ACCP Research Institute Review Panel, 1994
- Fellowship Review Committee member, 1995 to 1997
- Pharmacotherapy Self Assessment Program III - manuscript reviewer
- Educational Affairs Committee chair, 1998
- 2000 Annual Meeting Program Committee chair, 1999-2000
- Pharmacotherapy Self Assessment Program IV - manuscript reviewer
- **Elected Officer (Regent), Board of Regents, 2000 to 2003**
- Task Force on Science, secretary, 2001
- Editorial Board, Pharmacogenomics Curriculum, 2001 to present.
- Credentials Committee, secretary, 2002, 2003
- Member at large representative to Pharmacotherapy Board of Directors, 2004 to 2013

American Association of Colleges of Pharmacy

- Academic Affairs Committee, Chair, 2001-02.

- Volwiler Research Achievement Award Selection Committee, 2004-05.
- Paul Dawson Biotechnology Award Selection committee, member 2008, chair 2009

American Association for Advancement of Science

- Grant reviewer for grants program of King Abdulaziz City for Science and Technology, Saudi Arabia. March 2013

American Pharmaceutical Association

- Expert Reviewer for APhA Guidebook on Disease - Specific Pharmaceutical Care Protocols
 - Lipid Disorders, 1996
 - Hypertension, 1996, 1998
- Advisory Board – APhA Special Report on Primary and Secondary Prevention of Atherosclerotic Disease, 1998

Academy for Science Engineering and Medicine Florida

- Founding Board Member, 2018
- Inaugural Vice-President, 2018 to present.

Miscellaneous International

- Karolinska Institute External Reviewer Clinical Pharmacology Chair search – 2010
- Austrian Science Fund START Grant Program – reviewer – 2011
- Wellcome Trust Investigator Award, United Kingdom – reviewer – 2012
- Programma di Ricerca Regione-Universita 2010-2012 Regione Emilia-Romagna Innovative Research Grant Reviewer – 2012
- American Association for Advancement of Science/King Adulaziz City for Science and Technology (KACST) grant reviewer – 2013.

Board of Pharmaceutical Specialties

- Expert Review Panel member for 1994 Pharmacotherapy exam assembly, 1994
- Cardiology Item Writing Panel for BPS Specialty Council on Pharmacotherapy, 1995 to 1998.

Pharmacotherapy

- Quality Improvement Task Force, 1999
- Board of Directors, 2004-present

Scientific Editor

- *Pharmacotherapy*, 2006 to 2013
- Chair – Scientific Editors Council, 2008 to 2013

Editorial Boards:

- *Clinical Pharmacology and Therapeutics*, 2005 to present
- *Pharmacotherapy*, 1993-2013
- Pharmacogenomics: Applications to Patient Care; 2001 to present

- *Pharmacogenetics and Genomics*, 2002-present
- *Personalized Medicine*, 2004-present
- *Psychosomatic Medicine*, 2008 to 2013
- *Journal of the American Heart Association*, 2012 to present

Manuscript reviewer (examples):

- *American Journal of Pharmacogenomics*
- *American Pharmaceutical Association Special Publications*
- *Biopharmaceutics and Drug Disposition*
- *BMC Medical Genetics*
- *British Journal of Clinical Pharmacology*
- *Circulation*
- *Circulation Genetics*
- *Clinical Pharmacology and Therapeutics*
- *Current Pharmacogenomics*
- *Current Opinions in Molecular Therapeutics*
- *DICP - The Annals of Pharmacotherapy*
- *European Heart Journal*
- *Genomics*
- *Heart Journal*
- *Human Genetics*
- *HUMAN Genomics*
- *JAMA – Journal of the American Medical Association*
- *Journal of Pharmacology and Experimental Therapeutics*
- *Journal of Pharmacy and Pharmacology*
- *Journal of Pharmaceutical Sciences*
- *Nature Genetics*
- *Nature Cardiovascular Medicine*
- *New England Journal of Medicine*
- *Pharmacogenetics and Genomics*
- *Pharmacogenomics Journal*
- *Pharmacological Reviews*
- *Pharmacotherapy*
- *Pharmacotherapy Self Assessment Program IV*
- *Psychosomatic Medicine*
- *Science Translational Medicine*
- *Vascular Medicine*

UNIVERSITY SERVICE

UNIVERSITY OF TENNESSEE

- Faculty Senate, College of Pharmacy at Large Representative, 1991 - 1994.
Member, Communications Committee, 1993-94
Member, Faculty Affairs Committee, 1994-95
- Mentor, Office of Career Programs. Program for minority high school students, 1993.
- Campus Research Committee member, 1994 -1995.
Member, Research Development Subcommittee, 1994-95.
- General Clinical Research Center Scientific Advisory Committee member, 1994-1998.
- Mentor - Cardiovascular-Renal Summer Minority Research Program. 1995, 1996, 1997

University of Tennessee College of Pharmacy

- Department of Clinical Pharmacy Chairman Search Advisory Committee, 1990-91.

- Academic Standards and Promotion Review Committee, 1990-1994.
- Van Vleet Professor of Pharmacy (Endowed Chair) Search Advisory Committee, 1991-92.
- Chair, Sub-committee to review Drug Information Course, 1993
- Coordinator, Molecular Biology Journal Club, 1994 to 1997
- Curriculum committee, 1995-96
 - Chair, Subcommittee for development of external Pharm.D. degree, 1996
 - Chair, Subcommittee to review Pharmacology course, 1996.
- Promotion and Tenure Committee, appointed representative, 1996 to 1998.

University of Tennessee Department of Clinical Pharmacy

- Postdoctoral training committee, 1990-91.
- Coordinator, Pharmacotherapy Exam study group, 1992.
- Coordinator, Departmental Pharmacokinetics/dynamics Journal Club, 1991 to 1997.
- Research committee, 1993 to 1996.
- Coordinator - Department of Clinical Pharmacy Research Seminar, 1993 to 1998.

UNIVERSITY OF FLORIDA

University of Florida

- Institute on Aging Advisory Board, 2000 to 2001
- Institute on Aging Faculty Search Committee, 2000
- Center for Pharmacogenomics, Director, 2001-2013
- University of Florida Genetics Institute, Executive Committee member, 2003 – 2013
- University of Florida NIH K-30 funded Advanced Postgraduate Program in Clinical Investigation Advisory Committee – 2003 – 2008
- University of Florida CTSI KL2 Advisory Committee – 2009 to 2013
- University of Florida Interdisciplinary Center for Biotechnology Research Director Search Committee, 2005-2006.
- Center for Translational Science Award Steering Committee (Pharmacy Representative) – 2006 to 2012
- ICBR Molecular Services Core Advisory Committee – 2007 to present
- Clinical and Translational Science Institute Genotyping Core Laboratory Director – 2007 to 2013
- Dean of Medicine Search Committee member, 2009
- Chief Information Officer/Vice President Search Committee member, 2010
- Genetics Institute Director Search Committee member, 2011-2012
- Office of the President's Goal-Setting Task Force 2015
- CTSI Governing Board, 2015-present
- UF Foundation Deans and Directors Development Council, 2015-present
 - Vice chair – 2019 – 2021
 - Chair – 2021 to present
- UF Health Cancer Center Internal Advisory Board, 2019 to present
- Dean of Medicine Search Committee, Co-chair, 2020
- Future of Higher Education Task Force, 2020
- University Budget Optimization Working Group, 2021
- UF Foundation Executive Board, Director (ex-officio), 2021-present

College of Pharmacy (prior to appointment as Dean)

- Academic Performance Committee, 1999 to 2002
- Curriculum Committee, 1999 to 2001
- Tenure and Promotion Committee, 2001 to 2003
- Executive Committee, 2002 to 2011
- Tenure and Promotion Committee, 2007-2009

Department of Pharmacotherapy and Translational Research (formerly Pharmacy Practice)

- Faculty Search Committee, 1998-99.
- Chair, Department of Pharmacotherapy and Translational Research, 2002 to 2011

Department of Pharmaceutics

- Faculty Search Committee, 2002

TEACHING

AWARDS:

- Teaching Excellence Award, 1996 - Presented by the University of Tennessee Student Government Association
- Outstanding Faculty Award, University of Florida Working Professional Pharm.D. Program, 2001

UNIVERSITY OF TENNESSEE

CLPH 311 and 312 - Therapeutics I and II

1989-1998: Team taught therapeutics course for third year Pharm.D. students with class sizes of 70 to 100 students. Delivered approximately 20 lecture hours per year on cardiovascular therapeutics as well as leading 4 to 5 recitation sessions per year. Presented lectures on most topics in cardiovascular therapeutics. Course coordinator: 1991, 1992.

CLPH 410: Cardiology Clerkship

1990-1998: Preceptor for a cardiology clerkship based in the Coronary Care Unit/Cardiology Service at the Veterans Administration Medical Center at Memphis. Site co-precepted by Dr. Robert B. Parker; combined we had approximately 18 to 22 fourth year PharmD students per year.

CLPH 315 Applied Clinical Pharmacokinetics:

1991-1996: Course lecturer (3-6 hours per year) plus recitation leader. Class size of 70-100 students. Lecture topics included: clearance concepts, hepatic clearance, hepatic drug interactions, hepatic drug metabolism, P-glycoprotein's impact on kinetics and clinical pharmacokinetics of: lidocaine, procainamide, digoxin, other antiarrhythmics

1997: Course coordinator.

Other:

Also participated in Women's Health Selective Course, Applied Therapeutics, and Critical Care Selective Course for pharmacy students and Clinical Pharmacology and Therapeutics Course for 4th year medical students.

UNIVERSITY OF FLORIDA

PHA6449; Pharmacogenomics

Even years, starting 2008: Graduate course in pharmacogenomics; required course in Clinical Pharmaceutical Sciences PhD program. Course director; 8-12 students.

PHA5683; Ambulatory Care Clerkship

1999 to 2002: Co-precepted with 3 other faculty members. Precepted students in heart failure/heart transplantation clinic

Research Elective Clerkship – course number varies by month

2002 to present. Precept students in an elective research rotation that provides them with exposure to clinical research, informed consent, clinical trial design and statistic issues, pharmacogenomics, genetics and genomics nomenclature, laboratory aspects of pharmacogenomics research.

PHA 5781; Pharmacotherapy I

2001: Coursemaster and lecturer. Class size of approximately 130 students. Course covering introductory pharmacotherapy topics.

PHA 5782; Pharmacotherapy II

1998: Course co-coordinator and small group leader. Class size of approximately 130 students. Course covers the pharmacotherapy of cardiovascular, pulmonary, gastrointestinal, psychiatric and renal diseases and transplantation. Lectures given in cardiovascular pharmacotherapy.

1999: Coursemaster, lecturer and small group leader, class size of 130 students

2000-present: Lecturer on cardiovascular pharmacotherapy topics; class size – 2000-2002: 130 students; since 2003: 270 to 300 students.

PHA5784 Pharmacotherapy IV

2000-present: Pharmacokinetics case faculty leader. Course is a case-based course where students are provided a case assignment and then must answer in class the questions posed to them by a faculty member; class size – 130 students.

PHA5887; Pharmacotherapy V

2000-present: Pharmacokinetics case faculty leader. Course is a case-based course where students are provided a case assignment and then must answer in class the questions posed to them by a faculty member; class size – 130 students.

PHA 5128; Basic Principles of Dose Optimization II

1999-2004: Course lecturer on drug metabolism/drug-drug interactions, pharmacogenetics. Class size of approximately 130 students.

PHA 5516; Pharmacologic Basis of Therapeutics

1999-2001: Course lecturer on antihyperlipidemic agents pharmacology. Class size of approximately 130 students.

GMS6181; Science of Clinical Research

2000-2005. Lecturer. Survey course on clinical research for post-doctoral fellows, and graduate students enrolled in the K30 Clinical Sciences program. Class size: approximately 60 students.

PHA 5941; Practicum I

1998: Small group facilitator. Class size of approximately 20 students.